Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11108871,C(max),A single dose of 100 mg resulted in a mean C(max) of 31.53 +/- 9.15 nmol/l with a T(max) of 6.92 +/- 3.12 h.,Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11108871/),[nM] / [l],31.53,387,DB00396,Progesterone
,11108871,T(max),A single dose of 100 mg resulted in a mean C(max) of 31.53 +/- 9.15 nmol/l with a T(max) of 6.92 +/- 3.12 h.,Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11108871/),h,6.92,388,DB00396,Progesterone
,11108871,terminal half-life,The terminal half-life was 16.39 +/- 5.25 h.,Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11108871/),h,16.39,389,DB00396,Progesterone
,11108871,T(max),"Results indicated a similar mean T(max) of 6.92 +/- 3.12 and 6.23 +/- 6.57 h, respectively.",Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11108871/),h,6.92,390,DB00396,Progesterone
,11108871,T(max),"Results indicated a similar mean T(max) of 6.92 +/- 3.12 and 6.23 +/- 6.57 h, respectively.",Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11108871/),h,6.23,391,DB00396,Progesterone
,11108871,C(max),"However, a significantly higher C(max) was achieved by the vaginal tablet (31.95 +/- 9.15 and 23.85 +/- 9.57 nmol/l, respectively, P < 0.05).",Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11108871/),[nM] / [l],31.95,392,DB00396,Progesterone
,11108871,C(max),"However, a significantly higher C(max) was achieved by the vaginal tablet (31.95 +/- 9.15 and 23.85 +/- 9.57 nmol/l, respectively, P < 0.05).",Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11108871/),[nM] / [l],23.85,393,DB00396,Progesterone
,3572801,maximal levels,"After a single oral dose of 25 mg/kg (n = 11) or 10 mg/kg (n = 11) to normal volunteers, plasma concentrations of progesterone receptor-reactive material reached maximal levels of 754 +/- 288 (mean +/- S.D.) and 517 +/- 183 micrograms/dl.",Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3572801/),[μg] / [dl],754,479,DB00396,Progesterone
,3572801,maximal levels,"After a single oral dose of 25 mg/kg (n = 11) or 10 mg/kg (n = 11) to normal volunteers, plasma concentrations of progesterone receptor-reactive material reached maximal levels of 754 +/- 288 (mean +/- S.D.) and 517 +/- 183 micrograms/dl.",Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3572801/),[μg] / [dl],517,480,DB00396,Progesterone
,3572801,apparent plasma half-lives,The respective apparent plasma half-lives were 19.2 +/- 7.0 and 20.6 +/- 7.7 h.,Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3572801/),h,19.2,481,DB00396,Progesterone
,3572801,apparent plasma half-lives,The respective apparent plasma half-lives were 19.2 +/- 7.0 and 20.6 +/- 7.7 h.,Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3572801/),h,20.6,482,DB00396,Progesterone
,3572801,receptor reactivity,Four patients with Cushing's syndrome treated chronically (10-20 mg/kg/day) had relatively constant plasma levels of receptor reactivity ranging from 506 to 1184 micrograms/dl.,Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3572801/),[μg] / [dl],506 to 1184,483,DB00396,Progesterone
,7572183,flow rate of mobile phase,"The flow rate of mobile phase (methanol-dichloromethane--0.01 mol.L-1 phosphate buffer, pH 4.0, 67:5:28 v/v) was 1.1 ml.",[Determination of the progesterone antagonist lilopristone in serum by RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7572183/),ml,1.1,1637,DB00396,Progesterone
,7572183,retention times,The retention times of lilopristone and IS were 6.85 and 9.07 min respectively and the detection limit was 10 ng.,[Determination of the progesterone antagonist lilopristone in serum by RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7572183/),min,6.85,1638,DB00396,Progesterone
,7572183,retention times,The retention times of lilopristone and IS were 6.85 and 9.07 min respectively and the detection limit was 10 ng.,[Determination of the progesterone antagonist lilopristone in serum by RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7572183/),min,9.07,1639,DB00396,Progesterone
,7572183,detection limit,The retention times of lilopristone and IS were 6.85 and 9.07 min respectively and the detection limit was 10 ng.,[Determination of the progesterone antagonist lilopristone in serum by RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7572183/),ng,10,1640,DB00396,Progesterone
> or =,7572183,S/N,ml-1 (S/N > or = 4) serum.,[Determination of the progesterone antagonist lilopristone in serum by RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7572183/),,4,1641,DB00396,Progesterone
over,7572183,extraction recoveries,The extraction recoveries of lilopristone and IS were over 85%.,[Determination of the progesterone antagonist lilopristone in serum by RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7572183/),%,85,1642,DB00396,Progesterone
,16223868,affinities,All five analogs bound to guinea pig progesterone binding globulin with relatively high affinities (264-1020 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,264-1020,4000,DB00396,Progesterone
,16223868,binding affinity,Conjugation via the epsilon-amino function of D-Lys6 (conjugates A and B) produced compounds with high binding affinity for the human GnRH receptor (15 and 7 nM) comparable to that of the unconjugated GnRH antagonists (4 and 26 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,15,4001,DB00396,Progesterone
,16223868,binding affinity,Conjugation via the epsilon-amino function of D-Lys6 (conjugates A and B) produced compounds with high binding affinity for the human GnRH receptor (15 and 7 nM) comparable to that of the unconjugated GnRH antagonists (4 and 26 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,7,4002,DB00396,Progesterone
,16223868,binding affinity,Conjugation via the epsilon-amino function of D-Lys6 (conjugates A and B) produced compounds with high binding affinity for the human GnRH receptor (15 and 7 nM) comparable to that of the unconjugated GnRH antagonists (4 and 26 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,4,4003,DB00396,Progesterone
,16223868,binding affinity,Conjugation via the epsilon-amino function of D-Lys6 (conjugates A and B) produced compounds with high binding affinity for the human GnRH receptor (15 and 7 nM) comparable to that of the unconjugated GnRH antagonists (4 and 26 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,26,4004,DB00396,Progesterone
,6224604,t1/2,Discontinuation of the treatment produces a fast decay (t1/2 = 62.4 h) of the drug levels.,Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6224604/),h,62.4,4354,DB00396,Progesterone
,33183077,Recoveries,"Recoveries of PGT and IS were ranging from 114-119% and 96.5-112%, respectively.",LC-MS/MS quantification of progesterone in ovariectomized miniature swine and its application for preliminary pharmacokinetic study of a novel vaginal sustained release system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33183077/),%,114-119,4365,DB00396,Progesterone
,33183077,Recoveries,"Recoveries of PGT and IS were ranging from 114-119% and 96.5-112%, respectively.",LC-MS/MS quantification of progesterone in ovariectomized miniature swine and its application for preliminary pharmacokinetic study of a novel vaginal sustained release system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33183077/),%,96.5-112,4366,DB00396,Progesterone
,33183077,plasma concentration,"In vitro study showed that the EVA IVRs release 18 mg/day of PGT continuously over 7 days, and corresponding mean PGT plasma concentration in OVX minipigs (CAVG) was 4.892 ng/mL.",LC-MS/MS quantification of progesterone in ovariectomized miniature swine and its application for preliminary pharmacokinetic study of a novel vaginal sustained release system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33183077/),ng,4.892,4367,DB00396,Progesterone
,3254628,volume of distribution,"Progesterone had a volume of distribution of 1.75 +/- 0.3 L/kg, and a plasma elimination clearance of 0.06 +/- 0.03 L/kg/min.",Metabolism and pharmacokinetics of progesterone in the cynomolgus monkey (Macaca fascicularis). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3254628/),[l] / [kg],1.75,4752,DB00396,Progesterone
,3254628,plasma elimination clearance,"Progesterone had a volume of distribution of 1.75 +/- 0.3 L/kg, and a plasma elimination clearance of 0.06 +/- 0.03 L/kg/min.",Metabolism and pharmacokinetics of progesterone in the cynomolgus monkey (Macaca fascicularis). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3254628/),[l] / [kg·min],0.06,4753,DB00396,Progesterone
,11085188,GC-R,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),,5814,6172,DB00396,Progesterone
,11085188,GC-R,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),,6816,6173,DB00396,Progesterone
,11085188,numbers,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),,5814,6174,DB00396,Progesterone
,11085188,numbers,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),,6816,6175,DB00396,Progesterone
,11085188,Kd,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),nM,3.6,6176,DB00396,Progesterone
,11085188,Kd,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),nM,4.2,6177,DB00396,Progesterone
,21903773,disease control rate,"Of 69 evaluable patients, three had confirmed partial responses and six had stable disease for 16 weeks or more (disease control rate = 13.0%); all nine of these tumors were HR+ (two were also HER2+).",A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21903773/),%,13.0,6894,DB00396,Progesterone
,8195352,Maximal concentrations,Maximal concentrations of 0.7 mumol/l were seen on treatment day 4.,"Termination of early pregnancy with ZK 98,734: pharmacokinetic behaviour and clinical effect. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195352/),[μM] / [l],0.7,8253,DB00396,Progesterone
,9262934,relative bioavailability,"The estimates of relative bioavailability ranged from 13 to 51% in rabbits, monkeys, and women.","Pharmacokinetics of orally administered norethisterone enanthate in rabbit, monkey, and women. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9262934/),%,13 to 51,8428,DB00396,Progesterone
,9262934,elimination half-life,The elimination half-life was 5-10 days.,"Pharmacokinetics of orally administered norethisterone enanthate in rabbit, monkey, and women. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9262934/),d,5-10,8429,DB00396,Progesterone
,10073325,clearance,"Tirilazad clearance was significantly higher in premenopausal women (0.51 +/- 0.09 L/hr/kg) than in postmenopausal groups (0.34 +/- 0.07, 0.32 +/- 0.06, and 0.36 +/- 0.08 L/hr/kg, respectively) (p = 0.0001).",Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073325/),[l] / [h·kg],0.51,8972,DB00396,Progesterone
,10073325,clearance,"Tirilazad clearance was significantly higher in premenopausal women (0.51 +/- 0.09 L/hr/kg) than in postmenopausal groups (0.34 +/- 0.07, 0.32 +/- 0.06, and 0.36 +/- 0.08 L/hr/kg, respectively) (p = 0.0001).",Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073325/),[l] / [h·kg],0.34,8973,DB00396,Progesterone
,10073325,clearance,"Tirilazad clearance was significantly higher in premenopausal women (0.51 +/- 0.09 L/hr/kg) than in postmenopausal groups (0.34 +/- 0.07, 0.32 +/- 0.06, and 0.36 +/- 0.08 L/hr/kg, respectively) (p = 0.0001).",Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073325/),[l] / [h·kg],0.32,8974,DB00396,Progesterone
,10073325,clearance,"Tirilazad clearance was significantly higher in premenopausal women (0.51 +/- 0.09 L/hr/kg) than in postmenopausal groups (0.34 +/- 0.07, 0.32 +/- 0.06, and 0.36 +/- 0.08 L/hr/kg, respectively) (p = 0.0001).",Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073325/),[l] / [h·kg],0.36,8975,DB00396,Progesterone
,10073325,Midazolam clearance,"Midazolam clearance (0.64 +/- 0.12 L/hr/kg) was significantly higher in premenopausal women compared to postmenopausal groups (0.47 +/- 0.11, 0.49 +/- 0.11, and 0.53 +/- 0.19 L/hr/kg, respectively) (p = 0.037).",Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073325/),[l] / [h·kg],0.64,8976,DB00396,Progesterone
,10073325,Midazolam clearance,"Midazolam clearance (0.64 +/- 0.12 L/hr/kg) was significantly higher in premenopausal women compared to postmenopausal groups (0.47 +/- 0.11, 0.49 +/- 0.11, and 0.53 +/- 0.19 L/hr/kg, respectively) (p = 0.037).",Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073325/),[l] / [h·kg],0.47,8977,DB00396,Progesterone
,10073325,Midazolam clearance,"Midazolam clearance (0.64 +/- 0.12 L/hr/kg) was significantly higher in premenopausal women compared to postmenopausal groups (0.47 +/- 0.11, 0.49 +/- 0.11, and 0.53 +/- 0.19 L/hr/kg, respectively) (p = 0.037).",Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073325/),[l] / [h·kg],0.49,8978,DB00396,Progesterone
,10073325,Midazolam clearance,"Midazolam clearance (0.64 +/- 0.12 L/hr/kg) was significantly higher in premenopausal women compared to postmenopausal groups (0.47 +/- 0.11, 0.49 +/- 0.11, and 0.53 +/- 0.19 L/hr/kg, respectively) (p = 0.037).",Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073325/),[l] / [h·kg],0.53,8979,DB00396,Progesterone
<,24582292,Cmax,Cmax <2.88 ng/mL and elimination rate constant <0.021 ng/mL/day were associated (p<.05) with BMI increase ≥10%.,A pilot study of depot medroxyprogesterone acetate pharmacokinetics and weight gain in adolescent females. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24582292/),[ng] / [ml],2.88,9990,DB00396,Progesterone
<,24582292,elimination rate constant,Cmax <2.88 ng/mL and elimination rate constant <0.021 ng/mL/day were associated (p<.05) with BMI increase ≥10%.,A pilot study of depot medroxyprogesterone acetate pharmacokinetics and weight gain in adolescent females. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24582292/),[ng] / [d·ml],0.021,9991,DB00396,Progesterone
,22967833,half-life,The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days.,Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22967833/),d,16.2,10449,DB00396,Progesterone
,22967833,concentration ratios,Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection.,Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22967833/),,0.2,10450,DB00396,Progesterone
,28982161,peak progesterone levels,"Mean peak progesterone levels were 4.4 ± 1.8 ng mL-1 prior to IVR insertion and 0.075 ± 0.064 ng mL-1 for 5 weeks after insertion, suggesting that systemic EE/ENG levels were sufficient to suppress menstruation.","Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28982161/),[ng] / [ml],4.4,11833,DB00396,Progesterone
,28982161,peak progesterone levels,"Mean peak progesterone levels were 4.4 ± 1.8 ng mL-1 prior to IVR insertion and 0.075 ± 0.064 ng mL-1 for 5 weeks after insertion, suggesting that systemic EE/ENG levels were sufficient to suppress menstruation.","Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28982161/),[ng] / [ml],0.075,11834,DB00396,Progesterone
,28982161,release rates,"The TAF2 and ACV release rates and resulting vaginal tissue drug concentrations (medians: TFV, 2.4 ng mg-1; ACV, 0.2 ng mg-1) may be sufficient to protect against HIV and HSV infection, respectively.","Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28982161/),[ng] / [mg],2.4,11835,DB00396,Progesterone
,28982161,release rates,"The TAF2 and ACV release rates and resulting vaginal tissue drug concentrations (medians: TFV, 2.4 ng mg-1; ACV, 0.2 ng mg-1) may be sufficient to protect against HIV and HSV infection, respectively.","Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28982161/),[ng] / [mg],0.2,11836,DB00396,Progesterone
,1776487,times to reach peak levels,"Following a single im NET-EN 200 mg, the times to reach peak levels of NET-EN and NET were 4.0 +/- 2.8 d and 5.4 +/- 2.0 d, and their peak values were 5.0 +/- 1.8 and 12.6 +/- 0.9 ng.",[Pharmacokinetics of norethindrone enanthate 200 mg after intramuscular injection in 25 Chinese women]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1776487/),d,4.0,14512,DB00396,Progesterone
,1776487,times to reach peak levels,"Following a single im NET-EN 200 mg, the times to reach peak levels of NET-EN and NET were 4.0 +/- 2.8 d and 5.4 +/- 2.0 d, and their peak values were 5.0 +/- 1.8 and 12.6 +/- 0.9 ng.",[Pharmacokinetics of norethindrone enanthate 200 mg after intramuscular injection in 25 Chinese women]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1776487/),d,5.4,14513,DB00396,Progesterone
,1776487,peak values,"Following a single im NET-EN 200 mg, the times to reach peak levels of NET-EN and NET were 4.0 +/- 2.8 d and 5.4 +/- 2.0 d, and their peak values were 5.0 +/- 1.8 and 12.6 +/- 0.9 ng.",[Pharmacokinetics of norethindrone enanthate 200 mg after intramuscular injection in 25 Chinese women]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1776487/),ng,5.0,14514,DB00396,Progesterone
,1776487,peak values,"Following a single im NET-EN 200 mg, the times to reach peak levels of NET-EN and NET were 4.0 +/- 2.8 d and 5.4 +/- 2.0 d, and their peak values were 5.0 +/- 1.8 and 12.6 +/- 0.9 ng.",[Pharmacokinetics of norethindrone enanthate 200 mg after intramuscular injection in 25 Chinese women]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1776487/),ng,12.6,14515,DB00396,Progesterone
,1776487,apparent elimination T1/2,Mean apparent elimination T1/2 were 14.8 +/- 3.8 d for and 11.4 +/- 5.7 d for NET-EN.,[Pharmacokinetics of norethindrone enanthate 200 mg after intramuscular injection in 25 Chinese women]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1776487/),d,14.8,14516,DB00396,Progesterone
,1776487,apparent elimination T1/2,Mean apparent elimination T1/2 were 14.8 +/- 3.8 d for and 11.4 +/- 5.7 d for NET-EN.,[Pharmacokinetics of norethindrone enanthate 200 mg after intramuscular injection in 25 Chinese women]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1776487/),d,11.4,14517,DB00396,Progesterone
,25386671,half-life,"Mean (SD) cortisol half-life and Cmax were 1.01 (0.20) hours and 24.4 (5.4) μg/dL, respectively.","Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25386671/),h,1.01,15325,DB00396,Progesterone
,25386671,Cmax,"Mean (SD) cortisol half-life and Cmax were 1.01 (0.20) hours and 24.4 (5.4) μg/dL, respectively.","Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25386671/),[μg] / [dl],24.4,15326,DB00396,Progesterone
,25386671,AUCs,"The AUCs for cortisol, 17-hydroxyprogesterone and androstenedione were 40.8 (14.5) μg hour/dL, 29,490 (23,539) ng hour/dL, and 680 (795) ng hour/dL, respectively.","Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25386671/),[h·μg] / [dl],40.8,15327,DB00396,Progesterone
,25386671,AUCs,"The AUCs for cortisol, 17-hydroxyprogesterone and androstenedione were 40.8 (14.5) μg hour/dL, 29,490 (23,539) ng hour/dL, and 680 (795) ng hour/dL, respectively.","Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25386671/),[h·ng] / [dl],"29,490",15328,DB00396,Progesterone
,25386671,AUCs,"The AUCs for cortisol, 17-hydroxyprogesterone and androstenedione were 40.8 (14.5) μg hour/dL, 29,490 (23,539) ng hour/dL, and 680 (795) ng hour/dL, respectively.","Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25386671/),[h·ng] / [dl],680,15329,DB00396,Progesterone
,23515453,elimination half-life,The elimination half-life of Org 43553 was 30 to 47 hours and that of Org 43902 was 17 to 22 hours.,First evidence of ovulation induced by oral LH agonists in healthy female volunteers of reproductive age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23515453/),h,30 to 47,16128,DB00396,Progesterone
,23515453,elimination half-life,The elimination half-life of Org 43553 was 30 to 47 hours and that of Org 43902 was 17 to 22 hours.,First evidence of ovulation induced by oral LH agonists in healthy female volunteers of reproductive age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23515453/),h,17 to 22,16129,DB00396,Progesterone
,23515453,ovulation rate,"The minimal effective dose for ovulation induction was 300 mg in both studies and resulted in an ovulation rate of 83% and 82%, respectively.",First evidence of ovulation induced by oral LH agonists in healthy female volunteers of reproductive age. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23515453/),%,83,16130,DB00396,Progesterone
,23515453,ovulation rate,"The minimal effective dose for ovulation induction was 300 mg in both studies and resulted in an ovulation rate of 83% and 82%, respectively.",First evidence of ovulation induced by oral LH agonists in healthy female volunteers of reproductive age. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23515453/),%,82,16131,DB00396,Progesterone
,1388093,AUC0-144,"Based on the results of RIA analysis, Farlutal tablets produced significantly lower serum MPA concentrations compared with Provera tablets at most sampling times, resulting in statistically lower AUC0-144 for the Farlutal tablet (544 vs 768 ng.hr/ml; -29.2%).",Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),[h·ng] / [ml],544,16677,DB00396,Progesterone
,1388093,AUC0-144,"Based on the results of RIA analysis, Farlutal tablets produced significantly lower serum MPA concentrations compared with Provera tablets at most sampling times, resulting in statistically lower AUC0-144 for the Farlutal tablet (544 vs 768 ng.hr/ml; -29.2%).",Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),[h·ng] / [ml],768,16678,DB00396,Progesterone
,1388093,maximum concentration,The Farlutal tablet also had a significantly lower maximum concentration than the Provera tablet (27.8 vs 47.4 ng/ml; -41.4%).,Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),[ng] / [ml],27.8,16679,DB00396,Progesterone
,1388093,maximum concentration,The Farlutal tablet also had a significantly lower maximum concentration than the Provera tablet (27.8 vs 47.4 ng/ml; -41.4%).,Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),[ng] / [ml],47.4,16680,DB00396,Progesterone
,1388093,time of maximum concentration,"However, there was no significant difference in time of maximum concentration between the tablet formulations (3.71 vs 3.41 hr), indicating that the rates of absorption of the two tablet formulations were comparable.",Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),h,3.71,16681,DB00396,Progesterone
,1388093,time of maximum concentration,"However, there was no significant difference in time of maximum concentration between the tablet formulations (3.71 vs 3.41 hr), indicating that the rates of absorption of the two tablet formulations were comparable.",Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),h,3.41,16682,DB00396,Progesterone
,1388093,AUC0-144,"Provera granules provided significantly higher serum MPA levels than Provera tablets at 0.5, 1, 1.5, 2, and 6 hours, and the AUC0-144 for Provera granules was higher by 5.47% (810 vs 768 ng.hr/ml).",Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),[h·ng] / [ml],810,16683,DB00396,Progesterone
,1388093,AUC0-144,"Provera granules provided significantly higher serum MPA levels than Provera tablets at 0.5, 1, 1.5, 2, and 6 hours, and the AUC0-144 for Provera granules was higher by 5.47% (810 vs 768 ng.hr/ml).",Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),[h·ng] / [ml],768,16684,DB00396,Progesterone
,1388093,relative bioavailabilities,"The relative bioavailabilities of Provera granules and Farlutal tablets were 105% and 71.2%, respectively, compared with Provera tablets.",Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),%,105,16685,DB00396,Progesterone
,1388093,relative bioavailabilities,"The relative bioavailabilities of Provera granules and Farlutal tablets were 105% and 71.2%, respectively, compared with Provera tablets.",Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),%,71.2,16686,DB00396,Progesterone
,15778002,AUC,"Following one s.c. injection of 500 mg genistein/kg BW or 500 microg EB/kg BW, AUC for genistein was 20171.8 ng h/ml and was 15.7 ng h/ml for estradiol-17-beta.",Dynamic profiling of estrogen receptor and epidermal growth factor signaling in the uteri of genistein- and estrogen-treated rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778002/),[h·ng] / [ml],20171.8,18721,DB00396,Progesterone
,15778002,AUC,"Following one s.c. injection of 500 mg genistein/kg BW or 500 microg EB/kg BW, AUC for genistein was 20171.8 ng h/ml and was 15.7 ng h/ml for estradiol-17-beta.",Dynamic profiling of estrogen receptor and epidermal growth factor signaling in the uteri of genistein- and estrogen-treated rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778002/),[h·ng] / [ml],15.7,18722,DB00396,Progesterone
,7645623,Maximal serum progesterone levels,"Maximal serum progesterone levels ranged from 5.7 to 20.9 ng/ml, with the mean maximal levels 13.97, 16.09, and 12.68 ng/ml (not significantly different) and a mean area under the curve of 168.13, 207.64 and 227.71 ng/ml per hour on days 1, 7, and 14 (not statistically different).",Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7645623/),[ng] / [ml],5.7 to 20.9,19524,DB00396,Progesterone
,7645623,maximal levels,"Maximal serum progesterone levels ranged from 5.7 to 20.9 ng/ml, with the mean maximal levels 13.97, 16.09, and 12.68 ng/ml (not significantly different) and a mean area under the curve of 168.13, 207.64 and 227.71 ng/ml per hour on days 1, 7, and 14 (not statistically different).",Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7645623/),[ng] / [ml],13.97,19525,DB00396,Progesterone
,7645623,maximal levels,"Maximal serum progesterone levels ranged from 5.7 to 20.9 ng/ml, with the mean maximal levels 13.97, 16.09, and 12.68 ng/ml (not significantly different) and a mean area under the curve of 168.13, 207.64 and 227.71 ng/ml per hour on days 1, 7, and 14 (not statistically different).",Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7645623/),[ng] / [ml],16.09,19526,DB00396,Progesterone
,7645623,maximal levels,"Maximal serum progesterone levels ranged from 5.7 to 20.9 ng/ml, with the mean maximal levels 13.97, 16.09, and 12.68 ng/ml (not significantly different) and a mean area under the curve of 168.13, 207.64 and 227.71 ng/ml per hour on days 1, 7, and 14 (not statistically different).",Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7645623/),[ng] / [ml],12.68,19527,DB00396,Progesterone
,7645623,area under the curve,"Maximal serum progesterone levels ranged from 5.7 to 20.9 ng/ml, with the mean maximal levels 13.97, 16.09, and 12.68 ng/ml (not significantly different) and a mean area under the curve of 168.13, 207.64 and 227.71 ng/ml per hour on days 1, 7, and 14 (not statistically different).",Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7645623/),[ng] / [h·ml],168.13,19528,DB00396,Progesterone
,7645623,area under the curve,"Maximal serum progesterone levels ranged from 5.7 to 20.9 ng/ml, with the mean maximal levels 13.97, 16.09, and 12.68 ng/ml (not significantly different) and a mean area under the curve of 168.13, 207.64 and 227.71 ng/ml per hour on days 1, 7, and 14 (not statistically different).",Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7645623/),[ng] / [h·ml],207.64,19529,DB00396,Progesterone
,7645623,area under the curve,"Maximal serum progesterone levels ranged from 5.7 to 20.9 ng/ml, with the mean maximal levels 13.97, 16.09, and 12.68 ng/ml (not significantly different) and a mean area under the curve of 168.13, 207.64 and 227.71 ng/ml per hour on days 1, 7, and 14 (not statistically different).",Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7645623/),[ng] / [h·ml],227.71,19530,DB00396,Progesterone
,31222770,steady-state plasma concentration (Css ),"As a whole, the mean steady-state plasma concentration (Css ), degree fluctuation (DF), accumulation factor (Rac ), and area under the plasma concentration-time curve in steady state (AUCss ) were 22.69 ± 6.15 ng/ml, 270.64 ± 42.51%, 1.53 ± 0.23, and 544.63 ± 147.49 ng hr/ml, respectively.",Pharmacokinetics of altrenogest in gilts. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222770/),[ng] / [ml],22.69,21429,DB00396,Progesterone
,31222770,accumulation factor (Rac ),"As a whole, the mean steady-state plasma concentration (Css ), degree fluctuation (DF), accumulation factor (Rac ), and area under the plasma concentration-time curve in steady state (AUCss ) were 22.69 ± 6.15 ng/ml, 270.64 ± 42.51%, 1.53 ± 0.23, and 544.63 ± 147.49 ng hr/ml, respectively.",Pharmacokinetics of altrenogest in gilts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222770/),%,270.64,21430,DB00396,Progesterone
,31222770,area under the plasma concentration-time curve in steady state (AUCss ),"As a whole, the mean steady-state plasma concentration (Css ), degree fluctuation (DF), accumulation factor (Rac ), and area under the plasma concentration-time curve in steady state (AUCss ) were 22.69 ± 6.15 ng/ml, 270.64 ± 42.51%, 1.53 ± 0.23, and 544.63 ± 147.49 ng hr/ml, respectively.",Pharmacokinetics of altrenogest in gilts. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222770/),[h·ng] / [ml],544.63,21431,DB00396,Progesterone
,19639535,P(app),"Hoodigogenin A was efficiently transported by passive diffusion across Caco-2 and MDR1-MDCK monolayers with P(app) values in the range of 32 x 10(-6) cm/sec and 22 x 10(-6) cm/sec, respectively.",Characterization of in vitro pharmacokinetic properties of hoodigogenin A from Hoodia gordonii. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19639535/),[cm] / [s],32 x 10(-6),21432,DB00396,Progesterone
,19639535,P(app),"Hoodigogenin A was efficiently transported by passive diffusion across Caco-2 and MDR1-MDCK monolayers with P(app) values in the range of 32 x 10(-6) cm/sec and 22 x 10(-6) cm/sec, respectively.",Characterization of in vitro pharmacokinetic properties of hoodigogenin A from Hoodia gordonii. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19639535/),[cm] / [s],22 x 10(-6),21433,DB00396,Progesterone
,19639535,CL' (int),"The compound was metabolically unstable in human liver microsomes and S9 fractions with a CL' (int) of 71 and 120 mL/min/kg, respectively and was bound to the plasma proteins to an extent of 92 %.",Characterization of in vitro pharmacokinetic properties of hoodigogenin A from Hoodia gordonii. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19639535/),[ml] / [kg·min],71,21434,DB00396,Progesterone
,19639535,CL' (int),"The compound was metabolically unstable in human liver microsomes and S9 fractions with a CL' (int) of 71 and 120 mL/min/kg, respectively and was bound to the plasma proteins to an extent of 92 %.",Characterization of in vitro pharmacokinetic properties of hoodigogenin A from Hoodia gordonii. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19639535/),[ml] / [kg·min],120,21435,DB00396,Progesterone
,19639535,IC(50),"The compound strongly inhibited CYP3A4 activity (IC(50) 3 microM), indicating a possibility of drug-herb/botanical interactions when products containing H. gordonii are used simultaneously with other botanicals/herbs/drugs.",Characterization of in vitro pharmacokinetic properties of hoodigogenin A from Hoodia gordonii. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19639535/),μM,3,21436,DB00396,Progesterone
,24102384,t1/2.,"However, geometric mean t1/2.doubled from 24 h to 48 h.",Effects of erythromycin at steady-state concentrations on the pharmacokinetics of ulipristal acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102384/),h,24,21660,DB00396,Progesterone
,24102384,t1/2.,"However, geometric mean t1/2.doubled from 24 h to 48 h.",Effects of erythromycin at steady-state concentrations on the pharmacokinetics of ulipristal acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102384/),h,48,21661,DB00396,Progesterone
,17362705,elimination phase half-life,The elimination phase half-life was 18+/-5.1 h (mean+/-SD).,"Changes in vaginal morphology, steroid receptor and natural antimicrobial content following treatment with low-dose mifepristone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17362705/),h,18,23858,DB00396,Progesterone
,17362705,Cmax,"Mean Cmax measured at 1 h was 641.7 nmol/L (range, 502-740 nmol/L).","Changes in vaginal morphology, steroid receptor and natural antimicrobial content following treatment with low-dose mifepristone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17362705/),[nM] / [l],641.7,23859,DB00396,Progesterone
,12228205,area under the concentration-time curve (AUC),"One hundred patients with ABC received paclitaxel 135 mg/m(2) (group 1, n = 20) and carboplatin area under the concentration-time curve (AUC) of 2.",Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12228205/),,2,25349,DB00396,Progesterone
,12228205,overall response rate (ORR),"The overall response rate (ORR) among 95 assessable patients was 62%, including 8% complete responses and 54% partial responses.",Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12228205/),%,62,25350,DB00396,Progesterone
,12228205,time to response,"The median time to response was 1.8 months, and the median duration of response was 13.3 months.",Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12228205/),month,1.8,25351,DB00396,Progesterone
,12228205,duration of response,"The median time to response was 1.8 months, and the median duration of response was 13.3 months.",Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12228205/),month,13.3,25352,DB00396,Progesterone
,12228205,time to progression,The median time to progression was 4.8 months.,Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12228205/),month,4.8,25353,DB00396,Progesterone
,1729704,metabolic clearance rates,"Particularly striking were differences in the metabolic clearance rates for native bLH and bLH/CHO, 7.3% per min and 1.7% per min, respectively.",Circulatory half-life but not interaction with the lutropin/chorionic gonadotropin receptor is modulated by sulfation of bovine lutropin oligosaccharides. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1729704/),,7.3,25400,DB00396,Progesterone
,1729704,metabolic clearance rates,"Particularly striking were differences in the metabolic clearance rates for native bLH and bLH/CHO, 7.3% per min and 1.7% per min, respectively.",Circulatory half-life but not interaction with the lutropin/chorionic gonadotropin receptor is modulated by sulfation of bovine lutropin oligosaccharides. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1729704/),,1.7,25401,DB00396,Progesterone
,8284493,MCR,"The mean (SE) MCR of infused progesterone in ovariectomised ewes fed either 1/2M, M or 2M rations for seven days was 7.1 (0.59), 9.9 (1.64 and 13.0 (1.19) litre h-1 kg-1 of liveweight, respectively.",Feed intake affects metabolic clearance rate of progesterone in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8284493/),[l] / [h·kg],7.1,26537,DB00396,Progesterone
,8284493,MCR,"The mean (SE) MCR of infused progesterone in ovariectomised ewes fed either 1/2M, M or 2M rations for seven days was 7.1 (0.59), 9.9 (1.64 and 13.0 (1.19) litre h-1 kg-1 of liveweight, respectively.",Feed intake affects metabolic clearance rate of progesterone in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8284493/),[l] / [h·kg],9.9,26538,DB00396,Progesterone
,8284493,MCR,"The mean (SE) MCR of infused progesterone in ovariectomised ewes fed either 1/2M, M or 2M rations for seven days was 7.1 (0.59), 9.9 (1.64 and 13.0 (1.19) litre h-1 kg-1 of liveweight, respectively.",Feed intake affects metabolic clearance rate of progesterone in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8284493/),[l] / [h·kg],13.0,26539,DB00396,Progesterone
,30694918,E,"In REPLENISH (n = 1,835), mean P4 levels were 0.39 to 0.55 ng/mL with 100-mg P4 doses; E2 levels were 42.3 to 45.6 pg/mL and 23.0 to 27.4 pg/mL for the 1-mg and 0.5-mg E2 doses, respectively; E1 levels were 214 to 242 pg/mL and 114 to 129 pg/mL for the 1-mg and 0.5-mg E2 doses.",Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30694918/),[pg] / [ml],42.3 to 45.6,26826,DB00396,Progesterone
,30694918,E1,"In REPLENISH (n = 1,835), mean P4 levels were 0.39 to 0.55 ng/mL with 100-mg P4 doses; E2 levels were 42.3 to 45.6 pg/mL and 23.0 to 27.4 pg/mL for the 1-mg and 0.5-mg E2 doses, respectively; E1 levels were 214 to 242 pg/mL and 114 to 129 pg/mL for the 1-mg and 0.5-mg E2 doses.",Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30694918/),[pg] / [ml],214 to 242,26827,DB00396,Progesterone
,30694918,E1,"In REPLENISH (n = 1,835), mean P4 levels were 0.39 to 0.55 ng/mL with 100-mg P4 doses; E2 levels were 42.3 to 45.6 pg/mL and 23.0 to 27.4 pg/mL for the 1-mg and 0.5-mg E2 doses, respectively; E1 levels were 214 to 242 pg/mL and 114 to 129 pg/mL for the 1-mg and 0.5-mg E2 doses.",Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30694918/),[pg] / [ml],114 to 129,26828,DB00396,Progesterone
,30694918,Cavg,"In the phase 1 study (n = 40; day 7), mean Cavg for P4 was 0.66 ng/mL with 100-mg P4 doses; E2 was 38.1 pg/mL and 29.2 pg/mL for 1 mg and 0.5 mg E2, respectively; and E1 was 211 and 106 pg/mL for 1 mg and 0.5 mg E2.",Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules). ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30694918/),[ng] / [ml],0.66,26829,DB00396,Progesterone
,30694918,Cavg,"In the phase 1 study (n = 40; day 7), mean Cavg for P4 was 0.66 ng/mL with 100-mg P4 doses; E2 was 38.1 pg/mL and 29.2 pg/mL for 1 mg and 0.5 mg E2, respectively; and E1 was 211 and 106 pg/mL for 1 mg and 0.5 mg E2.",Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules). ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30694918/),[pg] / [ml],38.1,26830,DB00396,Progesterone
,30694918,Cavg,"In the phase 1 study (n = 40; day 7), mean Cavg for P4 was 0.66 ng/mL with 100-mg P4 doses; E2 was 38.1 pg/mL and 29.2 pg/mL for 1 mg and 0.5 mg E2, respectively; and E1 was 211 and 106 pg/mL for 1 mg and 0.5 mg E2.",Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules). ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30694918/),[pg] / [ml],29.2,26831,DB00396,Progesterone
,30694918,Cavg,"In the phase 1 study (n = 40; day 7), mean Cavg for P4 was 0.66 ng/mL with 100-mg P4 doses; E2 was 38.1 pg/mL and 29.2 pg/mL for 1 mg and 0.5 mg E2, respectively; and E1 was 211 and 106 pg/mL for 1 mg and 0.5 mg E2.",Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules). ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30694918/),[pg] / [ml],211,26832,DB00396,Progesterone
,30694918,E2,"In the phase 1 study (n = 40; day 7), mean Cavg for P4 was 0.66 ng/mL with 100-mg P4 doses; E2 was 38.1 pg/mL and 29.2 pg/mL for 1 mg and 0.5 mg E2, respectively; and E1 was 211 and 106 pg/mL for 1 mg and 0.5 mg E2.",Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30694918/),[pg] / [ml],38.1,26833,DB00396,Progesterone
,30694918,E2,"In the phase 1 study (n = 40; day 7), mean Cavg for P4 was 0.66 ng/mL with 100-mg P4 doses; E2 was 38.1 pg/mL and 29.2 pg/mL for 1 mg and 0.5 mg E2, respectively; and E1 was 211 and 106 pg/mL for 1 mg and 0.5 mg E2.",Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30694918/),[pg] / [ml],29.2,26834,DB00396,Progesterone
,30694918,E1,"In the phase 1 study (n = 40; day 7), mean Cavg for P4 was 0.66 ng/mL with 100-mg P4 doses; E2 was 38.1 pg/mL and 29.2 pg/mL for 1 mg and 0.5 mg E2, respectively; and E1 was 211 and 106 pg/mL for 1 mg and 0.5 mg E2.",Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30694918/),[pg] / [ml],211,26835,DB00396,Progesterone
,30694918,E1,"In the phase 1 study (n = 40; day 7), mean Cavg for P4 was 0.66 ng/mL with 100-mg P4 doses; E2 was 38.1 pg/mL and 29.2 pg/mL for 1 mg and 0.5 mg E2, respectively; and E1 was 211 and 106 pg/mL for 1 mg and 0.5 mg E2.",Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30694918/),[pg] / [ml],106,26836,DB00396,Progesterone
,30694918,accumulation ratios,All three analytes reached steady state within 7 days; accumulation ratios were 1.36 to 1.94.,Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30694918/),,1.36 to 1.94,26837,DB00396,Progesterone
,7370683,Maximal plasma concentrations,"Maximal plasma concentrations of progesterone were observed within four hours after ingestion of the last dose, when the range (22.11-34.18 nmol/l; 696-1077 ng/100 ml) was comparable with that observed during the mid-luteal phase of the ovarian cycle.",Absorption and metabolism of oral progesterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370683/),[nM] / [l],22.11-34.18,28625,DB00396,Progesterone
,7370683,Maximal plasma concentrations,"Maximal plasma concentrations of progesterone were observed within four hours after ingestion of the last dose, when the range (22.11-34.18 nmol/l; 696-1077 ng/100 ml) was comparable with that observed during the mid-luteal phase of the ovarian cycle.",Absorption and metabolism of oral progesterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370683/),[ng] / [100·ml],696-1077,28626,DB00396,Progesterone
,7370683,peak values,"Of the three metabolites studied, the plasma concentrations of pregnanediol-3 alpha-glucuronide were most raised by treatment, the peak values ranging from 1097 nmol/l (54.9 microgram/100 ml) to over 2000 nmol/l (100 microgram/100 ml), which was the upper limit of the assay used.",Absorption and metabolism of oral progesterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370683/),[nM] / [l],1097,28627,DB00396,Progesterone
,7370683,peak values,"Of the three metabolites studied, the plasma concentrations of pregnanediol-3 alpha-glucuronide were most raised by treatment, the peak values ranging from 1097 nmol/l (54.9 microgram/100 ml) to over 2000 nmol/l (100 microgram/100 ml), which was the upper limit of the assay used.",Absorption and metabolism of oral progesterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370683/),,54,28628,DB00396,Progesterone
over,7370683,peak values,"Of the three metabolites studied, the plasma concentrations of pregnanediol-3 alpha-glucuronide were most raised by treatment, the peak values ranging from 1097 nmol/l (54.9 microgram/100 ml) to over 2000 nmol/l (100 microgram/100 ml), which was the upper limit of the assay used.",Absorption and metabolism of oral progesterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370683/),[nM] / [l],2000,28629,DB00396,Progesterone
,7370683,peak values,"Concentrations of 17-hydroxyprogesterone were least raised, and the peak values ranged from 4.32 to 9.68 nmol/l (143-319 ng/100 ml).",Absorption and metabolism of oral progesterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370683/),[nM] / [l],4.32 to 9.68,28630,DB00396,Progesterone
,7370683,peak values,"Concentrations of 17-hydroxyprogesterone were least raised, and the peak values ranged from 4.32 to 9.68 nmol/l (143-319 ng/100 ml).",Absorption and metabolism of oral progesterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370683/),[ng] / [100·ml],143-319,28631,DB00396,Progesterone
,7370683,maximal,"The plasma profile of 20 alpha-dihydroprogesterone most closely approximated that of progesterone, although the range of maximal values was lower (7.11-16.06 nmol/l; 228-514 ng/100 ml).",Absorption and metabolism of oral progesterone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370683/),[nM] / [l],7.11-16.06,28632,DB00396,Progesterone
,7370683,maximal,"The plasma profile of 20 alpha-dihydroprogesterone most closely approximated that of progesterone, although the range of maximal values was lower (7.11-16.06 nmol/l; 228-514 ng/100 ml).",Absorption and metabolism of oral progesterone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370683/),[ng] / [100·ml],228-514,28633,DB00396,Progesterone
,10453729,peak plasma levels,High-dose progesterone increased the peak plasma levels (3.00 +/- 0.94 vs. 4.15 +/- 1.63 microM; P = 0.029; mean +/- SD) and the area under the curve (AUC; 14.3 +/- 4.75 vs. 17.3 +/- 5.59 microM x h; P = 0.006) of paclitaxel.,A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10453729/),μM,3.00,29077,DB00396,Progesterone
,10453729,peak plasma levels,High-dose progesterone increased the peak plasma levels (3.00 +/- 0.94 vs. 4.15 +/- 1.63 microM; P = 0.029; mean +/- SD) and the area under the curve (AUC; 14.3 +/- 4.75 vs. 17.3 +/- 5.59 microM x h; P = 0.006) of paclitaxel.,A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10453729/),μM,4.15,29078,DB00396,Progesterone
,10453729,area under the curve (AUC,High-dose progesterone increased the peak plasma levels (3.00 +/- 0.94 vs. 4.15 +/- 1.63 microM; P = 0.029; mean +/- SD) and the area under the curve (AUC; 14.3 +/- 4.75 vs. 17.3 +/- 5.59 microM x h; P = 0.006) of paclitaxel.,A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10453729/),h·μM,14.3,29079,DB00396,Progesterone
,10453729,area under the curve (AUC,High-dose progesterone increased the peak plasma levels (3.00 +/- 0.94 vs. 4.15 +/- 1.63 microM; P = 0.029; mean +/- SD) and the area under the curve (AUC; 14.3 +/- 4.75 vs. 17.3 +/- 5.59 microM x h; P = 0.006) of paclitaxel.,A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10453729/),h·μM,17.3,29080,DB00396,Progesterone
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],18,30139,DB00396,Progesterone
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],36,30140,DB00396,Progesterone
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],70,30141,DB00396,Progesterone
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],17,30142,DB00396,Progesterone
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],30,30143,DB00396,Progesterone
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],84,30144,DB00396,Progesterone
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],66,30145,DB00396,Progesterone
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],71,30146,DB00396,Progesterone
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],60,30147,DB00396,Progesterone
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],69,30148,DB00396,Progesterone
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],78,30149,DB00396,Progesterone
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],73,30150,DB00396,Progesterone
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,7.6,30151,DB00396,Progesterone
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,8.2,30152,DB00396,Progesterone
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,8.8,30153,DB00396,Progesterone
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,9.8,30154,DB00396,Progesterone
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,10,30155,DB00396,Progesterone
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,9.5,30156,DB00396,Progesterone
,10443692,t 1/2,"Regression analysis disclosed no relationship between serum estradiol concentrations and peak serum GH levels, GH t 1/2, or Vo. GH t 1/2 values were also invariant of menstrual cycle stage, e.g. t 1/2 values of 8.1+/-0.5, 9.1+/-1.0, and 8.1+/-0.4 min for the early follicular, late follicular, and midluteal phases, respectively.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,8.1,30157,DB00396,Progesterone
,10443692,t 1/2,"Regression analysis disclosed no relationship between serum estradiol concentrations and peak serum GH levels, GH t 1/2, or Vo. GH t 1/2 values were also invariant of menstrual cycle stage, e.g. t 1/2 values of 8.1+/-0.5, 9.1+/-1.0, and 8.1+/-0.4 min for the early follicular, late follicular, and midluteal phases, respectively.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,9.1,30158,DB00396,Progesterone
,10443692,t 1/2,"Regression analysis disclosed no relationship between serum estradiol concentrations and peak serum GH levels, GH t 1/2, or Vo. GH t 1/2 values were also invariant of menstrual cycle stage, e.g. t 1/2 values of 8.1+/-0.5, 9.1+/-1.0, and 8.1+/-0.4 min for the early follicular, late follicular, and midluteal phases, respectively.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,8.1,30159,DB00396,Progesterone
,10443692,normalized MCRs,"Corresponding normalized MCRs were 319+/-39 (early follicular), 340+/-48 (late follicular), and 340+/-71 (midluteal) L/m2 x day in women and 336+/-50 L/m2 x day in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[l] / [d·m2],319,30160,DB00396,Progesterone
,10443692,normalized MCRs,"Corresponding normalized MCRs were 319+/-39 (early follicular), 340+/-48 (late follicular), and 340+/-71 (midluteal) L/m2 x day in women and 336+/-50 L/m2 x day in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[l] / [d·m2],340,30161,DB00396,Progesterone
,10443692,normalized MCRs,"Corresponding normalized MCRs were 319+/-39 (early follicular), 340+/-48 (late follicular), and 340+/-71 (midluteal) L/m2 x day in women and 336+/-50 L/m2 x day in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[l] / [d·m2],340,30162,DB00396,Progesterone
,10443692,normalized MCRs,"Corresponding normalized MCRs were 319+/-39 (early follicular), 340+/-48 (late follicular), and 340+/-71 (midluteal) L/m2 x day in women and 336+/-50 L/m2 x day in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[l] / [d·m2],336,30163,DB00396,Progesterone
,10443692,t 1/2,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,9,30164,DB00396,Progesterone
,10443692,t 1/2,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,12,30165,DB00396,Progesterone
,10443692,t 1/2,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,15,30166,DB00396,Progesterone
,10443692,steady state serum GH concentrations,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],0.5,30167,DB00396,Progesterone
,10443692,steady state serum GH concentrations,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],2.1,30168,DB00396,Progesterone
,10443692,steady state serum GH concentrations,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],7.5,30169,DB00396,Progesterone
,10443692,t 1/2,"In a third analysis in the same volunteers, stopping the constant iv infusions revealed t 1/2 values of GH decay from equilibrium of 26+/-5 and 23+/-2.3 min for the two higher GH infusion rates.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,26,30170,DB00396,Progesterone
,10443692,t 1/2,"In a third analysis in the same volunteers, stopping the constant iv infusions revealed t 1/2 values of GH decay from equilibrium of 26+/-5 and 23+/-2.3 min for the two higher GH infusion rates.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,23,30171,DB00396,Progesterone
,10443692,t 1/2,"In a fourth paradigm, endogenous GH t 1/2 values, as assessed in the same individuals by deconvolution analysis of overnight (10-min sampled) serum GH concentration profiles, averaged 18+/-1.3 min.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,18,30172,DB00396,Progesterone
,10443692,t 1/2,"In summary, the foregoing clinical experiments in healthy men and women indicate that 1) the nonequilibrium GH t 1/2, (body surface area-normalized) Vo, and MCR are independent of GH dose, sex, menstrual cycle stage, and serum estradiol concentrations; 2) the GH t 1/2 calculated after iv bolus injection is significantly (50%) shorter than that assessed during or after steady-state GH infusions or endogenously (overnight) by deconvolution analysis; and 3) the descending rank order of GH t 1/2 values in healthy volunteers is approximately: decay from steady state (23+/-2.3 min) > endogenously secreted GH (18+/-1.3 min) > during equilibrium infusion (15+/-1 min) > after bolus infusion (9.8+/-0.8 min).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,23,30173,DB00396,Progesterone
,10443692,t 1/2,"In summary, the foregoing clinical experiments in healthy men and women indicate that 1) the nonequilibrium GH t 1/2, (body surface area-normalized) Vo, and MCR are independent of GH dose, sex, menstrual cycle stage, and serum estradiol concentrations; 2) the GH t 1/2 calculated after iv bolus injection is significantly (50%) shorter than that assessed during or after steady-state GH infusions or endogenously (overnight) by deconvolution analysis; and 3) the descending rank order of GH t 1/2 values in healthy volunteers is approximately: decay from steady state (23+/-2.3 min) > endogenously secreted GH (18+/-1.3 min) > during equilibrium infusion (15+/-1 min) > after bolus infusion (9.8+/-0.8 min).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,18,30174,DB00396,Progesterone
,10443692,t 1/2,"In summary, the foregoing clinical experiments in healthy men and women indicate that 1) the nonequilibrium GH t 1/2, (body surface area-normalized) Vo, and MCR are independent of GH dose, sex, menstrual cycle stage, and serum estradiol concentrations; 2) the GH t 1/2 calculated after iv bolus injection is significantly (50%) shorter than that assessed during or after steady-state GH infusions or endogenously (overnight) by deconvolution analysis; and 3) the descending rank order of GH t 1/2 values in healthy volunteers is approximately: decay from steady state (23+/-2.3 min) > endogenously secreted GH (18+/-1.3 min) > during equilibrium infusion (15+/-1 min) > after bolus infusion (9.8+/-0.8 min).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,15,30175,DB00396,Progesterone
,10443692,t 1/2,"In summary, the foregoing clinical experiments in healthy men and women indicate that 1) the nonequilibrium GH t 1/2, (body surface area-normalized) Vo, and MCR are independent of GH dose, sex, menstrual cycle stage, and serum estradiol concentrations; 2) the GH t 1/2 calculated after iv bolus injection is significantly (50%) shorter than that assessed during or after steady-state GH infusions or endogenously (overnight) by deconvolution analysis; and 3) the descending rank order of GH t 1/2 values in healthy volunteers is approximately: decay from steady state (23+/-2.3 min) > endogenously secreted GH (18+/-1.3 min) > during equilibrium infusion (15+/-1 min) > after bolus infusion (9.8+/-0.8 min).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,9.8,30176,DB00396,Progesterone
,25168884,CL,"The average CL and [Formula: see text] were 5.58 L/(h·kg) and 10.8 h, respectively.","Pharmacokinetics, tissue distribution, and excretion of nomegestrol acetate in female rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25168884/),[l] / [h·kg],5.58,34516,DB00396,Progesterone
,25168884,[Formula: see text],"The average CL and [Formula: see text] were 5.58 L/(h·kg) and 10.8 h, respectively.","Pharmacokinetics, tissue distribution, and excretion of nomegestrol acetate in female rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25168884/),h,10.8,34517,DB00396,Progesterone
,25168884,total cumulative excretion,"The total cumulative excretion of NOMAC in feces (0-72 h), urine (0-72 h), and bile (0-48 h) was ~1.06, 0.03, and 0.08 % of the oral administered dose, respectively.","Pharmacokinetics, tissue distribution, and excretion of nomegestrol acetate in female rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25168884/),%,1.06,34518,DB00396,Progesterone
,25168884,total cumulative excretion,"The total cumulative excretion of NOMAC in feces (0-72 h), urine (0-72 h), and bile (0-48 h) was ~1.06, 0.03, and 0.08 % of the oral administered dose, respectively.","Pharmacokinetics, tissue distribution, and excretion of nomegestrol acetate in female rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25168884/),%,0.03,34519,DB00396,Progesterone
,25168884,total cumulative excretion,"The total cumulative excretion of NOMAC in feces (0-72 h), urine (0-72 h), and bile (0-48 h) was ~1.06, 0.03, and 0.08 % of the oral administered dose, respectively.","Pharmacokinetics, tissue distribution, and excretion of nomegestrol acetate in female rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25168884/),%,0.08,34520,DB00396,Progesterone
,12008748,peak,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [ml],13.76,36625,DB00396,Progesterone
,12008748,peak,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [ml],4.77,36626,DB00396,Progesterone
,12008748,area under the curve,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [h·ml],190,36627,DB00396,Progesterone
,12008748,area under the curve,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [h·ml],96.75,36628,DB00396,Progesterone
,8023681,elimination half-life,The elimination half-life ranged between 80-90 hours.,[Pharmacokinetics of RU 486 and its active metabolites in humans]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8023681/),h,80-90,36745,DB00396,Progesterone
,31194965,AUClast,"LNG AUClast increased by 32.6% (312±60.9 vs. 243±82.6 ng/mL*h, p=.033, n=5) in women taking ritonavir compared to the control group (n=10).",Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [h·ml],312,38024,DB00396,Progesterone
,31194965,AUClast,"LNG AUClast increased by 32.6% (312±60.9 vs. 243±82.6 ng/mL*h, p=.033, n=5) in women taking ritonavir compared to the control group (n=10).",Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [h·ml],243,38025,DB00396,Progesterone
,31194965,Cmax,The Cmax (9.68±1.81 vs. 7.62±2.29 ng/mL) and Cmin (4.97±1.15 vs. 3.70±1.29 ng/mL) were also higher in the ritonavir arm.,Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [ml],9.68,38026,DB00396,Progesterone
,31194965,Cmax,The Cmax (9.68±1.81 vs. 7.62±2.29 ng/mL) and Cmin (4.97±1.15 vs. 3.70±1.29 ng/mL) were also higher in the ritonavir arm.,Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [ml],7.62,38027,DB00396,Progesterone
,31194965,Cmin,The Cmax (9.68±1.81 vs. 7.62±2.29 ng/mL) and Cmin (4.97±1.15 vs. 3.70±1.29 ng/mL) were also higher in the ritonavir arm.,Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [ml],4.97,38028,DB00396,Progesterone
,31194965,Cmin,The Cmax (9.68±1.81 vs. 7.62±2.29 ng/mL) and Cmin (4.97±1.15 vs. 3.70±1.29 ng/mL) were also higher in the ritonavir arm.,Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [ml],3.70,38029,DB00396,Progesterone
,15244497,area under the plasma concentration-time curve from zero to 24 hours (AUC24),"In Study I (tazarotene 1.1 mg), the area under the plasma concentration-time curve from zero to 24 hours (AUC24) and the peak concentration in plasma (Cmax) for tazarotenic acid were 121 +/- 27 microg.",Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244497/),μg,121,38951,DB00396,Progesterone
,15244497,AUC24,"In Study II (tazarotene 6 mg), AUC24 and Cmax for tazarotenic acid were 379 +/- 78 microg.",Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244497/),μg,379,38952,DB00396,Progesterone
,33021044,Cmax ratios,The rate of absorption was slightly decreased when the drug was taken after a meal as indicated by approximately 10% lower mean maximum concentrations (Cmax ) of vilaprisan in plasma (Cmax ratios: high-fat and -calorie meal/fasting 87.9 [75.6-102]; moderate-fat and -calorie meal/fasting 89.4 [76.9-104]) and a prolonged time to Cmax (fasting: 1.5 hours; fed conditions; ∼4 hours).,Effect of Food Intake on the Pharmacokinetics of the Selective Progesterone Receptor Modulator Vilaprisan: A Randomized Clinical Study in Healthy Postmenopausal Women. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33021044/),,87.9,38971,DB00396,Progesterone
,33021044,Cmax ratios,The rate of absorption was slightly decreased when the drug was taken after a meal as indicated by approximately 10% lower mean maximum concentrations (Cmax ) of vilaprisan in plasma (Cmax ratios: high-fat and -calorie meal/fasting 87.9 [75.6-102]; moderate-fat and -calorie meal/fasting 89.4 [76.9-104]) and a prolonged time to Cmax (fasting: 1.5 hours; fed conditions; ∼4 hours).,Effect of Food Intake on the Pharmacokinetics of the Selective Progesterone Receptor Modulator Vilaprisan: A Randomized Clinical Study in Healthy Postmenopausal Women. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33021044/),,89.4,38972,DB00396,Progesterone
,33021044,time to Cmax,The rate of absorption was slightly decreased when the drug was taken after a meal as indicated by approximately 10% lower mean maximum concentrations (Cmax ) of vilaprisan in plasma (Cmax ratios: high-fat and -calorie meal/fasting 87.9 [75.6-102]; moderate-fat and -calorie meal/fasting 89.4 [76.9-104]) and a prolonged time to Cmax (fasting: 1.5 hours; fed conditions; ∼4 hours).,Effect of Food Intake on the Pharmacokinetics of the Selective Progesterone Receptor Modulator Vilaprisan: A Randomized Clinical Study in Healthy Postmenopausal Women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33021044/),h,1.5,38973,DB00396,Progesterone
,33021044,time to Cmax,The rate of absorption was slightly decreased when the drug was taken after a meal as indicated by approximately 10% lower mean maximum concentrations (Cmax ) of vilaprisan in plasma (Cmax ratios: high-fat and -calorie meal/fasting 87.9 [75.6-102]; moderate-fat and -calorie meal/fasting 89.4 [76.9-104]) and a prolonged time to Cmax (fasting: 1.5 hours; fed conditions; ∼4 hours).,Effect of Food Intake on the Pharmacokinetics of the Selective Progesterone Receptor Modulator Vilaprisan: A Randomized Clinical Study in Healthy Postmenopausal Women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33021044/),h,∼4,38974,DB00396,Progesterone
,8213223,Maximum mean concentrations,"Maximum mean concentrations of salivary progesterone of 827.2 and 888 pmol/l in the 1st and 6th months of therapy, respectively, were achieved within 2 h of administration and were above the 95th percentile of a control corridor which corresponds to the range found in the luteal phase.",Assessment of bioavailability of oral micronized progesterone using a salivary progesterone enzymeimmunoassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8213223/),[pM] / [l],827.2,39605,DB00396,Progesterone
,8213223,Maximum mean concentrations,"Maximum mean concentrations of salivary progesterone of 827.2 and 888 pmol/l in the 1st and 6th months of therapy, respectively, were achieved within 2 h of administration and were above the 95th percentile of a control corridor which corresponds to the range found in the luteal phase.",Assessment of bioavailability of oral micronized progesterone using a salivary progesterone enzymeimmunoassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8213223/),[pM] / [l],888,39606,DB00396,Progesterone
,8213223,areas under the salivary progesterone curve (AUC0-24 h,"The areas under the salivary progesterone curve (AUC0-24 h, pmol/l) were 7177.75 and 7388.20 respectively, in the 1st and 6th months of therapy but the difference was not statistically significant.",Assessment of bioavailability of oral micronized progesterone using a salivary progesterone enzymeimmunoassay. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8213223/),[pM] / [l],7177.75,39607,DB00396,Progesterone
,8213223,areas under the salivary progesterone curve (AUC0-24 h,"The areas under the salivary progesterone curve (AUC0-24 h, pmol/l) were 7177.75 and 7388.20 respectively, in the 1st and 6th months of therapy but the difference was not statistically significant.",Assessment of bioavailability of oral micronized progesterone using a salivary progesterone enzymeimmunoassay. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8213223/),[pM] / [l],7388.20,39608,DB00396,Progesterone
,27841155,Terminal half-lives,Terminal half-lives ranged from 31 to 38 hours.,Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women . ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27841155/),h,31 to 38,40916,DB00396,Progesterone
,27841155,Maximum concentrations of vilaprisan (Cmax),"Maximum concentrations of vilaprisan (Cmax) and exposure to vilaprisan (AUC) increased roughly dose-proportionally from 3.74 µg/L (1 mg) to 68.6 µg/L (30 mg) and 58.5 µg×h/L to 1,590 µg×h/L, respectively.",Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27841155/),[μg] / [l],3.74,40917,DB00396,Progesterone
,27841155,Maximum concentrations of vilaprisan (Cmax),"Maximum concentrations of vilaprisan (Cmax) and exposure to vilaprisan (AUC) increased roughly dose-proportionally from 3.74 µg/L (1 mg) to 68.6 µg/L (30 mg) and 58.5 µg×h/L to 1,590 µg×h/L, respectively.",Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27841155/),[μg] / [l],68.6,40918,DB00396,Progesterone
,27841155,exposure to vilaprisan (AUC),"Maximum concentrations of vilaprisan (Cmax) and exposure to vilaprisan (AUC) increased roughly dose-proportionally from 3.74 µg/L (1 mg) to 68.6 µg/L (30 mg) and 58.5 µg×h/L to 1,590 µg×h/L, respectively.",Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27841155/),[μg] / [l],68.6,40919,DB00396,Progesterone
,27841155,exposure to vilaprisan (AUC),"Maximum concentrations of vilaprisan (Cmax) and exposure to vilaprisan (AUC) increased roughly dose-proportionally from 3.74 µg/L (1 mg) to 68.6 µg/L (30 mg) and 58.5 µg×h/L to 1,590 µg×h/L, respectively.",Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27841155/),[h·μg] / [l],58.5,40920,DB00396,Progesterone
,27841155,exposure to vilaprisan (AUC),"Maximum concentrations of vilaprisan (Cmax) and exposure to vilaprisan (AUC) increased roughly dose-proportionally from 3.74 µg/L (1 mg) to 68.6 µg/L (30 mg) and 58.5 µg×h/L to 1,590 µg×h/L, respectively.",Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27841155/),[h·μg] / [l],"1,590",40921,DB00396,Progesterone
,27841155,AUC(0-24)md/AUC(0-24),"With daily dosing, accumulation consistent with the long terminal half-life was observed (AUC(0-24)md/AUC(0-24)sd ratios: 1.9 to 3.2).",Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27841155/),,1.9 to 3.2,40922,DB00396,Progesterone
,29313260,zeta potentials,"The results showed that the mean particle size and the zeta potentials of NCs were 299.5 ± 9.0 nm and - 36.8 ± 1.5 mV, respectively.",Preparation and Evaluation of Progesterone Nanocrystals to Decrease Muscle Irritation and Improve Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29313260/),mv,-,42410,DB00396,Progesterone
,29313260,zeta potentials,"The results showed that the mean particle size and the zeta potentials of NCs were 299.5 ± 9.0 nm and - 36.8 ± 1.5 mV, respectively.",Preparation and Evaluation of Progesterone Nanocrystals to Decrease Muscle Irritation and Improve Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29313260/),mv,36.8,42411,DB00396,Progesterone
smaller,31817711,polydispersity index,"All formulations showed a mean diameter ranging from 200 nm to 236 nm, a polydispersity index smaller than 0.23, and a high progesterone encapsulation efficiency (83-95%).",Trimethyl Chitosan Hydrogel Nanoparticles for Progesterone Delivery in Neurodegenerative Disorders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31817711/),,0.23,42473,DB00396,Progesterone
,31817711,encap,"All formulations showed a mean diameter ranging from 200 nm to 236 nm, a polydispersity index smaller than 0.23, and a high progesterone encapsulation efficiency (83-95%).",Trimethyl Chitosan Hydrogel Nanoparticles for Progesterone Delivery in Neurodegenerative Disorders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31817711/),%,83-95,42474,DB00396,Progesterone
greater,31817711,z,"The zeta potential values were all positive and greater than 28 mV, thus ensuring nanoparticles stability against aggregation phenomena as well as interaction with negative sialic residues of the nasal mucosa.",Trimethyl Chitosan Hydrogel Nanoparticles for Progesterone Delivery in Neurodegenerative Disorders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31817711/),mv,28,42475,DB00396,Progesterone
,3133158,Half-lives,Half-lives varied from 5.6 to 25.1 hours.,Pharmacokinetic study of levonorgestrel used as a postcoital agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3133158/),h,5.6 to 25.1,45907,DB00396,Progesterone
,8804805,elimination half-life,"The distribution was also rapid, but the elimination was slow, the elimination half-life ranging between 83 and 90 hours.",Determination of RU486 (mifepristone) in blood by radioreceptorassay; a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8804805/),h,83 and 90,46642,DB00396,Progesterone
,1501071,bioavailability,"The bioavailability of aspirin following nasal administration was 100%, whereas the oral bioavailability was only 58.8% at the dose studied.",Absorption of acetylsalicylic acid from the rat nasal cavity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501071/),%,100,47766,DB00396,Progesterone
,1501071,oral bioavailability,"The bioavailability of aspirin following nasal administration was 100%, whereas the oral bioavailability was only 58.8% at the dose studied.",Absorption of acetylsalicylic acid from the rat nasal cavity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501071/),%,58.8,47767,DB00396,Progesterone
,6820337,removal half-life (first compartment),The removal half-life (first compartment) after 90 days of exposure in 19 subjects was 16.1 (13.7-18.6) hours.,"Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6820337/),h,16.1,51038,DB00396,Progesterone
,10335907,elimination half-life,"Mean pregnanolone elimination half-life varied between 28.4 min and 31.8 min and clearance between 59.6 ml x min(-1) x kg(-1) and 64.0 ml x min(-1) x kg(-1), depending on diagnostic group and cycle phase.",Lack of influence of menstrual cycle and premenstrual syndrome diagnosis on pregnanolone pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335907/),min,28.4,53078,DB00396,Progesterone
,10335907,elimination half-life,"Mean pregnanolone elimination half-life varied between 28.4 min and 31.8 min and clearance between 59.6 ml x min(-1) x kg(-1) and 64.0 ml x min(-1) x kg(-1), depending on diagnostic group and cycle phase.",Lack of influence of menstrual cycle and premenstrual syndrome diagnosis on pregnanolone pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335907/),min,31.8,53079,DB00396,Progesterone
,10335907,clearance,"Mean pregnanolone elimination half-life varied between 28.4 min and 31.8 min and clearance between 59.6 ml x min(-1) x kg(-1) and 64.0 ml x min(-1) x kg(-1), depending on diagnostic group and cycle phase.",Lack of influence of menstrual cycle and premenstrual syndrome diagnosis on pregnanolone pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335907/),[ml] / [kg·min],59.6,53080,DB00396,Progesterone
,10335907,clearance,"Mean pregnanolone elimination half-life varied between 28.4 min and 31.8 min and clearance between 59.6 ml x min(-1) x kg(-1) and 64.0 ml x min(-1) x kg(-1), depending on diagnostic group and cycle phase.",Lack of influence of menstrual cycle and premenstrual syndrome diagnosis on pregnanolone pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335907/),[ml] / [kg·min],64.0,53081,DB00396,Progesterone
,7205126,metabolic clearance rate,The metabolic clearance rate of progesterone was 0.116 l/min and the turn-over time was 0.006 min/ml plasma.,Fate of progesterone in the plasma and various tissues of anaesthetized rabbits. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205126/),[l] / [min],0.116,55003,DB00396,Progesterone
,7205126,turn-over time,The metabolic clearance rate of progesterone was 0.116 l/min and the turn-over time was 0.006 min/ml plasma.,Fate of progesterone in the plasma and various tissues of anaesthetized rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205126/),[min] / [ml·plasma],0.006,55004,DB00396,Progesterone
,12443967,Peak concentrations,Peak concentrations 1 week after the fourth injection were 31 +/- 2 nmol/liter.,Investigation of a novel preparation of testosterone decanoate in men: pharmacokinetics and spermatogenic suppression with etonogestrel implants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12443967/),[nM] / [l],31,57102,DB00396,Progesterone
,3705204,half-life,The pharmacokinetic investigations showed that androgen half-life in the organism decreased from 8 to 5 h under physical exercises.,[The steroid hormone levels and receptors of steroid hormone receptors in rat muscles during physical exertion]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705204/),h,8,58373,DB00396,Progesterone
,3705204,half-life,The pharmacokinetic investigations showed that androgen half-life in the organism decreased from 8 to 5 h under physical exercises.,[The steroid hormone levels and receptors of steroid hormone receptors in rat muscles during physical exertion]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705204/),h,5,58374,DB00396,Progesterone
,3705204,Kd,"Kd is 0.40 +/- 0.03 and 0.48 +/- 0.08 nM, respectively.",[The steroid hormone levels and receptors of steroid hormone receptors in rat muscles during physical exertion]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705204/),nM,0.40,58375,DB00396,Progesterone
,3705204,Kd,"Kd is 0.40 +/- 0.03 and 0.48 +/- 0.08 nM, respectively.",[The steroid hormone levels and receptors of steroid hormone receptors in rat muscles during physical exertion]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705204/),nM,0.48,58376,DB00396,Progesterone
,21620357,apparent half-life,The apparent half-life of 17-OHPC was 10 days.,Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21620357/),d,10,59455,DB00396,Progesterone
,24606090,Time to Cmax,Time to Cmax was 7.3 hours after PIO and 3.3 to 5.9 hours after PVI.,Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24606090/),h,7.3,60093,DB00396,Progesterone
,24606090,Time to Cmax,Time to Cmax was 7.3 hours after PIO and 3.3 to 5.9 hours after PVI.,Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24606090/),h,3.3 to 5.9,60094,DB00396,Progesterone
,9250420,half-life,"The pharmacokinetics of mifepristone are characterised by rapid absorption, a long half-life of 25 to 30 hours and micromolar serum concentrations following ingestion of doses currently in clinical use.",Clinical pharmacokinetics of mifepristone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9250420/),h,25 to 30,61689,DB00396,Progesterone
,9250420,metabolic clearance rate,"Binding to AAG limits the tissue availability of mifepristone, explaining the low metabolic clearance rate of 0.55 L/kg/day and the low volume of distribution of mifepristone.",Clinical pharmacokinetics of mifepristone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9250420/),[l] / [d·kg],0.55,61690,DB00396,Progesterone
,30947128,run time,The run time was 6 min and the calibration curve was linear over the range of 0.005-0.15 ng/mL.,Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947128/),min,6,62065,DB00396,Progesterone
,30947128,maximum plasma concentration (Cmax),The estradiol cypionate maximum plasma concentration (Cmax) was 0.14 ± 0.08 ng/mL reached at 16.83 ± 21.07 h and the area under the plasma concentration versus time curve (AUC0-last) was 14.07 ± 6.32 ng.h/mL.,Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947128/),[ng] / [ml],0.14,62066,DB00396,Progesterone
,30947128,area under the plasma concentration versus time curve (AUC0-last),The estradiol cypionate maximum plasma concentration (Cmax) was 0.14 ± 0.08 ng/mL reached at 16.83 ± 21.07 h and the area under the plasma concentration versus time curve (AUC0-last) was 14.07 ± 6.32 ng.h/mL.,Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947128/),[h·ng] / [ml],14.07,62067,DB00396,Progesterone
,30947128,Elimination half-life (t½),"Elimination half-life (t½), apparent volume of distribution (Vd/F), apparent clearance (CL/F) and mean residence time (MRT) were 89.65 ± 76.04 h, 28038 ± 9636 L, 49.02 ± 10.62 L/h and 576.05 ± 238.32 h, respectively, showing that the estradiol cypionate release from the administration site was prolonged and there was no drug accumulation.",Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947128/),h,89.65,62068,DB00396,Progesterone
,30947128,apparent volume of distribution (Vd/F),"Elimination half-life (t½), apparent volume of distribution (Vd/F), apparent clearance (CL/F) and mean residence time (MRT) were 89.65 ± 76.04 h, 28038 ± 9636 L, 49.02 ± 10.62 L/h and 576.05 ± 238.32 h, respectively, showing that the estradiol cypionate release from the administration site was prolonged and there was no drug accumulation.",Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947128/),l,28038,62069,DB00396,Progesterone
,30947128,apparent clearance (CL/F),"Elimination half-life (t½), apparent volume of distribution (Vd/F), apparent clearance (CL/F) and mean residence time (MRT) were 89.65 ± 76.04 h, 28038 ± 9636 L, 49.02 ± 10.62 L/h and 576.05 ± 238.32 h, respectively, showing that the estradiol cypionate release from the administration site was prolonged and there was no drug accumulation.",Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947128/),l,28038,62070,DB00396,Progesterone
,30947128,mean residence time (MRT),"Elimination half-life (t½), apparent volume of distribution (Vd/F), apparent clearance (CL/F) and mean residence time (MRT) were 89.65 ± 76.04 h, 28038 ± 9636 L, 49.02 ± 10.62 L/h and 576.05 ± 238.32 h, respectively, showing that the estradiol cypionate release from the administration site was prolonged and there was no drug accumulation.",Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947128/),h,576.05,62071,DB00396,Progesterone
,25264857,constant flow rate,"The chromatographic separation was achieved on a CAPCELL PAK C18 MGIII column (100 mm × 2.0 mm, i.d. 5 µm) using methanol and aqueous 0.1% formic acid solution gradient as the mobile phase with a constant flow rate of 0.45 mL/min.",Development and Validation of LC-MS/MS Assay for the Quantification of Progesterone in Rat Plasma and its Application to Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264857/),[ml] / [min],0.45,62521,DB00396,Progesterone
,10492057,area under the plasma concentration-time curve (AUCinf),"The average area under the plasma concentration-time curve (AUCinf) was 93.01 mg 1(-1) x h and the absorption rate constant (ka) was 2.88 h(-1) during the ovulatory phase, 83.0 mg 1(-1) h and 2.06 h(-1), respectively, during the luteal phase and 84.7 mg 1(-1) x h and 1.84 h(-1), respectively, during the follicular phase.","The effect of the menstrual cycle on the pharmacokinetics of caffeine in normal, healthy eumenorrheic females. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492057/),h·mg,93.01,63087,DB00396,Progesterone
,10492057,absorption rate constant (ka),"The average area under the plasma concentration-time curve (AUCinf) was 93.01 mg 1(-1) x h and the absorption rate constant (ka) was 2.88 h(-1) during the ovulatory phase, 83.0 mg 1(-1) h and 2.06 h(-1), respectively, during the luteal phase and 84.7 mg 1(-1) x h and 1.84 h(-1), respectively, during the follicular phase.","The effect of the menstrual cycle on the pharmacokinetics of caffeine in normal, healthy eumenorrheic females. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492057/),1/[h],2.88,63088,DB00396,Progesterone
,10492057,absorption rate constant (ka),"The average area under the plasma concentration-time curve (AUCinf) was 93.01 mg 1(-1) x h and the absorption rate constant (ka) was 2.88 h(-1) during the ovulatory phase, 83.0 mg 1(-1) h and 2.06 h(-1), respectively, during the luteal phase and 84.7 mg 1(-1) x h and 1.84 h(-1), respectively, during the follicular phase.","The effect of the menstrual cycle on the pharmacokinetics of caffeine in normal, healthy eumenorrheic females. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492057/),h·mg,83.0,63089,DB00396,Progesterone
,10492057,absorption rate constant (ka),"The average area under the plasma concentration-time curve (AUCinf) was 93.01 mg 1(-1) x h and the absorption rate constant (ka) was 2.88 h(-1) during the ovulatory phase, 83.0 mg 1(-1) h and 2.06 h(-1), respectively, during the luteal phase and 84.7 mg 1(-1) x h and 1.84 h(-1), respectively, during the follicular phase.","The effect of the menstrual cycle on the pharmacokinetics of caffeine in normal, healthy eumenorrheic females. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492057/),1/[h],2.06,63090,DB00396,Progesterone
,10492057,absorption rate constant (ka),"The average area under the plasma concentration-time curve (AUCinf) was 93.01 mg 1(-1) x h and the absorption rate constant (ka) was 2.88 h(-1) during the ovulatory phase, 83.0 mg 1(-1) h and 2.06 h(-1), respectively, during the luteal phase and 84.7 mg 1(-1) x h and 1.84 h(-1), respectively, during the follicular phase.","The effect of the menstrual cycle on the pharmacokinetics of caffeine in normal, healthy eumenorrheic females. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492057/),h·mg,84.7,63091,DB00396,Progesterone
,10492057,absorption rate constant (ka),"The average area under the plasma concentration-time curve (AUCinf) was 93.01 mg 1(-1) x h and the absorption rate constant (ka) was 2.88 h(-1) during the ovulatory phase, 83.0 mg 1(-1) h and 2.06 h(-1), respectively, during the luteal phase and 84.7 mg 1(-1) x h and 1.84 h(-1), respectively, during the follicular phase.","The effect of the menstrual cycle on the pharmacokinetics of caffeine in normal, healthy eumenorrheic females. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492057/),1/[h],1.84,63092,DB00396,Progesterone
,8143453,initial rate,"The pharmacokinetic and pharmacodynamic effects of vaginal rings releasing levonorgestrel (L-NOG) at an initial rate of 27 micrograms/24 h were studied in a group of 12 normally menstruating women during 90 days of continuous use (i.e., during three 30-day treatment segments).",Pharmacokinetic and pharmacodynamic effects of vaginal rings releasing levonorgestrel at a rate of 27 micrograms/24 hours: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8143453/),[μg] / [24·h],27,64085,DB00396,Progesterone
,3560943,peak plasma level,The peak plasma level of RU 486 (4.5 mumol/l) occurred within 1 h after ingestion of the compound; at this point significant amounts of the metabolites were also present in the plasma.,Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3560943/),[μM] / [l],4.5,64435,DB00396,Progesterone
,3560943,Kd,"The affinity of RU 486 for the human uterine progesterone receptor (Kd = 1.3 X 10(-9) M for RU 486) was higher than that of progesterone but lower than that of ORG-2058, a potent synthetic progestin.",Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3560943/),M,1.3 X 10(-9),64436,DB00396,Progesterone
,3560943,relative binding affinities,"The relative binding affinities of the monodemethylated, alcoholic and didemethylated metabolites to the progesterone receptor were 21, 15 and 9%, respectively, compared with the parent compound RU 486; each was lower than that of progesterone (43%).",Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3560943/),%,21,64437,DB00396,Progesterone
,3560943,relative binding affinities,"The relative binding affinities of the monodemethylated, alcoholic and didemethylated metabolites to the progesterone receptor were 21, 15 and 9%, respectively, compared with the parent compound RU 486; each was lower than that of progesterone (43%).",Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3560943/),%,15,64438,DB00396,Progesterone
,3560943,relative binding affinities,"The relative binding affinities of the monodemethylated, alcoholic and didemethylated metabolites to the progesterone receptor were 21, 15 and 9%, respectively, compared with the parent compound RU 486; each was lower than that of progesterone (43%).",Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3560943/),%,9,64439,DB00396,Progesterone
,3560943,relative binding affinities,"The relative binding affinities of the monodemethylated, alcoholic and didemethylated metabolites to the progesterone receptor were 21, 15 and 9%, respectively, compared with the parent compound RU 486; each was lower than that of progesterone (43%).",Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3560943/),%,43,64440,DB00396,Progesterone
,3560943,affinity,The affinity of dexamethasone to the human glucocorticoid receptor was 1.6 X 10(-9) M.,Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3560943/),M,1.6 X 10(-9),64441,DB00396,Progesterone
,15192285,serum concentration,"Progesterone serum concentration reached maximal levels within 2 or 3 h after the administration and was similar for the three groups (7.27 +/- 2.8 ng/ml; 8.84 +/- 3.14 ng/ml; 9.82 +/- 9.8 ng/ml, respectively).",Pharmacokinetics of natural progesterone vaginal suppository. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15192285/),[ng] / [ml],7.27,64694,DB00396,Progesterone
,15192285,serum concentration,"Progesterone serum concentration reached maximal levels within 2 or 3 h after the administration and was similar for the three groups (7.27 +/- 2.8 ng/ml; 8.84 +/- 3.14 ng/ml; 9.82 +/- 9.8 ng/ml, respectively).",Pharmacokinetics of natural progesterone vaginal suppository. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15192285/),[ng] / [ml],8.84,64695,DB00396,Progesterone
,15192285,serum concentration,"Progesterone serum concentration reached maximal levels within 2 or 3 h after the administration and was similar for the three groups (7.27 +/- 2.8 ng/ml; 8.84 +/- 3.14 ng/ml; 9.82 +/- 9.8 ng/ml, respectively).",Pharmacokinetics of natural progesterone vaginal suppository. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15192285/),[ng] / [ml],9.82,64696,DB00396,Progesterone
,15192285,maximal levels,"Progesterone serum concentration reached maximal levels within 2 or 3 h after the administration and was similar for the three groups (7.27 +/- 2.8 ng/ml; 8.84 +/- 3.14 ng/ml; 9.82 +/- 9.8 ng/ml, respectively).",Pharmacokinetics of natural progesterone vaginal suppository. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15192285/),[ng] / [ml],7.27,64697,DB00396,Progesterone
,15192285,maximal levels,"Progesterone serum concentration reached maximal levels within 2 or 3 h after the administration and was similar for the three groups (7.27 +/- 2.8 ng/ml; 8.84 +/- 3.14 ng/ml; 9.82 +/- 9.8 ng/ml, respectively).",Pharmacokinetics of natural progesterone vaginal suppository. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15192285/),[ng] / [ml],8.84,64698,DB00396,Progesterone
,15192285,maximal levels,"Progesterone serum concentration reached maximal levels within 2 or 3 h after the administration and was similar for the three groups (7.27 +/- 2.8 ng/ml; 8.84 +/- 3.14 ng/ml; 9.82 +/- 9.8 ng/ml, respectively).",Pharmacokinetics of natural progesterone vaginal suppository. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15192285/),[ng] / [ml],9.82,64699,DB00396,Progesterone
,17217407,maximal concentrations,The plasma levels of altrenogest reached maximal concentrations of 23-75 ng/mL.,Pharmacokinetics of altrenogest in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217407/),[ng] / [ml],23-75,65446,DB00396,Progesterone
,17217407,peak concentrations,Urine peak concentrations of total altrenogest ranged from 823 to 3895 ng/mL.,Pharmacokinetics of altrenogest in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17217407/),[ng] / [ml],823 to 3895,65447,DB00396,Progesterone
,17046384,elimination half-life (t(1/2)),"The elimination half-life (t(1/2)) ranged from 12 to 30 h, and the oral clearance was approximately 70 L/h.","Pharmacokinetics and safety of tanaproget, a nonsteroidal progesterone receptor agonist, in healthy women. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17046384/),h,12 to 30,65492,DB00396,Progesterone
,17046384,oral clearance,"The elimination half-life (t(1/2)) ranged from 12 to 30 h, and the oral clearance was approximately 70 L/h.","Pharmacokinetics and safety of tanaproget, a nonsteroidal progesterone receptor agonist, in healthy women. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17046384/),[l] / [h],70,65493,DB00396,Progesterone
,2496951,peak level,"A peak level of 16 nmol/l was reached after 2 hours, T 1/2 was estimated to be 14.5 hours (8.5-18.5) in the 24-48-hour interval after dosing.",The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496951/),[nM] / [l],16,68175,DB00396,Progesterone
,2496951,T 1/2,"A peak level of 16 nmol/l was reached after 2 hours, T 1/2 was estimated to be 14.5 hours (8.5-18.5) in the 24-48-hour interval after dosing.",The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496951/),h,14.5,68176,DB00396,Progesterone
,12441190,detection limit,The detection limit was 51pg/ml.,Development of a new sensitive and specific time-resolved fluoroimmunoassay (TR-FIA) of chlormadinone acetate in the serum of treated menopausal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12441190/),[pg] / [ml],51,68416,DB00396,Progesterone
,29445971,AUC0-t,"The pharmacokinetic parameters of the PRG H-NPs, PRG-NPs, Oil-L and Oil-H were AUC0-t(ng·h·mL-1) 8762.1, 1546.1, 1914.5, and 12,138.9, t1/2 (h)52.7, 44.1, 8.4 and 44.6 respectively.",Progesterone PLGA/mPEG-PLGA Hybrid Nanoparticle Sustained-Release System by Intramuscular Injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29445971/),[h·ng] / [ml],8762.1,70807,DB00396,Progesterone
,29445971,AUC0-t,"The pharmacokinetic parameters of the PRG H-NPs, PRG-NPs, Oil-L and Oil-H were AUC0-t(ng·h·mL-1) 8762.1, 1546.1, 1914.5, and 12,138.9, t1/2 (h)52.7, 44.1, 8.4 and 44.6 respectively.",Progesterone PLGA/mPEG-PLGA Hybrid Nanoparticle Sustained-Release System by Intramuscular Injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29445971/),[h·ng] / [ml],1546.1,70808,DB00396,Progesterone
,29445971,AUC0-t,"The pharmacokinetic parameters of the PRG H-NPs, PRG-NPs, Oil-L and Oil-H were AUC0-t(ng·h·mL-1) 8762.1, 1546.1, 1914.5, and 12,138.9, t1/2 (h)52.7, 44.1, 8.4 and 44.6 respectively.",Progesterone PLGA/mPEG-PLGA Hybrid Nanoparticle Sustained-Release System by Intramuscular Injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29445971/),[h·ng] / [ml],1914.5,70809,DB00396,Progesterone
,29445971,AUC0-t,"The pharmacokinetic parameters of the PRG H-NPs, PRG-NPs, Oil-L and Oil-H were AUC0-t(ng·h·mL-1) 8762.1, 1546.1, 1914.5, and 12,138.9, t1/2 (h)52.7, 44.1, 8.4 and 44.6 respectively.",Progesterone PLGA/mPEG-PLGA Hybrid Nanoparticle Sustained-Release System by Intramuscular Injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29445971/),[h·ng] / [ml],"12,138.9",70810,DB00396,Progesterone
,29445971,t1/2,"The pharmacokinetic parameters of the PRG H-NPs, PRG-NPs, Oil-L and Oil-H were AUC0-t(ng·h·mL-1) 8762.1, 1546.1, 1914.5, and 12,138.9, t1/2 (h)52.7, 44.1, 8.4 and 44.6 respectively.",Progesterone PLGA/mPEG-PLGA Hybrid Nanoparticle Sustained-Release System by Intramuscular Injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29445971/),h,52.7,70811,DB00396,Progesterone
,29445971,t1/2,"The pharmacokinetic parameters of the PRG H-NPs, PRG-NPs, Oil-L and Oil-H were AUC0-t(ng·h·mL-1) 8762.1, 1546.1, 1914.5, and 12,138.9, t1/2 (h)52.7, 44.1, 8.4 and 44.6 respectively.",Progesterone PLGA/mPEG-PLGA Hybrid Nanoparticle Sustained-Release System by Intramuscular Injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29445971/),h,44.1,70812,DB00396,Progesterone
,29445971,t1/2,"The pharmacokinetic parameters of the PRG H-NPs, PRG-NPs, Oil-L and Oil-H were AUC0-t(ng·h·mL-1) 8762.1, 1546.1, 1914.5, and 12,138.9, t1/2 (h)52.7, 44.1, 8.4 and 44.6 respectively.",Progesterone PLGA/mPEG-PLGA Hybrid Nanoparticle Sustained-Release System by Intramuscular Injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29445971/),h,8.4,70813,DB00396,Progesterone
,29445971,t1/2,"The pharmacokinetic parameters of the PRG H-NPs, PRG-NPs, Oil-L and Oil-H were AUC0-t(ng·h·mL-1) 8762.1, 1546.1, 1914.5, and 12,138.9, t1/2 (h)52.7, 44.1, 8.4 and 44.6 respectively.",Progesterone PLGA/mPEG-PLGA Hybrid Nanoparticle Sustained-Release System by Intramuscular Injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29445971/),h,44.6,70814,DB00396,Progesterone
,1775083,maximum concentration (CMax),The spray formulation yielded a mean maximum concentration (CMax) of 3.75 ng/ml after 60 min (TMax) and the area under the curve (AUC) 0-720 min was 1481.6 +/- 343 ng.h/ml.,Nasally-administered progesterone: comparison of ointment and spray formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1775083/),[ng] / [ml],3.75,71484,DB00396,Progesterone
,1775083,area under the curve (AUC) 0-720 min,The spray formulation yielded a mean maximum concentration (CMax) of 3.75 ng/ml after 60 min (TMax) and the area under the curve (AUC) 0-720 min was 1481.6 +/- 343 ng.h/ml.,Nasally-administered progesterone: comparison of ointment and spray formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1775083/),[h·ng] / [ml],1481.6,71485,DB00396,Progesterone
,1775083,CMax,"The ointment yielded a mean CMax of 1.19 ng/ml at TMax = 30 min, the AUC 0-720 value being 404.35 +/- 148 ng.h/ml.",Nasally-administered progesterone: comparison of ointment and spray formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1775083/),[ng] / [ml],1.19,71486,DB00396,Progesterone
,1775083,TMax,"The ointment yielded a mean CMax of 1.19 ng/ml at TMax = 30 min, the AUC 0-720 value being 404.35 +/- 148 ng.h/ml.",Nasally-administered progesterone: comparison of ointment and spray formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1775083/),min,30,71487,DB00396,Progesterone
,1775083,AUC 0-720,"The ointment yielded a mean CMax of 1.19 ng/ml at TMax = 30 min, the AUC 0-720 value being 404.35 +/- 148 ng.h/ml.",Nasally-administered progesterone: comparison of ointment and spray formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1775083/),[h·ng] / [ml],404.35,71488,DB00396,Progesterone
,21475623,Time to maximum saliva concentrations (Tmax),"Time to maximum saliva concentrations (Tmax), in all experimental cases, was observed after 6 hours.",Efficacy of biorhythmic transdermal combined hormone treatment in relieving climacteric symptoms: a pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21475623/),h,6,71669,DB00396,Progesterone
,9842982,time of maximum concentration (tmax),"The time of maximum concentration (tmax) was 4 h in most cases, and 6 h in the others.",Pharmacokinetics of progesterone in postmenopausal women: 1. Pharmacokinetics following intravaginal administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842982/),h,4,73213,DB00396,Progesterone
,9842982,time of maximum concentration (tmax),"The time of maximum concentration (tmax) was 4 h in most cases, and 6 h in the others.",Pharmacokinetics of progesterone in postmenopausal women: 1. Pharmacokinetics following intravaginal administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842982/),h,6,73214,DB00396,Progesterone
,9842982,Peak plasma concentrations,Peak plasma concentrations were in the range of 10-15 ng/ml with a mean of 10.5 ng/ml for the 100 mg and 12 ng/ml for the 200 mg doses.,Pharmacokinetics of progesterone in postmenopausal women: 1. Pharmacokinetics following intravaginal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842982/),[ng] / [ml],10-15,73215,DB00396,Progesterone
,9842982,Peak plasma concentrations,Peak plasma concentrations were in the range of 10-15 ng/ml with a mean of 10.5 ng/ml for the 100 mg and 12 ng/ml for the 200 mg doses.,Pharmacokinetics of progesterone in postmenopausal women: 1. Pharmacokinetics following intravaginal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842982/),[ng] / [ml],10.5,73216,DB00396,Progesterone
,9842982,Peak plasma concentrations,Peak plasma concentrations were in the range of 10-15 ng/ml with a mean of 10.5 ng/ml for the 100 mg and 12 ng/ml for the 200 mg doses.,Pharmacokinetics of progesterone in postmenopausal women: 1. Pharmacokinetics following intravaginal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842982/),[ng] / [ml],12,73217,DB00396,Progesterone
,9842982,Elimination half-time,Elimination half-time was in the range of 9-10 h for BC and 14 h for ME suppositories.,Pharmacokinetics of progesterone in postmenopausal women: 1. Pharmacokinetics following intravaginal administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842982/),h,9-10,73218,DB00396,Progesterone
,9842982,Elimination half-time,Elimination half-time was in the range of 9-10 h for BC and 14 h for ME suppositories.,Pharmacokinetics of progesterone in postmenopausal women: 1. Pharmacokinetics following intravaginal administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842982/),h,14,73219,DB00396,Progesterone
,15867239,maximum tolerated dose,The maximum tolerated dose was 295 mg/m2.,"Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15867239/),[mg] / [m2],295,74380,DB00396,Progesterone
,8131396,half-lives,"After administration, as a single i.v. bolus, the plasma disappearance rate of immunoreactive ST 1435 had two components with half-lives (mean +/- SE) of 3.5 +/- 0.5 and 83 +/- 14 min, respectively.",Pharmacokinetics and bioavailability of ST 1435 administered by different routes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131396/),min,3.5,75612,DB00396,Progesterone
,8131396,half-lives,"After administration, as a single i.v. bolus, the plasma disappearance rate of immunoreactive ST 1435 had two components with half-lives (mean +/- SE) of 3.5 +/- 0.5 and 83 +/- 14 min, respectively.",Pharmacokinetics and bioavailability of ST 1435 administered by different routes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131396/),min,83,75613,DB00396,Progesterone
,8131396,volume of distribution,The volume of distribution was 4.7 +/- 1.3 L/Kg and the metabolic clearance rate was 55 +/- 6 L/Kg/d.,Pharmacokinetics and bioavailability of ST 1435 administered by different routes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131396/),[l] / [kg],4.7,75614,DB00396,Progesterone
,8131396,metabolic clearance rate,The volume of distribution was 4.7 +/- 1.3 L/Kg and the metabolic clearance rate was 55 +/- 6 L/Kg/d.,Pharmacokinetics and bioavailability of ST 1435 administered by different routes. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131396/),[l] / [d·kg],55,75615,DB00396,Progesterone
,8131396,bioavailability,"After oral administration, the bioavailability was about 10% of the dose.",Pharmacokinetics and bioavailability of ST 1435 administered by different routes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131396/),%,10,75616,DB00396,Progesterone
,10701698,Partition coefficients (log P),"Partition coefficients (log P) of FMPA and MPA were 3.1 and 3.8, respectively, while the solubilities of FMPA and MPA in phosphate buffer saline were 3.8 and 1.1 microg/mL, respectively.",Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701698/),,3.1,75822,DB00396,Progesterone
,10701698,Partition coefficients (log P),"Partition coefficients (log P) of FMPA and MPA were 3.1 and 3.8, respectively, while the solubilities of FMPA and MPA in phosphate buffer saline were 3.8 and 1.1 microg/mL, respectively.",Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701698/),,3.8,75823,DB00396,Progesterone
,10701698,solubilities,"Partition coefficients (log P) of FMPA and MPA were 3.1 and 3.8, respectively, while the solubilities of FMPA and MPA in phosphate buffer saline were 3.8 and 1.1 microg/mL, respectively.",Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701698/),[μg] / [ml],3.8,75824,DB00396,Progesterone
,10701698,solubilities,"Partition coefficients (log P) of FMPA and MPA were 3.1 and 3.8, respectively, while the solubilities of FMPA and MPA in phosphate buffer saline were 3.8 and 1.1 microg/mL, respectively.",Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701698/),[μg] / [ml],1.1,75825,DB00396,Progesterone
,10701698,hepatic intrinsic clearances,"Assuming the well-stirred model, hepatic intrinsic clearances of FMPA and MPA were estimated to be 64 and 293 L/h per kg, respectively.",Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701698/),[l] / [h·kg],64,75826,DB00396,Progesterone
,10701698,hepatic intrinsic clearances,"Assuming the well-stirred model, hepatic intrinsic clearances of FMPA and MPA were estimated to be 64 and 293 L/h per kg, respectively.",Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701698/),[l] / [h·kg],293,75827,DB00396,Progesterone
,27796907,zeta potential,The droplets of PILE had the smallest possible diameters of 218.0 ± 1.8 nm and adequate zeta potential of -41.1 ± 0.9 mV.,"Formulation, Optimization, Characterization, and Pharmacokinetics of Progesterone Intravenous Lipid Emulsion for Traumatic Brain Injury Therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27796907/),mv,-,75931,DB00396,Progesterone
,27796907,zeta potential,The droplets of PILE had the smallest possible diameters of 218.0 ± 1.8 nm and adequate zeta potential of -41.1 ± 0.9 mV.,"Formulation, Optimization, Characterization, and Pharmacokinetics of Progesterone Intravenous Lipid Emulsion for Traumatic Brain Injury Therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27796907/),mv,41.1,75932,DB00396,Progesterone
,15124207,T(50%),"A pellet formulation of progesterone in a self-emulsifying system (SES) was prepared by the process of extrusion/spheronization to provide a good in vitro drug release (100% within 30 min, T(50%) at 13 min).",Comparative bioavailability study in dogs of a self-emulsifying formulation of progesterone presented in a pellet and liquid form compared with an aqueous suspension of progesterone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15124207/),min,13,78232,DB00396,Progesterone
,23384975,AUC-estradiol,The difference was statistically significant for Bi-est 2.0mg (AUC-estradiol=181 vs. 956; p<0.001) and 2.5mg (AUC-estradiol=286 vs. 917; p<0.001).,Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23384975/),,181,80339,DB00396,Progesterone
,23384975,AUC-estradiol,The difference was statistically significant for Bi-est 2.0mg (AUC-estradiol=181 vs. 956; p<0.001) and 2.5mg (AUC-estradiol=286 vs. 917; p<0.001).,Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23384975/),,956,80340,DB00396,Progesterone
,23384975,AUC-estradiol,The difference was statistically significant for Bi-est 2.0mg (AUC-estradiol=181 vs. 956; p<0.001) and 2.5mg (AUC-estradiol=286 vs. 917; p<0.001).,Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23384975/),,286,80341,DB00396,Progesterone
,23384975,AUC-estradiol,The difference was statistically significant for Bi-est 2.0mg (AUC-estradiol=181 vs. 956; p<0.001) and 2.5mg (AUC-estradiol=286 vs. 917; p<0.001).,Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23384975/),,917,80342,DB00396,Progesterone
,10221683,serum Cmax,"After the initial administration of 50 mg or 100 mg, a mean serum Cmax of 20.43 +/- 8.01 nmol/l and 31.61 +/- 12.62 nmol/l (P < 0.0004) was reached at a Tmax of 6.1 +/- 2.63 and 6.4 +/- 3.35 h respectively.",Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221683/),[nM] / [l],20.43,80977,DB00396,Progesterone
,10221683,serum Cmax,"After the initial administration of 50 mg or 100 mg, a mean serum Cmax of 20.43 +/- 8.01 nmol/l and 31.61 +/- 12.62 nmol/l (P < 0.0004) was reached at a Tmax of 6.1 +/- 2.63 and 6.4 +/- 3.35 h respectively.",Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221683/),[nM] / [l],31.61,80978,DB00396,Progesterone
,10221683,Tmax,"After the initial administration of 50 mg or 100 mg, a mean serum Cmax of 20.43 +/- 8.01 nmol/l and 31.61 +/- 12.62 nmol/l (P < 0.0004) was reached at a Tmax of 6.1 +/- 2.63 and 6.4 +/- 3.35 h respectively.",Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221683/),h,6.1,80979,DB00396,Progesterone
,10221683,Tmax,"After the initial administration of 50 mg or 100 mg, a mean serum Cmax of 20.43 +/- 8.01 nmol/l and 31.61 +/- 12.62 nmol/l (P < 0.0004) was reached at a Tmax of 6.1 +/- 2.63 and 6.4 +/- 3.35 h respectively.",Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221683/),h,6.4,80980,DB00396,Progesterone
,10221683,terminal half-life,The terminal half-life was 13.18 +/- 1.3 and 13.7 +/- 1.05 h respectively.,Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221683/),h,13.18,80981,DB00396,Progesterone
,10221683,terminal half-life,The terminal half-life was 13.18 +/- 1.3 and 13.7 +/- 1.05 h respectively.,Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221683/),h,13.7,80982,DB00396,Progesterone
,10221683,serum,Continuous use of the 100-mg tablet resulted in a mean serum progesterone concentration of 26.08 +/- 13.96 nmol/l and 21.42 +/- 16.32 nmol/l after 14 and 30 days respectively.,Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221683/),nm,26.08,80983,DB00396,Progesterone
,10221683,serum,Continuous use of the 100-mg tablet resulted in a mean serum progesterone concentration of 26.08 +/- 13.96 nmol/l and 21.42 +/- 16.32 nmol/l after 14 and 30 days respectively.,Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221683/),nm,21.42,80984,DB00396,Progesterone
,23058048,fast component half-life,Intraperitoneally injected progesterone had a short half-life (fast component half-life of 0.2 h) in both plasma and brain.,Progesterone pharmacokinetics in the mouse: implications for potential stroke therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23058048/),h,0.2,81552,DB00396,Progesterone
,23058048,volume of distribution,The volume of distribution with intraperitoneal injection was 172.78 versus 1641.84 ng/h per g via minipump in the first 24 h.,Progesterone pharmacokinetics in the mouse: implications for potential stroke therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23058048/),[ng] / [g·h],172.78,81553,DB00396,Progesterone
,23058048,volume of distribution,The volume of distribution with intraperitoneal injection was 172.78 versus 1641.84 ng/h per g via minipump in the first 24 h.,Progesterone pharmacokinetics in the mouse: implications for potential stroke therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23058048/),[ng] / [g·h],1641.84,81554,DB00396,Progesterone
,9219927,peak plasma levels,"Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),μM,13.4,83627,DB00396,Progesterone
,9219927,peak plasma levels,"Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),μM,3.4,83628,DB00396,Progesterone
,9219927,terminal half-lives,"Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),h,2.7,83629,DB00396,Progesterone
,9219927,terminal half-lives,"Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),h,3.3,83630,DB00396,Progesterone
,9219927,K(i),"When tested in vitro against the WHT testicular enzyme, the CB7645 and CB7661 were competitive inhibitors with K(i) values of 10 and 13 nM, respectively.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),nM,10,83631,DB00396,Progesterone
,9219927,K(i),"When tested in vitro against the WHT testicular enzyme, the CB7645 and CB7661 were competitive inhibitors with K(i) values of 10 and 13 nM, respectively.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),nM,13,83632,DB00396,Progesterone
,9219927,K(m),"However, the K(m) for the substrate progesterone was lower at 4.3 nM.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),nM,4.3,83633,DB00396,Progesterone
,25495693,bioavailability,"After oral ingestion, perampanel is rapidly absorbed and peak plasma concentrations occur 0.5-2.5 h later; its bioavailability is ~100%.",The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495693/),%,100,83917,DB00396,Progesterone
,25495693,apparent terminal half-life,"In healthy volunteers, the apparent terminal half-life is ~105 h, whereas the calculated effective half-life is 48 h.",The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495693/),h,105,83918,DB00396,Progesterone
,25495693,effective half-life,"In healthy volunteers, the apparent terminal half-life is ~105 h, whereas the calculated effective half-life is 48 h.",The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495693/),h,48,83919,DB00396,Progesterone
,25495693,half-life,"In healthy volunteers prescribed carbamazepine, half-life decreases to 25 h.",The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495693/),h,25,83920,DB00396,Progesterone
,25495693,Clearance,Clearance values are not significantly different in adolescents (~13.0 ml/min) and the elderly (~10.5 ml/min) compared with adults (10.9 ml/min).,The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495693/),[ml] / [min],13.0,83921,DB00396,Progesterone
,25495693,Clearance,Clearance values are not significantly different in adolescents (~13.0 ml/min) and the elderly (~10.5 ml/min) compared with adults (10.9 ml/min).,The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495693/),[ml] / [min],10.5,83922,DB00396,Progesterone
,25495693,Clearance,Clearance values are not significantly different in adolescents (~13.0 ml/min) and the elderly (~10.5 ml/min) compared with adults (10.9 ml/min).,The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495693/),[ml] / [min],10.9,83923,DB00396,Progesterone
,8629456,Cmax,The mean Cmax was 4.50 +/- 2.31 ng/ml at a Tmax of 30 min; levels returned to baseline after 720 min.,Administration of unmodified progesterone by nasal spray in fertile women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8629456/),[ng] / [ml],4.50,86187,DB00396,Progesterone
,8629456,Tmax,The mean Cmax was 4.50 +/- 2.31 ng/ml at a Tmax of 30 min; levels returned to baseline after 720 min.,Administration of unmodified progesterone by nasal spray in fertile women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8629456/),min,30,86188,DB00396,Progesterone
,8629456,AUC,The mean AUC value was 1180.50 +/- 613.90 ng.h/ml.,Administration of unmodified progesterone by nasal spray in fertile women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8629456/),[h·ng] / [ml],1180.50,86189,DB00396,Progesterone
,21115001,circulating half-life,"From pharmacokinetic studies, circulating half-life of corifollitropin alfa was calculated to be 17.3h in rats and 46.9h in dogs, 1.5- to 2-fold longer than recombinant FSH.","Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21115001/),h,17.3,86524,DB00396,Progesterone
,21115001,circulating half-life,"From pharmacokinetic studies, circulating half-life of corifollitropin alfa was calculated to be 17.3h in rats and 46.9h in dogs, 1.5- to 2-fold longer than recombinant FSH.","Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21115001/),h,46.9,86525,DB00396,Progesterone
,124325,metabolic clearance rate,The metabolic clearance rate of progesterone from blood was 3-13 plus or minus 0-35 (S.E.M.) 1/min in ten experiments on six goats; values tended to be slightly higher in pregnant than in non-pregnant goats.,"Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[1] / [min],3-13,86668,DB00396,Progesterone
less,124325,production rate,"The production rate of progesterone at oestrus, and at day 3 of the normal cycle, was less than 0-01 mug/min.","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],0-01,86669,DB00396,Progesterone
,124325,production rate,"During the luteal phase of the oestrous cycle the production rate was 8-5 and 14-6 mug/min in 2 animals, and in the second half of pregnancy, 15-3 plus or minus 0-6 mug/min (5 animals).","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],8-5,86670,DB00396,Progesterone
,124325,production rate,"During the luteal phase of the oestrous cycle the production rate was 8-5 and 14-6 mug/min in 2 animals, and in the second half of pregnancy, 15-3 plus or minus 0-6 mug/min (5 animals).","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],14-6,86671,DB00396,Progesterone
,124325,production rate,"During the luteal phase of the oestrous cycle the production rate was 8-5 and 14-6 mug/min in 2 animals, and in the second half of pregnancy, 15-3 plus or minus 0-6 mug/min (5 animals).","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],15-3,86672,DB00396,Progesterone
,124325,production rate,"During the luteal phase of the oestrous cycle the production rate was 8-5 and 14-6 mug/min in 2 animals, and in the second half of pregnancy, 15-3 plus or minus 0-6 mug/min (5 animals).","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],0-6,86673,DB00396,Progesterone
,124325,clearance rate,"The mean clearance rate of progesterone by the udder was 0-279 1/min, 8-8% of the metabolic clearance rate.","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[1] / [min],0-279,86674,DB00396,Progesterone
,124325,Mammary uptake,"Mammary uptake of progesterone in goats with an actively secreting corpus luteum was 0-64 plus or minus 0-29 mug/min, which gave an estimated value of 0-11-1-88 ng/min/g mammary gland.","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],0-64,86675,DB00396,Progesterone
,124325,Mammary uptake,"Mammary uptake of progesterone in goats with an actively secreting corpus luteum was 0-64 plus or minus 0-29 mug/min, which gave an estimated value of 0-11-1-88 ng/min/g mammary gland.","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[ng] / [g·min],0-11-1-88,86676,DB00396,Progesterone
,15276776,half-life,"The mean (+/- SD) half-life calculated from the slower component of this decline, was 26.0 +/- 2.0 min after I.V. injection of P4 and 28.0 +/- 2.1 min after ovariectomy.",Pharmacokinetics of progesterone in dromedary camels (Camelus dromedarim). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15276776/),min,26.0,87876,DB00396,Progesterone
,15276776,half-life,"The mean (+/- SD) half-life calculated from the slower component of this decline, was 26.0 +/- 2.0 min after I.V. injection of P4 and 28.0 +/- 2.1 min after ovariectomy.",Pharmacokinetics of progesterone in dromedary camels (Camelus dromedarim). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15276776/),min,28.0,87877,DB00396,Progesterone
,15276776,apparent volume of distribution,The apparent volume of distribution (1370 ml kg(-1)) exceeded total body water suggesting extensive tissue penetration.,Pharmacokinetics of progesterone in dromedary camels (Camelus dromedarim). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15276776/),[ml] / [kg],1370,87878,DB00396,Progesterone
,26153441,half-life,"4. After IV or IM administration as a solution, the mean half-life of 17-OHPC was around 11 h.",Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153441/),h,11,88842,DB00396,Progesterone
,26153441,bioavailability,"The bioavailability was nearly 100% after IM administration, but was very low (<3%) after PO administration of a solution dosage form.",Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153441/),%,100,88843,DB00396,Progesterone
<,26153441,bioavailability,"The bioavailability was nearly 100% after IM administration, but was very low (<3%) after PO administration of a solution dosage form.",Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153441/),%,3,88844,DB00396,Progesterone
,26153441,bioavailability,5. Intramuscular injection of the oily formulation resulted in low levels of 17-OHPC that were sustained for a prolonged time period with a projected bioavailability close to 100%.,Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153441/),%,100,88845,DB00396,Progesterone
>,25257727,trough concentrations,"Despite dose escalation in 90 % of patients, only 17 (57 %) patients ever achieved MPA trough concentrations >50 ng/ml.",A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25257727/),[ng] / [ml],50,89376,DB00396,Progesterone
,23127204,peak serum levels,"Aqueous formulation (100 mg) was promptly absorbed, achieving progesterone peak serum levels at an earlier time than the reference (1 h vs. 7 h; p < 0.0001).",Pharmacokinetics and safety profile of a novel progesterone aqueous formulation administered by the s.c. route. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23127204/),h,1,89698,DB00396,Progesterone
,23127204,peak serum levels,"Aqueous formulation (100 mg) was promptly absorbed, achieving progesterone peak serum levels at an earlier time than the reference (1 h vs. 7 h; p < 0.0001).",Pharmacokinetics and safety profile of a novel progesterone aqueous formulation administered by the s.c. route. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23127204/),h,7,89699,DB00396,Progesterone
,26497877,Rates of progression-free survival,"Rates of progression-free survival at 6 months were 17 and 8 % in the pilaralisib and voxtalisib arms, respectively.",Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26497877/),%,17,90896,DB00396,Progesterone
,26497877,Rates of progression-free survival,"Rates of progression-free survival at 6 months were 17 and 8 % in the pilaralisib and voxtalisib arms, respectively.",Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26497877/),%,8,90897,DB00396,Progesterone
,14663455,oral clearance,"Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023).",The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],8.2,91245,DB00396,Progesterone
,14663455,oral clearance,"Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023).",The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],9.5,91246,DB00396,Progesterone
,14663455,half-life,"Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023).",The interaction between St John's wort and an oral contraceptive. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),h,23.4,91247,DB00396,Progesterone
,14663455,half-life,"Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023).",The interaction between St John's wort and an oral contraceptive. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),h,12.2,91248,DB00396,Progesterone
,14663455,oral clearance,"The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567).",The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],109.2,91249,DB00396,Progesterone
,14663455,oral clearance,"The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567).",The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],166.7,91250,DB00396,Progesterone
,14663455,systemic clearance,"The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567).",The interaction between St John's wort and an oral contraceptive. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],37.7,91251,DB00396,Progesterone
,14663455,systemic clearance,"The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567).",The interaction between St John's wort and an oral contraceptive. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],39.0,91252,DB00396,Progesterone
,14663455,oral clearance,The oral clearance of midazolam after St John's wort dosing was greater in women who had breakthrough bleeding (215.9 +/- 66.5 L/h) than in those who did not (97.5 +/- 37.2 L/h) (P =.005).,The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],215.9,91253,DB00396,Progesterone
,14663455,oral clearance,The oral clearance of midazolam after St John's wort dosing was greater in women who had breakthrough bleeding (215.9 +/- 66.5 L/h) than in those who did not (97.5 +/- 37.2 L/h) (P =.005).,The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],97.5,91254,DB00396,Progesterone
,10095978,absorption rate,"Implanon had an absorption rate of almost 60 micrograms/day after 3 months, which slowly decreased to 30 micrograms/day at the end of 2 years.",Pharmacokinetics of Implanon. An integrated analysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10095978/),[μg] / [d],60,91505,DB00396,Progesterone
,10095978,absorption rate,"Implanon had an absorption rate of almost 60 micrograms/day after 3 months, which slowly decreased to 30 micrograms/day at the end of 2 years.",Pharmacokinetics of Implanon. An integrated analysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10095978/),[μg] / [d],30,91506,DB00396,Progesterone
,10095978,bioavailability,The bioavailability over this period of time was constant and close to 100%.,Pharmacokinetics of Implanon. An integrated analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10095978/),%,100,91507,DB00396,Progesterone
,10095978,clearance,The clearance remained around 7.5 L/h.,Pharmacokinetics of Implanon. An integrated analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10095978/),[l] / [h],7.5,91508,DB00396,Progesterone
,10095978,Maximum mean serum concentrations (Cmax),Maximum mean serum concentrations (Cmax) amounted to 813 pg/mL and the time (tmax) to reach Cmax was 4 days.,Pharmacokinetics of Implanon. An integrated analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10095978/),[pg] / [ml],813,91509,DB00396,Progesterone
,10095978,time (tmax) to reach Cmax,Maximum mean serum concentrations (Cmax) amounted to 813 pg/mL and the time (tmax) to reach Cmax was 4 days.,Pharmacokinetics of Implanon. An integrated analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10095978/),d,4,91510,DB00396,Progesterone
,2971841,half-lives,"MPA was distributed very rapidly into three compartments after i.v. injections, revealing half-lives of 4-7 h.",Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2971841/),h,4-7,94522,DB00396,Progesterone
,2971841,metabolic clearance rates (MCR),"Using a nonlinear model fitting metabolic clearance rates (MCR) were found to be 652 1/day before and 601 1/day during MPA treatment, and distribution volumes (V0) 5.9 and 3.41 respectively.",Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2971841/),[1] / [d],652,94523,DB00396,Progesterone
,2971841,metabolic clearance rates (MCR),"Using a nonlinear model fitting metabolic clearance rates (MCR) were found to be 652 1/day before and 601 1/day during MPA treatment, and distribution volumes (V0) 5.9 and 3.41 respectively.",Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2971841/),[1] / [d],601,94524,DB00396,Progesterone
,2971841,distribution volumes (V0),"Using a nonlinear model fitting metabolic clearance rates (MCR) were found to be 652 1/day before and 601 1/day during MPA treatment, and distribution volumes (V0) 5.9 and 3.41 respectively.",Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2971841/),,5.9,94525,DB00396,Progesterone
,2971841,distribution volumes (V0),"Using a nonlinear model fitting metabolic clearance rates (MCR) were found to be 652 1/day before and 601 1/day during MPA treatment, and distribution volumes (V0) 5.9 and 3.41 respectively.",Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2971841/),,3.41,94526,DB00396,Progesterone
,8449020,initial release rate,Ethylene-vinyl acetate (EVA) polymeric contraceptive implants (Implanon) containing 3-keto-desogestrel have been prepared aiming at an in vitro initial release rate of 60 micrograms 3-keto-desogestrel/day.,Release kinetics of 3-keto-desogestrel from contraceptive implants (Implanon) in dogs: comparison with in vitro data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8449020/),μg,60,95248,DB00396,Progesterone
,8449020,life-time,These implants are designed to have an intended life-time of 2 years.,Release kinetics of 3-keto-desogestrel from contraceptive implants (Implanon) in dogs: comparison with in vitro data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8449020/),years,2,95249,DB00396,Progesterone
,8449020,plasma level,"At the end of the second year, the level had decreased further to 0.45 nmol/l while after 3 years, the mean 3-keto-desogestrel plasma level was 0.42 nmol/l.",Release kinetics of 3-keto-desogestrel from contraceptive implants (Implanon) in dogs: comparison with in vitro data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8449020/),,0.42,95250,DB00396,Progesterone
,8449020,daily release,The calculated mean daily release of 3-keto-desogestrel decreased during the first year from 70 micrograms/day to 30 micrograms/day.,Release kinetics of 3-keto-desogestrel from contraceptive implants (Implanon) in dogs: comparison with in vitro data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8449020/),[μg] / [d],70,95251,DB00396,Progesterone
,8449020,daily release,The calculated mean daily release of 3-keto-desogestrel decreased during the first year from 70 micrograms/day to 30 micrograms/day.,Release kinetics of 3-keto-desogestrel from contraceptive implants (Implanon) in dogs: comparison with in vitro data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8449020/),[μg] / [d],30,95252,DB00396,Progesterone
,8449020,cumulative amount,The calculated cumulative amount of 3-keto-desogestrel released from the implant during the dog study was 34.0 mg.,Release kinetics of 3-keto-desogestrel from contraceptive implants (Implanon) in dogs: comparison with in vitro data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8449020/),mg,34.0,95253,DB00396,Progesterone
,8449020,release rate,"After one year, the in vitro release rate was about 43 micrograms/day whereas this release rate was 33 and 27 micrograms/day after 2 and 3 years, respectively.",Release kinetics of 3-keto-desogestrel from contraceptive implants (Implanon) in dogs: comparison with in vitro data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8449020/),[μg] / [d],43,95254,DB00396,Progesterone
,8449020,release rate,"After one year, the in vitro release rate was about 43 micrograms/day whereas this release rate was 33 and 27 micrograms/day after 2 and 3 years, respectively.",Release kinetics of 3-keto-desogestrel from contraceptive implants (Implanon) in dogs: comparison with in vitro data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8449020/),[μg] / [d],33,95255,DB00396,Progesterone
,8449020,release rate,"After one year, the in vitro release rate was about 43 micrograms/day whereas this release rate was 33 and 27 micrograms/day after 2 and 3 years, respectively.",Release kinetics of 3-keto-desogestrel from contraceptive implants (Implanon) in dogs: comparison with in vitro data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8449020/),[μg] / [d],27,95256,DB00396,Progesterone
,31440031,steady-state maximum concentration (Cmax),"By the vaginal route, steady-state maximum concentration (Cmax) of Yimaxin and Utrogestan was 29.13±8.09 and 12.30±1.60 mg/L, time to Cmax 9.72±10.50 and 11.03±9.62 hours, central compartment volume of distribution 4.26±1.86 and 10.40±2.32 L, clearance rate 0.18±0.05 and 0.38±0.10 L/h, and AUC 261.42±74.36 and 116.83±19.72 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),[mg] / [l],29.13,96961,DB00396,Progesterone
,31440031,steady-state maximum concentration (Cmax),"By the vaginal route, steady-state maximum concentration (Cmax) of Yimaxin and Utrogestan was 29.13±8.09 and 12.30±1.60 mg/L, time to Cmax 9.72±10.50 and 11.03±9.62 hours, central compartment volume of distribution 4.26±1.86 and 10.40±2.32 L, clearance rate 0.18±0.05 and 0.38±0.10 L/h, and AUC 261.42±74.36 and 116.83±19.72 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),[mg] / [l],12.30,96962,DB00396,Progesterone
,31440031,time to Cmax,"By the vaginal route, steady-state maximum concentration (Cmax) of Yimaxin and Utrogestan was 29.13±8.09 and 12.30±1.60 mg/L, time to Cmax 9.72±10.50 and 11.03±9.62 hours, central compartment volume of distribution 4.26±1.86 and 10.40±2.32 L, clearance rate 0.18±0.05 and 0.38±0.10 L/h, and AUC 261.42±74.36 and 116.83±19.72 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),h,9.72,96963,DB00396,Progesterone
,31440031,time to Cmax,"By the vaginal route, steady-state maximum concentration (Cmax) of Yimaxin and Utrogestan was 29.13±8.09 and 12.30±1.60 mg/L, time to Cmax 9.72±10.50 and 11.03±9.62 hours, central compartment volume of distribution 4.26±1.86 and 10.40±2.32 L, clearance rate 0.18±0.05 and 0.38±0.10 L/h, and AUC 261.42±74.36 and 116.83±19.72 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),h,11.03,96964,DB00396,Progesterone
,31440031,central compartment volume of distribution,"By the vaginal route, steady-state maximum concentration (Cmax) of Yimaxin and Utrogestan was 29.13±8.09 and 12.30±1.60 mg/L, time to Cmax 9.72±10.50 and 11.03±9.62 hours, central compartment volume of distribution 4.26±1.86 and 10.40±2.32 L, clearance rate 0.18±0.05 and 0.38±0.10 L/h, and AUC 261.42±74.36 and 116.83±19.72 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),l,4.26,96965,DB00396,Progesterone
,31440031,central compartment volume of distribution,"By the vaginal route, steady-state maximum concentration (Cmax) of Yimaxin and Utrogestan was 29.13±8.09 and 12.30±1.60 mg/L, time to Cmax 9.72±10.50 and 11.03±9.62 hours, central compartment volume of distribution 4.26±1.86 and 10.40±2.32 L, clearance rate 0.18±0.05 and 0.38±0.10 L/h, and AUC 261.42±74.36 and 116.83±19.72 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),l,10.40,96966,DB00396,Progesterone
,31440031,clearance rate,"By the vaginal route, steady-state maximum concentration (Cmax) of Yimaxin and Utrogestan was 29.13±8.09 and 12.30±1.60 mg/L, time to Cmax 9.72±10.50 and 11.03±9.62 hours, central compartment volume of distribution 4.26±1.86 and 10.40±2.32 L, clearance rate 0.18±0.05 and 0.38±0.10 L/h, and AUC 261.42±74.36 and 116.83±19.72 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),[l] / [h],0.18,96967,DB00396,Progesterone
,31440031,clearance rate,"By the vaginal route, steady-state maximum concentration (Cmax) of Yimaxin and Utrogestan was 29.13±8.09 and 12.30±1.60 mg/L, time to Cmax 9.72±10.50 and 11.03±9.62 hours, central compartment volume of distribution 4.26±1.86 and 10.40±2.32 L, clearance rate 0.18±0.05 and 0.38±0.10 L/h, and AUC 261.42±74.36 and 116.83±19.72 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),[l] / [h],0.38,96968,DB00396,Progesterone
,31440031,AUC,"By the vaginal route, steady-state maximum concentration (Cmax) of Yimaxin and Utrogestan was 29.13±8.09 and 12.30±1.60 mg/L, time to Cmax 9.72±10.50 and 11.03±9.62 hours, central compartment volume of distribution 4.26±1.86 and 10.40±2.32 L, clearance rate 0.18±0.05 and 0.38±0.10 L/h, and AUC 261.42±74.36 and 116.83±19.72 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),[h·ng] / [ml],261.42,96969,DB00396,Progesterone
,31440031,AUC,"By the vaginal route, steady-state maximum concentration (Cmax) of Yimaxin and Utrogestan was 29.13±8.09 and 12.30±1.60 mg/L, time to Cmax 9.72±10.50 and 11.03±9.62 hours, central compartment volume of distribution 4.26±1.86 and 10.40±2.32 L, clearance rate 0.18±0.05 and 0.38±0.10 L/h, and AUC 261.42±74.36 and 116.83±19.72 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),[h·ng] / [ml],116.83,96970,DB00396,Progesterone
,31440031,Cmax,"By the oral route, Cmax of Yimaxin and Utrogestan was 62.97±40.59 and 169.53±130.24 mg/L, time to Cmax was 2.88±1.35 and 2.06±1.55 hours, central compartment volume of distribution 132.16±52.13 and 85.08±55.07 L, clearance rate 3.43±1.07 and 2.50±1.04 L/h, and AUC 274.86±160.28 and 472.00±250.54 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),[mg] / [l],62.97,96971,DB00396,Progesterone
,31440031,Cmax,"By the oral route, Cmax of Yimaxin and Utrogestan was 62.97±40.59 and 169.53±130.24 mg/L, time to Cmax was 2.88±1.35 and 2.06±1.55 hours, central compartment volume of distribution 132.16±52.13 and 85.08±55.07 L, clearance rate 3.43±1.07 and 2.50±1.04 L/h, and AUC 274.86±160.28 and 472.00±250.54 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),[mg] / [l],169.53,96972,DB00396,Progesterone
,31440031,time to Cmax,"By the oral route, Cmax of Yimaxin and Utrogestan was 62.97±40.59 and 169.53±130.24 mg/L, time to Cmax was 2.88±1.35 and 2.06±1.55 hours, central compartment volume of distribution 132.16±52.13 and 85.08±55.07 L, clearance rate 3.43±1.07 and 2.50±1.04 L/h, and AUC 274.86±160.28 and 472.00±250.54 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),h,2.88,96973,DB00396,Progesterone
,31440031,time to Cmax,"By the oral route, Cmax of Yimaxin and Utrogestan was 62.97±40.59 and 169.53±130.24 mg/L, time to Cmax was 2.88±1.35 and 2.06±1.55 hours, central compartment volume of distribution 132.16±52.13 and 85.08±55.07 L, clearance rate 3.43±1.07 and 2.50±1.04 L/h, and AUC 274.86±160.28 and 472.00±250.54 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),h,2.06,96974,DB00396,Progesterone
,31440031,central compartment volume of distribution,"By the oral route, Cmax of Yimaxin and Utrogestan was 62.97±40.59 and 169.53±130.24 mg/L, time to Cmax was 2.88±1.35 and 2.06±1.55 hours, central compartment volume of distribution 132.16±52.13 and 85.08±55.07 L, clearance rate 3.43±1.07 and 2.50±1.04 L/h, and AUC 274.86±160.28 and 472.00±250.54 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),l,132.16,96975,DB00396,Progesterone
,31440031,central compartment volume of distribution,"By the oral route, Cmax of Yimaxin and Utrogestan was 62.97±40.59 and 169.53±130.24 mg/L, time to Cmax was 2.88±1.35 and 2.06±1.55 hours, central compartment volume of distribution 132.16±52.13 and 85.08±55.07 L, clearance rate 3.43±1.07 and 2.50±1.04 L/h, and AUC 274.86±160.28 and 472.00±250.54 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),l,85.08,96976,DB00396,Progesterone
,31440031,clearance rate,"By the oral route, Cmax of Yimaxin and Utrogestan was 62.97±40.59 and 169.53±130.24 mg/L, time to Cmax was 2.88±1.35 and 2.06±1.55 hours, central compartment volume of distribution 132.16±52.13 and 85.08±55.07 L, clearance rate 3.43±1.07 and 2.50±1.04 L/h, and AUC 274.86±160.28 and 472.00±250.54 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),[l] / [h],3.43,96977,DB00396,Progesterone
,31440031,clearance rate,"By the oral route, Cmax of Yimaxin and Utrogestan was 62.97±40.59 and 169.53±130.24 mg/L, time to Cmax was 2.88±1.35 and 2.06±1.55 hours, central compartment volume of distribution 132.16±52.13 and 85.08±55.07 L, clearance rate 3.43±1.07 and 2.50±1.04 L/h, and AUC 274.86±160.28 and 472.00±250.54 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),[l] / [h],2.50,96978,DB00396,Progesterone
,31440031,AUC,"By the oral route, Cmax of Yimaxin and Utrogestan was 62.97±40.59 and 169.53±130.24 mg/L, time to Cmax was 2.88±1.35 and 2.06±1.55 hours, central compartment volume of distribution 132.16±52.13 and 85.08±55.07 L, clearance rate 3.43±1.07 and 2.50±1.04 L/h, and AUC 274.86±160.28 and 472.00±250.54 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),[h·ng] / [ml],274.86,96979,DB00396,Progesterone
,31440031,AUC,"By the oral route, Cmax of Yimaxin and Utrogestan was 62.97±40.59 and 169.53±130.24 mg/L, time to Cmax was 2.88±1.35 and 2.06±1.55 hours, central compartment volume of distribution 132.16±52.13 and 85.08±55.07 L, clearance rate 3.43±1.07 and 2.50±1.04 L/h, and AUC 274.86±160.28 and 472.00±250.54 h·ng/mL, respectively.",Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31440031/),[h·ng] / [ml],472.00,96980,DB00396,Progesterone
,7343970,MCR,The MCR was calculated to be 77.3 +/- 14.2 (mean +/- SE) ml plasma/min/kg and the PR 6.36 +/- 1.46 ng/min.,Pharmacokinetics of estradiol-17 beta in the laying hen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7343970/),[ml·plasma] / [kg·min],77.3,97777,DB00396,Progesterone
,7343970,MCR,The MCR was calculated to be 77.3 +/- 14.2 (mean +/- SE) ml plasma/min/kg and the PR 6.36 +/- 1.46 ng/min.,Pharmacokinetics of estradiol-17 beta in the laying hen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7343970/),[ng] / [min],6.36,97778,DB00396,Progesterone
,7343970,PR,The MCR was calculated to be 77.3 +/- 14.2 (mean +/- SE) ml plasma/min/kg and the PR 6.36 +/- 1.46 ng/min.,Pharmacokinetics of estradiol-17 beta in the laying hen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7343970/),[ng] / [min],6.36,97779,DB00396,Progesterone
,7343970,T 1/2,"The T 1/2 for the distribution (or alpha) phase was 1.1 +/- .2 min and for the storage, metabolism, and excretory (or beta) phase was 27.5 +/- 6.5 min.",Pharmacokinetics of estradiol-17 beta in the laying hen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7343970/),min,1.1,97780,DB00396,Progesterone
,7343970,T 1/2,"The T 1/2 for the distribution (or alpha) phase was 1.1 +/- .2 min and for the storage, metabolism, and excretory (or beta) phase was 27.5 +/- 6.5 min.",Pharmacokinetics of estradiol-17 beta in the laying hen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7343970/),min,27.5,97781,DB00396,Progesterone
,17519152,maximum concentrations (Cmax),"Serum LNG maximum concentrations (Cmax) were 14.1+/-2.1 and 11.7+/-2.7 nmol/L and Tmax was 12.0 and 6.0 h for the low and high dose, respectively, with large intersubject variability within the first 48 h.","Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for ""dual protection"" contraception. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17519152/),[nM] / [l],14.1,97960,DB00396,Progesterone
,17519152,maximum concentrations (Cmax),"Serum LNG maximum concentrations (Cmax) were 14.1+/-2.1 and 11.7+/-2.7 nmol/L and Tmax was 12.0 and 6.0 h for the low and high dose, respectively, with large intersubject variability within the first 48 h.","Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for ""dual protection"" contraception. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17519152/),[nM] / [l],11.7,97961,DB00396,Progesterone
,17519152,Tmax,"Serum LNG maximum concentrations (Cmax) were 14.1+/-2.1 and 11.7+/-2.7 nmol/L and Tmax was 12.0 and 6.0 h for the low and high dose, respectively, with large intersubject variability within the first 48 h.","Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for ""dual protection"" contraception. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17519152/),h,12.0,97962,DB00396,Progesterone
,17519152,Tmax,"Serum LNG maximum concentrations (Cmax) were 14.1+/-2.1 and 11.7+/-2.7 nmol/L and Tmax was 12.0 and 6.0 h for the low and high dose, respectively, with large intersubject variability within the first 48 h.","Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for ""dual protection"" contraception. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17519152/),h,6.0,97963,DB00396,Progesterone
,2193662,half-life,"The pharmacokinetics of RU 486 are characterised by high micromolar serum concentrations, long half-life of 26-48 hours and substantial metabolism after oral administration.",Antiprogesterone RU 486--a drug for non-surgical abortion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2193662/),h,26-48,98131,DB00396,Progesterone
,8549229,half-life,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),h,1.150,98700,DB00396,Progesterone
,8549229,excretion constant,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ke] / [h],0.686,98701,DB00396,Progesterone
,8549229,volume of distribution,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ml] / [kg],607,98702,DB00396,Progesterone
,8549229,clearance rate,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ml] / [h·kg],374,98703,DB00396,Progesterone
,30043470,maximum concentrations,"Mean maximum concentrations were 14.9 ± 2.24 and 14.3 ± 2.16 ng/ml for Group A versus Group B (p = 0.58), and they were registered on Day 1.5 ± 0.22 and 1.7 ± 0.34 days, respectively (p = 0.10).",Administration of progesterone BioRelease LA inhibits follicular growth in llamas (Lama glama) regardless of follicle diameter at the start of treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30043470/),[ng] / [ml],14.9,99589,DB00396,Progesterone
,30043470,maximum concentrations,"Mean maximum concentrations were 14.9 ± 2.24 and 14.3 ± 2.16 ng/ml for Group A versus Group B (p = 0.58), and they were registered on Day 1.5 ± 0.22 and 1.7 ± 0.34 days, respectively (p = 0.10).",Administration of progesterone BioRelease LA inhibits follicular growth in llamas (Lama glama) regardless of follicle diameter at the start of treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30043470/),[ng] / [ml],14.3,99590,DB00396,Progesterone
,18061638,EC50,"Dienogest activate PR (EC50=3.4 or 10.5 nmol/l) with antagonistic activity on AR (EC50=420.6 or 775.0 nmol/l) but not agonistic nor antagonistic action on GR, MR (3000 nmol/l).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[nM] / [l],3.4,100284,DB00396,Progesterone
,18061638,EC50,"Dienogest activate PR (EC50=3.4 or 10.5 nmol/l) with antagonistic activity on AR (EC50=420.6 or 775.0 nmol/l) but not agonistic nor antagonistic action on GR, MR (3000 nmol/l).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[nM] / [l],10.5,100285,DB00396,Progesterone
,18061638,EC50,"Dienogest activate PR (EC50=3.4 or 10.5 nmol/l) with antagonistic activity on AR (EC50=420.6 or 775.0 nmol/l) but not agonistic nor antagonistic action on GR, MR (3000 nmol/l).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[nM] / [l],420.6,100286,DB00396,Progesterone
,18061638,EC50,"Dienogest activate PR (EC50=3.4 or 10.5 nmol/l) with antagonistic activity on AR (EC50=420.6 or 775.0 nmol/l) but not agonistic nor antagonistic action on GR, MR (3000 nmol/l).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[nM] / [l],775.0,100287,DB00396,Progesterone
,18061638,ED50,"By oral treatment, dienogest showed the strongest endometrial activity (ED50=0.0042 mg/kg) in McPhail test among other progestins (ED50 values for MPA, DYG, NES were 0.074, 1.9, >0.05 mg/kg, respectively).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[mg] / [kg],0.0042,100288,DB00396,Progesterone
,18061638,ED50,"By oral treatment, dienogest showed the strongest endometrial activity (ED50=0.0042 mg/kg) in McPhail test among other progestins (ED50 values for MPA, DYG, NES were 0.074, 1.9, >0.05 mg/kg, respectively).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[mg] / [kg],0.074,100289,DB00396,Progesterone
,18061638,ED50,"By oral treatment, dienogest showed the strongest endometrial activity (ED50=0.0042 mg/kg) in McPhail test among other progestins (ED50 values for MPA, DYG, NES were 0.074, 1.9, >0.05 mg/kg, respectively).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[mg] / [kg],1.9,100290,DB00396,Progesterone
,18061638,ED50,"By oral treatment, dienogest showed the strongest endometrial activity (ED50=0.0042 mg/kg) in McPhail test among other progestins (ED50 values for MPA, DYG, NES were 0.074, 1.9, >0.05 mg/kg, respectively).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[mg] / [kg],0.05,100291,DB00396,Progesterone
,18061638,ED50,The estimated plasma concentration of dienogest at ED50 (3.66 nmol/l) was close to its EC50 value to activate PR.,Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[nM] / [l],3.66,100292,DB00396,Progesterone
,11245553,terminal half-lives,"Serum concentrations ofdrospirenone declined, with mean terminal half-lives of 30.8-32.5 h.",A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11245553/),h,30.8-32.5,100703,DB00396,Progesterone
,11245553,accumulation ratio,"Accumulation of both drospirenone and ethinylestradiol was observed within a treatment cycle, with a mean accumulation ratio of 3.0 for drospirenone and 2.1 for ethinylestradiol.",A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11245553/),,3.0,100704,DB00396,Progesterone
,11245553,accumulation ratio,"Accumulation of both drospirenone and ethinylestradiol was observed within a treatment cycle, with a mean accumulation ratio of 3.0 for drospirenone and 2.1 for ethinylestradiol.",A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11245553/),,2.1,100705,DB00396,Progesterone
,3937664,release rate,The pharmacokinetic and pharmacodynamic effects of a new type of levonorgestrel-releasing vaginal device (with an in vitro release rate of 25 micrograms/24 h) were studied in a group of 18 normally menstruating women during a period of 90 days of continuous use.,A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937664/),[μg] / [24·h],25,101141,DB00396,Progesterone
,22028249,absorption rate constant (Ka),Telapristone was rapidly absorbed with an absorption rate constant (Ka) of 1.26 h(-1).,"Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028249/),1/[h],1.26,101209,DB00396,Progesterone
,22028249,oral clearance (CL/F),"The population estimates for oral clearance (CL/F) for the two populations were 11.6 and 3.34 L/h, respectively, with 25% of the subjects being allocated to the high-clearance group.","Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028249/),[l] / [h],11.6,101210,DB00396,Progesterone
,22028249,oral clearance (CL/F),"The population estimates for oral clearance (CL/F) for the two populations were 11.6 and 3.34 L/h, respectively, with 25% of the subjects being allocated to the high-clearance group.","Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028249/),[l] / [h],3.34,101211,DB00396,Progesterone
,22028249,Apparent volume of distribution for the central compartment (V2/F),"Apparent volume of distribution for the central compartment (V2/F) was 37.4 L, apparent inter-compartmental clearance (Q/F) was 21.9 L/h, and apparent peripheral volume of distribution for the parent (V4/F) was 120 L.","Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028249/),l,37.4,101212,DB00396,Progesterone
,22028249,apparent inter-compartmental clearance (Q/F),"Apparent volume of distribution for the central compartment (V2/F) was 37.4 L, apparent inter-compartmental clearance (Q/F) was 21.9 L/h, and apparent peripheral volume of distribution for the parent (V4/F) was 120 L.","Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028249/),[l] / [h],21.9,101213,DB00396,Progesterone
,22028249,apparent peripheral volume of distribution,"Apparent volume of distribution for the central compartment (V2/F) was 37.4 L, apparent inter-compartmental clearance (Q/F) was 21.9 L/h, and apparent peripheral volume of distribution for the parent (V4/F) was 120 L.","Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028249/),l,120,101214,DB00396,Progesterone
,22028249,V4/F),"Apparent volume of distribution for the central compartment (V2/F) was 37.4 L, apparent inter-compartmental clearance (Q/F) was 21.9 L/h, and apparent peripheral volume of distribution for the parent (V4/F) was 120 L.","Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028249/),l,120,101215,DB00396,Progesterone
,22028249,Apparent volume of distribution of the metabolite compartment (V3/F),Apparent volume of distribution of the metabolite compartment (V3/F) was fixed to 1 L and apparent clearance of the metabolite (CLM/F) was 2.43 L/h.,"Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028249/),l,1,101216,DB00396,Progesterone
,22028249,apparent clearance of the metabolite (CLM/F),Apparent volume of distribution of the metabolite compartment (V3/F) was fixed to 1 L and apparent clearance of the metabolite (CLM/F) was 2.43 L/h.,"Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028249/),[l] / [h],2.43,101217,DB00396,Progesterone
,9842983,Time of maximum concentration (tmax),"Time of maximum concentration (tmax) was, in all cases, in the neighborhood of 4 h.",Pharmacokinetics of progesterone in postmenopausal women: 2. Pharmacokinetics following percutaneous administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842983/),h,4,101851,DB00396,Progesterone
,9842983,peak plasma concentrations,"Mean peak plasma concentrations were: 1 ng/ml for the lipophilic, 1.24 ng/ml for the hydrophilic and 2.26 ng/ml for the emulsion type base.",Pharmacokinetics of progesterone in postmenopausal women: 2. Pharmacokinetics following percutaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842983/),[ng] / [ml],1,101852,DB00396,Progesterone
,9842983,peak plasma concentrations,"Mean peak plasma concentrations were: 1 ng/ml for the lipophilic, 1.24 ng/ml for the hydrophilic and 2.26 ng/ml for the emulsion type base.",Pharmacokinetics of progesterone in postmenopausal women: 2. Pharmacokinetics following percutaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842983/),[ng] / [ml],1.24,101853,DB00396,Progesterone
,9842983,peak plasma concentrations,"Mean peak plasma concentrations were: 1 ng/ml for the lipophilic, 1.24 ng/ml for the hydrophilic and 2.26 ng/ml for the emulsion type base.",Pharmacokinetics of progesterone in postmenopausal women: 2. Pharmacokinetics following percutaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842983/),[ng] / [ml],2.26,101854,DB00396,Progesterone
,9842983,half-time,"The elimination was slow, with a half-time varying in the range of 3040 h for all three types of base, a value that was much higher than those obtained after administration of progesterone via vaginal suppositories.",Pharmacokinetics of progesterone in postmenopausal women: 2. Pharmacokinetics following percutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842983/),h,3040,101855,DB00396,Progesterone
,24738581,IC50,"From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration.","Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24738581/),nM,4.5,101928,DB00396,Progesterone
,1816419,t 1/2 ka,"Average t 1/2 ka, t 1/2 alpha and t 1/2 beta with standard deviation for oral administration were 0.21 +/- 0.08 (h), 1.28 +/- 0.31 (h) and 10.01 +/- 4.59 (h) for NET and 0.37 +/- 0.81 (h), 0.90 +/- 0.26 (h) and 8.55 +/- 2.21 (h) for NETO respectively.",Pharmacokinetic studies of norethisterone-3-oxime and norethisterone-3-oxime acetate in rhesus monkey. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1816419/),h,0.21,109947,DB00396,Progesterone
,1816419,t 1/2 alpha,"Average t 1/2 ka, t 1/2 alpha and t 1/2 beta with standard deviation for oral administration were 0.21 +/- 0.08 (h), 1.28 +/- 0.31 (h) and 10.01 +/- 4.59 (h) for NET and 0.37 +/- 0.81 (h), 0.90 +/- 0.26 (h) and 8.55 +/- 2.21 (h) for NETO respectively.",Pharmacokinetic studies of norethisterone-3-oxime and norethisterone-3-oxime acetate in rhesus monkey. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1816419/),h,1.28,109948,DB00396,Progesterone
,1816419,t 1/2 alpha,"Average t 1/2 ka, t 1/2 alpha and t 1/2 beta with standard deviation for oral administration were 0.21 +/- 0.08 (h), 1.28 +/- 0.31 (h) and 10.01 +/- 4.59 (h) for NET and 0.37 +/- 0.81 (h), 0.90 +/- 0.26 (h) and 8.55 +/- 2.21 (h) for NETO respectively.",Pharmacokinetic studies of norethisterone-3-oxime and norethisterone-3-oxime acetate in rhesus monkey. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1816419/),h,0.37,109949,DB00396,Progesterone
,1816419,t 1/2 alpha,"Average t 1/2 ka, t 1/2 alpha and t 1/2 beta with standard deviation for oral administration were 0.21 +/- 0.08 (h), 1.28 +/- 0.31 (h) and 10.01 +/- 4.59 (h) for NET and 0.37 +/- 0.81 (h), 0.90 +/- 0.26 (h) and 8.55 +/- 2.21 (h) for NETO respectively.",Pharmacokinetic studies of norethisterone-3-oxime and norethisterone-3-oxime acetate in rhesus monkey. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1816419/),h,0.90,109950,DB00396,Progesterone
,1816419,t 1/2 beta,"Average t 1/2 ka, t 1/2 alpha and t 1/2 beta with standard deviation for oral administration were 0.21 +/- 0.08 (h), 1.28 +/- 0.31 (h) and 10.01 +/- 4.59 (h) for NET and 0.37 +/- 0.81 (h), 0.90 +/- 0.26 (h) and 8.55 +/- 2.21 (h) for NETO respectively.",Pharmacokinetic studies of norethisterone-3-oxime and norethisterone-3-oxime acetate in rhesus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1816419/),h,10.01,109951,DB00396,Progesterone
,1816419,t 1/2 beta,"Average t 1/2 ka, t 1/2 alpha and t 1/2 beta with standard deviation for oral administration were 0.21 +/- 0.08 (h), 1.28 +/- 0.31 (h) and 10.01 +/- 4.59 (h) for NET and 0.37 +/- 0.81 (h), 0.90 +/- 0.26 (h) and 8.55 +/- 2.21 (h) for NETO respectively.",Pharmacokinetic studies of norethisterone-3-oxime and norethisterone-3-oxime acetate in rhesus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1816419/),h,8.55,109952,DB00396,Progesterone
,4054341,Peak concentrations,Peak concentrations of P rose from a negligible baseline level to 17.0 +/- 4.9 ng/ml at an average of 2.8 +/- 0.35 hours after administration.,Bioavailability of oral micronized progesterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4054341/),[ng] / [ml],17.0,110188,DB00396,Progesterone
,4054341,peak concentrations,The peak concentrations of P were equivalent to those observed in the midluteal phase in normal control cycles (14.1 +/- 2.7 ng/ml).,Bioavailability of oral micronized progesterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4054341/),[ng] / [ml],14.1,110189,DB00396,Progesterone
,10073327,Noncompartmental clearances,"Noncompartmental clearances (mean +/- SD) were 7.36 +/- 2.73, 6.34 +/- 3.59, and 6.23 +/- 2.04 ml/kg/min, respectively, on days 2, 13, and 21 of the menstrual cycle.",Menstrual cycle variability in midazolam pharmacokinetics. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073327/),[ml] / [kg·min],7.36,111359,DB00396,Progesterone
,10073327,Noncompartmental clearances,"Noncompartmental clearances (mean +/- SD) were 7.36 +/- 2.73, 6.34 +/- 3.59, and 6.23 +/- 2.04 ml/kg/min, respectively, on days 2, 13, and 21 of the menstrual cycle.",Menstrual cycle variability in midazolam pharmacokinetics. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073327/),[ml] / [kg·min],6.34,111360,DB00396,Progesterone
,10073327,Noncompartmental clearances,"Noncompartmental clearances (mean +/- SD) were 7.36 +/- 2.73, 6.34 +/- 3.59, and 6.23 +/- 2.04 ml/kg/min, respectively, on days 2, 13, and 21 of the menstrual cycle.",Menstrual cycle variability in midazolam pharmacokinetics. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073327/),[ml] / [kg·min],6.23,111361,DB00396,Progesterone
,23153898,clearance,"Key LNG PK parameters were as follows: clearance, 0.52 L/h (SD 0.24); half-life, 65 h (SD 40); area under the curve (AUC), 232 h*ng/mL (SD 102); and time to reach steady state, 13.6 days (SD 8.4).",Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153898/),[l] / [h],0.52,111704,DB00396,Progesterone
,23153898,half-life,"Key LNG PK parameters were as follows: clearance, 0.52 L/h (SD 0.24); half-life, 65 h (SD 40); area under the curve (AUC), 232 h*ng/mL (SD 102); and time to reach steady state, 13.6 days (SD 8.4).",Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153898/),h,65,111705,DB00396,Progesterone
,23153898,area under the curve (AUC),"Key LNG PK parameters were as follows: clearance, 0.52 L/h (SD 0.24); half-life, 65 h (SD 40); area under the curve (AUC), 232 h*ng/mL (SD 102); and time to reach steady state, 13.6 days (SD 8.4).",Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153898/),[h·ng] / [ml],232,111706,DB00396,Progesterone
,23153898,time to reach steady state,"Key LNG PK parameters were as follows: clearance, 0.52 L/h (SD 0.24); half-life, 65 h (SD 40); area under the curve (AUC), 232 h*ng/mL (SD 102); and time to reach steady state, 13.6 days (SD 8.4).",Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153898/),d,13.6,111707,DB00396,Progesterone
,8725700,Serum concentrations,"Serum concentrations vary between individual women but generally plateau at about 1.0 ng/mL for about three months, after which there is a gradual decline.",Pharmacokinetics of depot medroxyprogesterone acetate contraception. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8725700/),[ng] / [ml],1.0,111745,DB00396,Progesterone
,16196307,Cmax,"The main parameters of T were: for single and multiple doses, Cmax was 48.8 +/- 11.8 ng/mL and 43.5 +/- 9.4 ng/mL, Tmax was 0.5 +/- 0.3 h and 0.4 +/- 0.3 h, AUC(0-24 h) was 362.4 +/- 143 ng x h x mL(-1) and 310.6 +/- 70.3 ng x h x mL(-1), respectively.",Bioequivalence of progesterone sustained release suppository in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16196307/),[ng] / [ml],48.8,112083,DB00396,Progesterone
,16196307,Cmax,"The main parameters of T were: for single and multiple doses, Cmax was 48.8 +/- 11.8 ng/mL and 43.5 +/- 9.4 ng/mL, Tmax was 0.5 +/- 0.3 h and 0.4 +/- 0.3 h, AUC(0-24 h) was 362.4 +/- 143 ng x h x mL(-1) and 310.6 +/- 70.3 ng x h x mL(-1), respectively.",Bioequivalence of progesterone sustained release suppository in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16196307/),[ng] / [ml],43.5,112084,DB00396,Progesterone
,16196307,Tmax,"The main parameters of T were: for single and multiple doses, Cmax was 48.8 +/- 11.8 ng/mL and 43.5 +/- 9.4 ng/mL, Tmax was 0.5 +/- 0.3 h and 0.4 +/- 0.3 h, AUC(0-24 h) was 362.4 +/- 143 ng x h x mL(-1) and 310.6 +/- 70.3 ng x h x mL(-1), respectively.",Bioequivalence of progesterone sustained release suppository in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16196307/),h,0.5,112085,DB00396,Progesterone
,16196307,Tmax,"The main parameters of T were: for single and multiple doses, Cmax was 48.8 +/- 11.8 ng/mL and 43.5 +/- 9.4 ng/mL, Tmax was 0.5 +/- 0.3 h and 0.4 +/- 0.3 h, AUC(0-24 h) was 362.4 +/- 143 ng x h x mL(-1) and 310.6 +/- 70.3 ng x h x mL(-1), respectively.",Bioequivalence of progesterone sustained release suppository in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16196307/),h,0.4,112086,DB00396,Progesterone
,16196307,AUC(0-24 h),"The main parameters of T were: for single and multiple doses, Cmax was 48.8 +/- 11.8 ng/mL and 43.5 +/- 9.4 ng/mL, Tmax was 0.5 +/- 0.3 h and 0.4 +/- 0.3 h, AUC(0-24 h) was 362.4 +/- 143 ng x h x mL(-1) and 310.6 +/- 70.3 ng x h x mL(-1), respectively.",Bioequivalence of progesterone sustained release suppository in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16196307/),[h·ng] / [ml],362.4,112087,DB00396,Progesterone
,16196307,AUC(0-24 h),"The main parameters of T were: for single and multiple doses, Cmax was 48.8 +/- 11.8 ng/mL and 43.5 +/- 9.4 ng/mL, Tmax was 0.5 +/- 0.3 h and 0.4 +/- 0.3 h, AUC(0-24 h) was 362.4 +/- 143 ng x h x mL(-1) and 310.6 +/- 70.3 ng x h x mL(-1), respectively.",Bioequivalence of progesterone sustained release suppository in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16196307/),[h·ng] / [ml],310.6,112088,DB00396,Progesterone
,16196307,relative bioavailability,"The relative bioavailability of T to R were (104.2 +/- 13.4)% and (111.4 +/- 19.1)%, respectively.",Bioequivalence of progesterone sustained release suppository in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16196307/),%,104.2,112089,DB00396,Progesterone
,16196307,relative bioavailability,"The relative bioavailability of T to R were (104.2 +/- 13.4)% and (111.4 +/- 19.1)%, respectively.",Bioequivalence of progesterone sustained release suppository in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16196307/),%,111.4,112090,DB00396,Progesterone
,2368944,peak serum progesterone concentration,The mean (+/- SD) peak serum progesterone concentration (34.3 +/- 7.8 ng/ml) was reached at 1.8 +/- 0.2 hours after progesterone administration.,Serum disposition of exogenous progesterone after intramuscular administration in bitches. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2368944/),[ng] / [ml],34.3,112204,DB00396,Progesterone
,2368944,serum progesterone concentration,The mean serum progesterone concentration was 6.9 +/- 1.4 ng/ml at 24 hours and 2.0 +/- 0.4 ng/ml at 48 hours after progesterone administration.,Serum disposition of exogenous progesterone after intramuscular administration in bitches. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2368944/),[ng] / [ml],6.9,112205,DB00396,Progesterone
,2368944,serum progesterone concentration,The mean serum progesterone concentration was 6.9 +/- 1.4 ng/ml at 24 hours and 2.0 +/- 0.4 ng/ml at 48 hours after progesterone administration.,Serum disposition of exogenous progesterone after intramuscular administration in bitches. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2368944/),[ng] / [ml],2.0,112206,DB00396,Progesterone
,2368944,half-life of the absorption phase,"The mean half-life of the absorption phase was 0.5 hours (range, 0.3 to 0.7 hours).",Serum disposition of exogenous progesterone after intramuscular administration in bitches. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2368944/),h,0.5,112207,DB00396,Progesterone
,2368944,half-life of elimination,"The mean half-life of elimination was 12.1 hours (range, 9.5 to 13.8 hours).",Serum disposition of exogenous progesterone after intramuscular administration in bitches. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2368944/),h,12.1,112208,DB00396,Progesterone
,1823082,maximal EE levels,"In the steady state, the maximal EE levels were 75 +/- 34 pg/ml (20EE/DG) and 136 +/- 55 pg/ml (30EE/DG), and the AUC were 464 +/- 236 pg.h/ml and 840 +/- 492 pg.h/ml.",Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823082/),[pg] / [ml],75,112755,DB00396,Progesterone
,1823082,maximal EE levels,"In the steady state, the maximal EE levels were 75 +/- 34 pg/ml (20EE/DG) and 136 +/- 55 pg/ml (30EE/DG), and the AUC were 464 +/- 236 pg.h/ml and 840 +/- 492 pg.h/ml.",Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823082/),[pg] / [ml],136,112756,DB00396,Progesterone
,1823082,AUC,"In the steady state, the maximal EE levels were 75 +/- 34 pg/ml (20EE/DG) and 136 +/- 55 pg/ml (30EE/DG), and the AUC were 464 +/- 236 pg.h/ml and 840 +/- 492 pg.h/ml.",Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823082/),[h·pg] / [ml],464,112757,DB00396,Progesterone
,1823082,AUC,"In the steady state, the maximal EE levels were 75 +/- 34 pg/ml (20EE/DG) and 136 +/- 55 pg/ml (30EE/DG), and the AUC were 464 +/- 236 pg.h/ml and 840 +/- 492 pg.h/ml.",Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823082/),[h·pg] / [ml],840,112758,DB00396,Progesterone
,10235296,BECs,Mean BECs 60 min after 1.0 g/kg ethanol were: males = 86 mg/dl (+/- 2; n = 4) and females = 82 mg/dl (+/- 5; n = 4).,Comparison of ethanol metabolism in male and female cynomolgus macaques (Macaca fascicularis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235296/),[mg] / [dl],86,112842,DB00396,Progesterone
,10235296,BECs,Mean BECs 60 min after 1.0 g/kg ethanol were: males = 86 mg/dl (+/- 2; n = 4) and females = 82 mg/dl (+/- 5; n = 4).,Comparison of ethanol metabolism in male and female cynomolgus macaques (Macaca fascicularis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235296/),[mg] / [dl],82,112843,DB00396,Progesterone
,10235296,rates of ethanol elimination,Female monkeys did have faster average rates of ethanol elimination [34 +/- 2 (mg/dl)/hr] compared with males [23 +/- 1 (mg/dl)/hr].,Comparison of ethanol metabolism in male and female cynomolgus macaques (Macaca fascicularis). ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235296/),[mg] / [dl)·h],34,112844,DB00396,Progesterone
,10235296,rates of ethanol elimination,Female monkeys did have faster average rates of ethanol elimination [34 +/- 2 (mg/dl)/hr] compared with males [23 +/- 1 (mg/dl)/hr].,Comparison of ethanol metabolism in male and female cynomolgus macaques (Macaca fascicularis). ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235296/),[mg] / [dl],23,112845,DB00396,Progesterone
,3743792,peak plasma concentrations,"Mean peak plasma concentrations of P were observed 2 hours after ingestion of both the 100 and 200 mg doses and were 22.7 and 47.7 nmol/l, respectively.",Absorption and metabolism of oral progesterone when administered twice daily. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743792/),[nM] / [l],22.7,117559,DB00396,Progesterone
,3743792,peak plasma concentrations,"Mean peak plasma concentrations of P were observed 2 hours after ingestion of both the 100 and 200 mg doses and were 22.7 and 47.7 nmol/l, respectively.",Absorption and metabolism of oral progesterone when administered twice daily. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743792/),[nM] / [l],47.7,117560,DB00396,Progesterone
,3741527,t1/2,The half-life of the slow disposition phase of RU 486 was significantly lower (t1/2 = 52 min: P greater than 0.05) than those of RU 486 metabolites (t1/2 = 99 min).,"Pharmacokinetics of the progesterone antagonist 17 beta-hydroxy-11 beta-(4-dimethylaminophenyl)-17 alpha-(1-propynyl) estra-4,9-dien-3-one in the rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741527/),min,52,120015,DB00396,Progesterone
,3741527,t1/2,The half-life of the slow disposition phase of RU 486 was significantly lower (t1/2 = 52 min: P greater than 0.05) than those of RU 486 metabolites (t1/2 = 99 min).,"Pharmacokinetics of the progesterone antagonist 17 beta-hydroxy-11 beta-(4-dimethylaminophenyl)-17 alpha-(1-propynyl) estra-4,9-dien-3-one in the rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741527/),min,99,120016,DB00396,Progesterone
,3741527,apparent volumes of distribution,"High apparent volumes of distribution of RU 486 and RU 486 metabolites (5.8 and 6.0 l/kg, respectively) indicated a high extravascular binding.","Pharmacokinetics of the progesterone antagonist 17 beta-hydroxy-11 beta-(4-dimethylaminophenyl)-17 alpha-(1-propynyl) estra-4,9-dien-3-one in the rabbit. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741527/),[l] / [kg],5.8,120017,DB00396,Progesterone
,3741527,apparent volumes of distribution,"High apparent volumes of distribution of RU 486 and RU 486 metabolites (5.8 and 6.0 l/kg, respectively) indicated a high extravascular binding.","Pharmacokinetics of the progesterone antagonist 17 beta-hydroxy-11 beta-(4-dimethylaminophenyl)-17 alpha-(1-propynyl) estra-4,9-dien-3-one in the rabbit. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741527/),[l] / [kg],6.0,120018,DB00396,Progesterone
,30280353,z-average particle size,"In the current study, a CMA-based self-microemulsifying drug delivery system (SMEDDS) was developed using 32% ethyl oleate as an oil phase, 40% Tween-80 as a surfactant, and 12% Transcutol P combined with 16% PEG400 as a cosurfactant, resulting in spherical droplets with a z-average particle size of 38.92 nm and an average zeta potential of - 3.18 mv.",Enhanced Oral Bioavailability of Chlormadinone Acetate through a Self-Microemulsifying Drug Delivery System for a Potential Dose Reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30280353/),nm,38.92,120785,DB00396,Progesterone
,30280353,zeta potential,"In the current study, a CMA-based self-microemulsifying drug delivery system (SMEDDS) was developed using 32% ethyl oleate as an oil phase, 40% Tween-80 as a surfactant, and 12% Transcutol P combined with 16% PEG400 as a cosurfactant, resulting in spherical droplets with a z-average particle size of 38.92 nm and an average zeta potential of - 3.18 mv.",Enhanced Oral Bioavailability of Chlormadinone Acetate through a Self-Microemulsifying Drug Delivery System for a Potential Dose Reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30280353/),mv,- 3.18,120786,DB00396,Progesterone
,29191450,Cmax,"Subcutaneous administration resulted in a higher geometric mean Cmax than intramuscular administration (7.88 vs 6.91 ng/mL), but median Tmax values were comparable (48.1 vs 49.7 hours).","Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29191450/),[ng] / [ml],7.88,121890,DB00396,Progesterone
,29191450,Cmax,"Subcutaneous administration resulted in a higher geometric mean Cmax than intramuscular administration (7.88 vs 6.91 ng/mL), but median Tmax values were comparable (48.1 vs 49.7 hours).","Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29191450/),[ng] / [ml],6.91,121891,DB00396,Progesterone
,29191450,Tmax,"Subcutaneous administration resulted in a higher geometric mean Cmax than intramuscular administration (7.88 vs 6.91 ng/mL), but median Tmax values were comparable (48.1 vs 49.7 hours).","Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29191450/),h,48.1,121892,DB00396,Progesterone
,29191450,Tmax,"Subcutaneous administration resulted in a higher geometric mean Cmax than intramuscular administration (7.88 vs 6.91 ng/mL), but median Tmax values were comparable (48.1 vs 49.7 hours).","Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29191450/),h,49.7,121893,DB00396,Progesterone
,29191450,t½,The geometric mean t½ of HPC was 212 hours for the subcutaneous administration and 188 hours for the intramuscular administration.,"Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29191450/),h,212,121894,DB00396,Progesterone
,29191450,t½,The geometric mean t½ of HPC was 212 hours for the subcutaneous administration and 188 hours for the intramuscular administration.,"Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29191450/),h,188,121895,DB00396,Progesterone
,21543556,Clearance (CL),"Clearance (CL) of PF-02413873 was found to be high in rat (84 ml · min(-1) · kg(-1)) and low in dog (3.8 ml · min(-1) · kg(-1)), consistent with metabolic stability determined in liver microsomes and hepatocytes in these species.","Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonist. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21543556/),[ml] / [kg·min],84,123419,DB00396,Progesterone
,21543556,Clearance (CL),"Clearance (CL) of PF-02413873 was found to be high in rat (84 ml · min(-1) · kg(-1)) and low in dog (3.8 ml · min(-1) · kg(-1)), consistent with metabolic stability determined in liver microsomes and hepatocytes in these species.","Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonist. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21543556/),[ml] / [kg·min],3.8,123420,DB00396,Progesterone
,1535103,Css min,"A wide interpatient variability was noted in MPA Css min for the 70 patients who received 1,000 mg/d orally (median, 51 ng/mL; range, 10 to 269 ng/mL).",Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535103/),[ng] / [ml],51,124372,DB00396,Progesterone
,1535103,Css min,These data suggested an optimal therapeutic window for MPA Css min located within 50 to 70 ng/mL.,Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535103/),[ng] / [ml],50 to 70,124373,DB00396,Progesterone
,10689005,AUC(0-24),Progesterone given vaginally resulted in greater bioavailability with less relative variability in absorption than oral progesterone (mean AUC(0-24) = 1.48 +/- 0.16 ng.,Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women(3). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10689005/),ng,1.48,125260,DB00396,Progesterone
,10689005,C(max),"Mean C(max) for oral progesterone was much lower than that of vaginal progesterone (i.e., 2.20 +/- 3. 06 ng/mL vs. 10.51 +/- 0.46 ng/mL).",Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women(3). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10689005/),[ng] / [ml],2.20,125261,DB00396,Progesterone
,10689005,C(max),"Mean C(max) for oral progesterone was much lower than that of vaginal progesterone (i.e., 2.20 +/- 3. 06 ng/mL vs. 10.51 +/- 0.46 ng/mL).",Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women(3). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10689005/),[ng] / [ml],10.51,125262,DB00396,Progesterone
,10689005,T(max),Mean T(max) occurred earlier for oral progesterone than for Crinone (1.00 +/- 0.41 hours vs. 7.67 +/- 3.67 hours).,Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women(3). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10689005/),h,1.00,125263,DB00396,Progesterone
,10689005,T(max),Mean T(max) occurred earlier for oral progesterone than for Crinone (1.00 +/- 0.41 hours vs. 7.67 +/- 3.67 hours).,Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women(3). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10689005/),h,7.67,125264,DB00396,Progesterone
,10640166,trough concentrations (Cmin),"More important, the average MPA trough concentrations (Cmin) at the fifth and sixth monthly injections were similar (range 0.42-0.51 ng/mL) for the three injection sites and well above the threshold levels of 0.10-0.20 ng/mL required to suppress ovulation.",Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): effects of body weight and injection sites on pharmacokinetics. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640166/),[ng] / [ml],0.42-0.51,125425,DB00396,Progesterone
,10640166,trough concentrations (Cmin),"More important, the average MPA trough concentrations (Cmin) at the fifth and sixth monthly injections were similar (range 0.42-0.51 ng/mL) for the three injection sites and well above the threshold levels of 0.10-0.20 ng/mL required to suppress ovulation.",Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): effects of body weight and injection sites on pharmacokinetics. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640166/),[ng] / [ml],0.10-0.20,125426,DB00396,Progesterone
,9806255,terminal half-life,The median terminal half-life ranged from 5 to 10 h in the three different dose groups.,Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806255/),h,5 to 10,127081,DB00396,Progesterone
,9806255,terminal half-life,The median terminal half-life of Cetrorelix varied between 20 and 80 h.,Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806255/),h,20 and 80,127082,DB00396,Progesterone
,1115177,metabolic clearance rates (MCR),"Corresponding values for the metabolic clearance rates (MCR) of cortisol (by the continuous infusion method) were 306 plus or minus 33, 172 plus or minus 18, 136 plus or minus 14, and 258 plus or minus 23 (S. E.) L. per day.",Estrogen and the metabolism of progesterone in vivo. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115177/),[l] / [d],306,127236,DB00396,Progesterone
,1115177,metabolic clearance rates (MCR),"Corresponding values for the metabolic clearance rates (MCR) of cortisol (by the continuous infusion method) were 306 plus or minus 33, 172 plus or minus 18, 136 plus or minus 14, and 258 plus or minus 23 (S. E.) L. per day.",Estrogen and the metabolism of progesterone in vivo. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115177/),[l] / [d],172,127237,DB00396,Progesterone
,1115177,metabolic clearance rates (MCR),"Corresponding values for the metabolic clearance rates (MCR) of cortisol (by the continuous infusion method) were 306 plus or minus 33, 172 plus or minus 18, 136 plus or minus 14, and 258 plus or minus 23 (S. E.) L. per day.",Estrogen and the metabolism of progesterone in vivo. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115177/),[l] / [d],136,127238,DB00396,Progesterone
,1115177,metabolic clearance rates (MCR),"Corresponding values for the metabolic clearance rates (MCR) of cortisol (by the continuous infusion method) were 306 plus or minus 33, 172 plus or minus 18, 136 plus or minus 14, and 258 plus or minus 23 (S. E.) L. per day.",Estrogen and the metabolism of progesterone in vivo. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115177/),[l] / [d],258,127239,DB00396,Progesterone
,12638392,terminal half-life,"A two-compartment model described the PK of CET with median terminal half-life estimates of 9.2 and 54.5 hours after SD and MD, respectively.",Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638392/),h,9.2,127252,DB00396,Progesterone
,12638392,terminal half-life,"A two-compartment model described the PK of CET with median terminal half-life estimates of 9.2 and 54.5 hours after SD and MD, respectively.",Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638392/),h,54.5,127253,DB00396,Progesterone
,12638392,IC50,"The IC50 (for suppression) estimate was 0.73 ng/ml for SD, and EC50 (surge delay) was 1.42 ng/ml for MD.",Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638392/),[ng] / [ml],0.73,127254,DB00396,Progesterone
,12638392,EC50,"The IC50 (for suppression) estimate was 0.73 ng/ml for SD, and EC50 (surge delay) was 1.42 ng/ml for MD.",Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638392/),[ng] / [ml],1.42,127255,DB00396,Progesterone
,10839467,clearance,"Initial (day 2) caffeine clearance (n = 15, geometric mean) was 1.37 ml/min/kg body weight (coefficient of variation (CV) 48%).",Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839467/),[ml] / [body·kg·min·weight],1.37,127292,DB00396,Progesterone
,15823769,AUC over a 24-hour dosing interval (AUC(tau)),"For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg.h/mL in cycle 2 and 1143 (312) pg.h/mL in cycle 3; the mean C(max) in the respective cycles was 133 (39) and 141 (46) pg/mL.",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[h·pg] / [ml],1139,127782,DB00396,Progesterone
,15823769,AUC over a 24-hour dosing interval (AUC(tau)),"For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg.h/mL in cycle 2 and 1143 (312) pg.h/mL in cycle 3; the mean C(max) in the respective cycles was 133 (39) and 141 (46) pg/mL.",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[h·pg] / [ml],1143,127783,DB00396,Progesterone
,15823769,C(max),"For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg.h/mL in cycle 2 and 1143 (312) pg.h/mL in cycle 3; the mean C(max) in the respective cycles was 133 (39) and 141 (46) pg/mL.",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[pg] / [ml],133,127784,DB00396,Progesterone
,15823769,C(max),"For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg.h/mL in cycle 2 and 1143 (312) pg.h/mL in cycle 3; the mean C(max) in the respective cycles was 133 (39) and 141 (46) pg/mL.",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[pg] / [ml],141,127785,DB00396,Progesterone
,15823769,AUC(tau),"For NOR, the corresponding values were 140 (48) and 159 (46) ng.h/mL for AUC(tau) and 21 (5.4) and 23 (6.7) ng/mL for C(max).",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[h·ng] / [ml],140,127786,DB00396,Progesterone
,15823769,AUC(tau),"For NOR, the corresponding values were 140 (48) and 159 (46) ng.h/mL for AUC(tau) and 21 (5.4) and 23 (6.7) ng/mL for C(max).",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[h·ng] / [ml],159,127787,DB00396,Progesterone
,15823769,C(max),"For NOR, the corresponding values were 140 (48) and 159 (46) ng.h/mL for AUC(tau) and 21 (5.4) and 23 (6.7) ng/mL for C(max).",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[ng] / [ml],21,127788,DB00396,Progesterone
,15823769,C(max),"For NOR, the corresponding values were 140 (48) and 159 (46) ng.h/mL for AUC(tau) and 21 (5.4) and 23 (6.7) ng/mL for C(max).",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[ng] / [ml],23,127789,DB00396,Progesterone
,25065668,progression free survival,L steady-state plasma concentrations were 20% lower after 28 days of co-administration with T. Eight (36.4%) patients experienced stable disease and median progression free survival was 2.7 months.,A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25065668/),month,2.7,130192,DB00396,Progesterone
,2801843,peak progesterone levels,Mean peak progesterone levels (30.3 +/- 7.0 ng/ml) (p less than 0.005) were achieved with micronized progesterone in oil at 2.0 +/- 0.3 (p less than 0.05) hours after administration.,Absorption of oral progesterone is influenced by vehicle and particle size. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2801843/),[ng] / [ml],30.3,130547,DB00396,Progesterone
,2801843,peak,"Four types of oral progesterone had equivalent mean peak elevations and mean times to peak: plain milled, 9.6 +/- 2.5 ng/ml at 4.0 +/- 0.5 hours; micronized 13.2 +/- 2.4 ng/ml at 3.2 +/- 0.4 hours; plain milled in oil, 11.3 +/- 3.0 ng/ml at 4.0 +/- 0.5 hours; and micronized in enteric-coated capsules, 11.2 +/- 3.0 ng/ml at 4.1 +/- 0.7 hours.",Absorption of oral progesterone is influenced by vehicle and particle size. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2801843/),[ng] / [ml],9.6,130548,DB00396,Progesterone
,2801843,peak,"Four types of oral progesterone had equivalent mean peak elevations and mean times to peak: plain milled, 9.6 +/- 2.5 ng/ml at 4.0 +/- 0.5 hours; micronized 13.2 +/- 2.4 ng/ml at 3.2 +/- 0.4 hours; plain milled in oil, 11.3 +/- 3.0 ng/ml at 4.0 +/- 0.5 hours; and micronized in enteric-coated capsules, 11.2 +/- 3.0 ng/ml at 4.1 +/- 0.7 hours.",Absorption of oral progesterone is influenced by vehicle and particle size. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2801843/),[ng] / [ml],11.3,130549,DB00396,Progesterone
,2801843,times to peak,"Four types of oral progesterone had equivalent mean peak elevations and mean times to peak: plain milled, 9.6 +/- 2.5 ng/ml at 4.0 +/- 0.5 hours; micronized 13.2 +/- 2.4 ng/ml at 3.2 +/- 0.4 hours; plain milled in oil, 11.3 +/- 3.0 ng/ml at 4.0 +/- 0.5 hours; and micronized in enteric-coated capsules, 11.2 +/- 3.0 ng/ml at 4.1 +/- 0.7 hours.",Absorption of oral progesterone is influenced by vehicle and particle size. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2801843/),ng,13,130550,DB00396,Progesterone
,2801843,times to peak,"Four types of oral progesterone had equivalent mean peak elevations and mean times to peak: plain milled, 9.6 +/- 2.5 ng/ml at 4.0 +/- 0.5 hours; micronized 13.2 +/- 2.4 ng/ml at 3.2 +/- 0.4 hours; plain milled in oil, 11.3 +/- 3.0 ng/ml at 4.0 +/- 0.5 hours; and micronized in enteric-coated capsules, 11.2 +/- 3.0 ng/ml at 4.1 +/- 0.7 hours.",Absorption of oral progesterone is influenced by vehicle and particle size. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2801843/),[ng] / [ml],11.3,130551,DB00396,Progesterone
,2801843,times to peak,"Four types of oral progesterone had equivalent mean peak elevations and mean times to peak: plain milled, 9.6 +/- 2.5 ng/ml at 4.0 +/- 0.5 hours; micronized 13.2 +/- 2.4 ng/ml at 3.2 +/- 0.4 hours; plain milled in oil, 11.3 +/- 3.0 ng/ml at 4.0 +/- 0.5 hours; and micronized in enteric-coated capsules, 11.2 +/- 3.0 ng/ml at 4.1 +/- 0.7 hours.",Absorption of oral progesterone is influenced by vehicle and particle size. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2801843/),[ng] / [ml],11.2,130552,DB00396,Progesterone
,31211965,peak concentration,"Median baseline serum progesterone was 47 (40-52) ng/mL, median peak concentration was 54 (48-68) ng/mL, and median time to peak was 12 (4-15) hours.",Pharmacokinetics of vaginal progesterone in pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31211965/),[ng] / [ml],54,131201,DB00396,Progesterone
,31211965,time to peak,"Median baseline serum progesterone was 47 (40-52) ng/mL, median peak concentration was 54 (48-68) ng/mL, and median time to peak was 12 (4-15) hours.",Pharmacokinetics of vaginal progesterone in pregnancy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31211965/),h,12,131202,DB00396,Progesterone
,31211965,peak concentration,There was a trend in rising serum progesterone over baseline with a median change in peak concentration of 11 ng/mL and interquartile range of 2-22.,Pharmacokinetics of vaginal progesterone in pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31211965/),[ng] / [ml],11,131203,DB00396,Progesterone
,31211965,area under the curve,"However, there was no clear elimination phase and the median area under the curve was 112 ng*h/mL with an interquartile range of -43 to 239.",Pharmacokinetics of vaginal progesterone in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31211965/),[h·ng] / [ml],112,131204,DB00396,Progesterone
,6692762,remission rate,"A remission rate of 37% (total and partial remissions) indicated that high-dosage oral treatment with gestagens can be used as ""failure-regime"" in patients at the end of conventional treatment.",[High-dosage oral gestagen therapy as a failure-regime in metastatic breast cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6692762/),%,37,134525,DB00396,Progesterone
,925940,biological half-life,The pharmacokinetic parameters showed that the progesterone biological half-life in the uterine tissue during the alpha-phase was about 6.5 min while that in the beta-phase was about 230 min.,Progesterone retention by rat uterus I. Pharmacokinetics after uterine intraluminal instillation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/925940/),min,6.5,135276,DB00396,Progesterone
,925940,biological half-life,The pharmacokinetic parameters showed that the progesterone biological half-life in the uterine tissue during the alpha-phase was about 6.5 min while that in the beta-phase was about 230 min.,Progesterone retention by rat uterus I. Pharmacokinetics after uterine intraluminal instillation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/925940/),min,230,135277,DB00396,Progesterone
,28323948,half-life,"Elagolix was rapidly absorbed after oral dosing, reaching maximum concentrations at 1.0 to 1.5 hours, with a half-life of 4 to 6 hours.",Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28323948/),h,4 to 6,136180,DB00396,Progesterone
,7921520,peak estradiol concentration,"Preliminary pharmacokinetic results obtained from 14 postmenopausal women being treated with the low-dose estrogen-progestogen replacement demonstrated peak estradiol concentration of 120-160 pmol/l (32-43 pg/ml) 10 hours after oral ingestion, suggesting bone preserving properties by these considerably lower estradiol concentrations.",Estrogen-progestogen replacement therapy in postmenopausal women--is 1 mg estradiolvalerate sufficient to maintain axial trabecular bone density? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7921520/),[pM] / [l],120-160,136709,DB00396,Progesterone
,7217832,MCR,The MCR of non-laying birds (163.2 +/- 6.4 (S.E.M.) ml/min) was significantly greater than that of laying hens (122.4 +/- 6.1 ml/min).,Pharmacokinetics of progesterone in laying and non-laying hens (Gallus domesticus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7217832/),[ml] / [min],163.2,139932,DB00396,Progesterone
,7217832,MCR,The MCR of non-laying birds (163.2 +/- 6.4 (S.E.M.) ml/min) was significantly greater than that of laying hens (122.4 +/- 6.1 ml/min).,Pharmacokinetics of progesterone in laying and non-laying hens (Gallus domesticus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7217832/),[ml] / [min],122.4,139933,DB00396,Progesterone
,7217832,PR,The mean PR of progesterone in laying hens measured 8 h before and 8 h after the preovulatory peak of progesterone (42.498 +/- 6.509 ng/min per kg 0.75) was comparable to that of moulting hens (61.771 +/- 14.363 ng/min per kg 0.75).,Pharmacokinetics of progesterone in laying and non-laying hens (Gallus domesticus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7217832/),[ng] / [kg·min],42.498,139934,DB00396,Progesterone
,7217832,PR,The mean PR of progesterone in laying hens measured 8 h before and 8 h after the preovulatory peak of progesterone (42.498 +/- 6.509 ng/min per kg 0.75) was comparable to that of moulting hens (61.771 +/- 14.363 ng/min per kg 0.75).,Pharmacokinetics of progesterone in laying and non-laying hens (Gallus domesticus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7217832/),[ng] / [kg·min],61.771,139935,DB00396,Progesterone
,7217832,PR,"However, the PR of progesterone in hens when measured during the preovulatory surge of progesterone (254.335 +/- 53.972 ng/min per kg 0.75) was significantly greater than 8 h before and 8 h after the surge.",Pharmacokinetics of progesterone in laying and non-laying hens (Gallus domesticus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7217832/),[ng] / [0.75·kg·min],254.335,139936,DB00396,Progesterone
,7217832,t 1/2 of the distribution phase,"There were no significant differences among groups in the t 1/2 of the distribution phase (combined mean, 1.03 +/- 0.05 min), biologically active t 1/2 (combined mean, 10.93 +/- 0.31 min) or Vd of the central compartment (VdA; combined mean, 609.4 +/- 46.7 ml).",Pharmacokinetics of progesterone in laying and non-laying hens (Gallus domesticus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7217832/),min,1.03,139937,DB00396,Progesterone
,7217832,t 1/2,"There were no significant differences among groups in the t 1/2 of the distribution phase (combined mean, 1.03 +/- 0.05 min), biologically active t 1/2 (combined mean, 10.93 +/- 0.31 min) or Vd of the central compartment (VdA; combined mean, 609.4 +/- 46.7 ml).",Pharmacokinetics of progesterone in laying and non-laying hens (Gallus domesticus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7217832/),min,10.93,139938,DB00396,Progesterone
,7217832,Vd of the central compartment (VdA,"There were no significant differences among groups in the t 1/2 of the distribution phase (combined mean, 1.03 +/- 0.05 min), biologically active t 1/2 (combined mean, 10.93 +/- 0.31 min) or Vd of the central compartment (VdA; combined mean, 609.4 +/- 46.7 ml).",Pharmacokinetics of progesterone in laying and non-laying hens (Gallus domesticus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7217832/),ml,609.4,139939,DB00396,Progesterone
,7217832,Vd in the peripheral compartment (VdB),"However, the Vd in the peripheral compartment (VdB) was significantly greater in non-laying birds (combined mean, 3891.3 +/- 399.5 ml) compared with that of laying hens (combined mean, 2879.2 +/- 154.4 ml).",Pharmacokinetics of progesterone in laying and non-laying hens (Gallus domesticus). ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7217832/),ml,3891.3,139940,DB00396,Progesterone
,7217832,Vd in the peripheral compartment (VdB),"However, the Vd in the peripheral compartment (VdB) was significantly greater in non-laying birds (combined mean, 3891.3 +/- 399.5 ml) compared with that of laying hens (combined mean, 2879.2 +/- 154.4 ml).",Pharmacokinetics of progesterone in laying and non-laying hens (Gallus domesticus). ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7217832/),ml,2879.2,139941,DB00396,Progesterone
,1098113,metabolic clearance rate,"During a 30-minute infusion (0.5 mg/minute) of PGF2alpha, blood PGF plateaued at 29.5 ng/ml with a metabolic clearance rate of 17.0 liters per minute.","Luteolysis, estrus and ovulation, and blood prostaglandin F after intramuscular administration of 15, 30 or 60 mg prostaglanding F2alpha. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1098113/),[l] / [min],17.0,142689,DB00396,Progesterone
,6682793,Bioavailability,"Bioavailability of orally administered STS 557 was found to be 80--90% in man and beagle dog, 70--80% in baboon and rat.",Studies on pharmacokinetics of STS 557 in animal species and man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6682793/),%,80,145855,DB00396,Progesterone
,6682793,Bioavailability,"Bioavailability of orally administered STS 557 was found to be 80--90% in man and beagle dog, 70--80% in baboon and rat.",Studies on pharmacokinetics of STS 557 in animal species and man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6682793/),%,90,145856,DB00396,Progesterone
,6682793,Bioavailability,"Bioavailability of orally administered STS 557 was found to be 80--90% in man and beagle dog, 70--80% in baboon and rat.",Studies on pharmacokinetics of STS 557 in animal species and man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6682793/),,70,145857,DB00396,Progesterone
,6682793,Bioavailability,"Bioavailability of orally administered STS 557 was found to be 80--90% in man and beagle dog, 70--80% in baboon and rat.",Studies on pharmacokinetics of STS 557 in animal species and man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6682793/),%,80,145858,DB00396,Progesterone
less,6682793,half lives,STS 557 is rather rapidly eliminated from the plasma compartment of all species investigated with half lives less than or equal to 10 h.,Studies on pharmacokinetics of STS 557 in animal species and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6682793/),h,10,145859,DB00396,Progesterone
,4028723,maximum level,The (geometric) mean maximum level of MPA was 2.9 (2.4-3.7) nmol/1 and that of NET 10.1 (6.4-15.8) nmol/l.,Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028723/),nM,2.9,148043,DB00396,Progesterone
,4028723,maximum level,The (geometric) mean maximum level of MPA was 2.9 (2.4-3.7) nmol/1 and that of NET 10.1 (6.4-15.8) nmol/l.,Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028723/),[nM] / [l],10.1,148044,DB00396,Progesterone
,4028723,maximum level,The maximum level of exogenous E2 was 890 (700-1130) pmol/l after Cycloprovera and 1570 (870-2820) pmol/l after HRP-102 administration.,Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028723/),[pM] / [l],890,148045,DB00396,Progesterone
,4028723,maximum level,The maximum level of exogenous E2 was 890 (700-1130) pmol/l after Cycloprovera and 1570 (870-2820) pmol/l after HRP-102 administration.,Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028723/),[pM] / [l],1570,148046,DB00396,Progesterone
,22763464,progression-free survival,"Median progression-free survival was 7.4 and 7.7 weeks in Cohorts A and B, respectively.",A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22763464/),weeks,7.4,149707,DB00396,Progesterone
,22763464,progression-free survival,"Median progression-free survival was 7.4 and 7.7 weeks in Cohorts A and B, respectively.",A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22763464/),weeks,7.7,149708,DB00396,Progesterone
exceeded,125164,Production rate (PR),"Production rate (PR) of testosterone exceeded 417 mug/24 h (1 SD above the mean reported for normal women), in nineteen of the twenty-five patients.",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],417,150467,DB00396,Progesterone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],509,150468,DB00396,Progesterone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],356,150469,DB00396,Progesterone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],612,150470,DB00396,Progesterone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],345,150471,DB00396,Progesterone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],528,150472,DB00396,Progesterone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],148,150473,DB00396,Progesterone
,11204938,tmax,Identical median tmax was observed for E2 (6 h) and for E1 (5 h).,Bioequivalence and relative bioavailability of three estradiol and norethisterone acetate-containing hormone replacement therapy tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204938/),h,6,150801,DB00396,Progesterone
,11204938,tmax,Identical median tmax was observed for E2 (6 h) and for E1 (5 h).,Bioequivalence and relative bioavailability of three estradiol and norethisterone acetate-containing hormone replacement therapy tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204938/),h,5,150802,DB00396,Progesterone
,11204938,tmax,The median tmax for Novofem was 0.75 h and for Trisequens 1.0 h.,Bioequivalence and relative bioavailability of three estradiol and norethisterone acetate-containing hormone replacement therapy tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204938/),h,0.75,150803,DB00396,Progesterone
,11204938,tmax,The median tmax for Novofem was 0.75 h and for Trisequens 1.0 h.,Bioequivalence and relative bioavailability of three estradiol and norethisterone acetate-containing hormone replacement therapy tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204938/),h,1.0,150804,DB00396,Progesterone
,15907580,oral bioavailability,The oral bioavailability of FNB from these self-assemblies revealed 156% and 15% increases vs.,Enhancement of oral bioavailability of poorly water-soluble drugs by poly(ethylene glycol)-block-poly(alkyl acrylate-co-methacrylic acid) self-assemblies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907580/),%,156,152632,DB00396,Progesterone
,15907580,oral bioavailability,The oral bioavailability of FNB from these self-assemblies revealed 156% and 15% increases vs.,Enhancement of oral bioavailability of poorly water-soluble drugs by poly(ethylene glycol)-block-poly(alkyl acrylate-co-methacrylic acid) self-assemblies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907580/),%,15,152633,DB00396,Progesterone
,23993431,AUC0-91,Mean AUC0-91 was 45.1 ng·day/mL.,Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23993431/),[d·ng] / [ml],45.1,154382,DB00396,Progesterone
,16356876,peak plasma concentrations,Multiple dosing studies have demonstrated that steady state is reached by day 7 after oral administration with peak plasma concentrations in the region of 2 ng/ml.,Chlormadinone acetate (CMA) in oral contraception--a new opportunity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16356876/),[ng] / [ml],2,158854,DB00396,Progesterone
,16356876,half-life time,After a single dose of CMA the half-life time is around 34 hours and after multiple dose administration approximately 38 hours.,Chlormadinone acetate (CMA) in oral contraception--a new opportunity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16356876/),h,34,158855,DB00396,Progesterone
,16356876,half-life time,After a single dose of CMA the half-life time is around 34 hours and after multiple dose administration approximately 38 hours.,Chlormadinone acetate (CMA) in oral contraception--a new opportunity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16356876/),h,38,158856,DB00396,Progesterone
,8513955,relative bioavailability,Oral P had lower relative bioavailability (8.6%) than intramuscular P.,"The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513955/),%,8.6,159522,DB00396,Progesterone
,8513955,Bioavailability,Bioavailability of the oral P was approximately 10% compared with intramuscular P.,"The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513955/),%,10,159523,DB00396,Progesterone
,9232131,Noncompartmental clearances,"Noncompartmental clearances (mean +/- SD) were 3.62 +/- 0.76, 3.81 +/- 0.96, and 3.60 +/- 0.84 ml/kg/ min, respectively, on days 2, 13, and 21 of the menstrual cycle.",Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232131/),[ml] / [·kg·min],3.62,159632,DB00396,Progesterone
,9232131,Noncompartmental clearances,"Noncompartmental clearances (mean +/- SD) were 3.62 +/- 0.76, 3.81 +/- 0.96, and 3.60 +/- 0.84 ml/kg/ min, respectively, on days 2, 13, and 21 of the menstrual cycle.",Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232131/),[ml] / [·kg·min],3.81,159633,DB00396,Progesterone
,9232131,Noncompartmental clearances,"Noncompartmental clearances (mean +/- SD) were 3.62 +/- 0.76, 3.81 +/- 0.96, and 3.60 +/- 0.84 ml/kg/ min, respectively, on days 2, 13, and 21 of the menstrual cycle.",Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232131/),[ml] / [·kg·min],3.60,159634,DB00396,Progesterone
,31981708,t50%,"This formulation exhibited pH-dependent swelling, negligible drug release in simulated gastric fluid and sustained-release pattern in simulated small intestinal fluid with a mean t50% of 26.5 h.",Colon-targeting of progesterone using hybrid polymeric microspheres improves its bioavailability and in vivo biological efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31981708/),h,26.5,159827,DB00396,Progesterone
,15901742,AUC(0-24),"No significant differences were found in dose-normalized 24-hour progesterone exposure comparing the cream to oral capsules (median AUC(0-24) 12.5 ng x h/mL vs 10.5 ng x h/mL, respectively; P = .81).",Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901742/),[h·ng] / [ml],12.5,161129,DB00396,Progesterone
,15901742,AUC(0-24),"No significant differences were found in dose-normalized 24-hour progesterone exposure comparing the cream to oral capsules (median AUC(0-24) 12.5 ng x h/mL vs 10.5 ng x h/mL, respectively; P = .81).",Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901742/),[h·ng] / [ml],10.5,161130,DB00396,Progesterone
,30963506,Cmax ratios,"Least-squares mean estimates (90% confidence interval) for Cmax ratios were 1.05 (0.90-1.23), 1.06 (0.97-1.16), and 1.04 (0.88-1.22) for norelgestromin, norgestrel, and ethinyl estradiol, respectively.","A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963506/),,1,161813,DB00396,Progesterone
,30963506,AUCtau ratios,"Respective AUCtau ratios were 1.02 (0.94-1.12), 1.03 (0.96-1.10), and 1.02 (0.91-1.14).","A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963506/),,1.02,161814,DB00396,Progesterone
,30963506,AUCtau ratios,"Respective AUCtau ratios were 1.02 (0.94-1.12), 1.03 (0.96-1.10), and 1.02 (0.91-1.14).","A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963506/),,1.03,161815,DB00396,Progesterone
,30963506,AUCtau ratios,"Respective AUCtau ratios were 1.02 (0.94-1.12), 1.03 (0.96-1.10), and 1.02 (0.91-1.14).","A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963506/),,1.02,161816,DB00396,Progesterone
,10640167,Cmax,The mean MPA Cmax and AUC0-t(last) were 1.25 ng/mL and 32.13 ng.,Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640167/),[ng] / [ml],1.25,161972,DB00396,Progesterone
,10640167,AUC0-t(last),The mean MPA Cmax and AUC0-t(last) were 1.25 ng/mL and 32.13 ng.,Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640167/),ng,32.13,161973,DB00396,Progesterone
,10640167,terminal half-life,"Serum MPA concentrations declined with a mean terminal half-life of 14.7 days, indicating that absorption from the injection site is prolonged after administration of MPA/E2C.",Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640167/),d,14.7,161974,DB00396,Progesterone
,10640167,trough (Cmin' day 28) concentrations,"The average MPA trough (Cmin' day 28) concentrations for the three consecutive monthly injections ranged from 0.44 to 0.47 pg/mL, indicating that steady-state conditions were achieved after the first injection.",Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640167/),[pg] / [ml],0.44 to 0.47,161975,DB00396,Progesterone
,10640167,Cmax,"Mean concentrations of E2 peaked at approximately 2 days after the third injection, and the average Cmax was 247 pg/mL.",Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640167/),[pg] / [ml],247,161976,DB00396,Progesterone
,10640167,terminal half-life,"Serum E2 levels declined with a terminal half-life of approximately 8 days; E2 levels returned to baseline (typically, approximately 100 pg/mL) by 14 days after each injection.",Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640167/),d,8,161977,DB00396,Progesterone
,10640167,trough (Cmin' day 28),The average trough (Cmin' day 28) levels for E2 ranged from 40 to 55 pg/mL.,Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640167/),[pg] / [ml],40 to 55,161978,DB00396,Progesterone
,2840310,apparent half-life,The disappearance of RU486 and its metabolites conformed to a noncompartmental model with a mean apparent half-life of 53.7 +/- 6.9 hours.,Pharmacodynamics of the antiprogesterone RU486 in women after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2840310/),h,53.7,162792,DB00396,Progesterone
,2840310,apparent volume of distribution,"The mean apparent volume of distribution and clearance rate were 1.47 +/- 0.25 l/kg and 1.04 +/- 0.09 1/hour, respectively.",Pharmacodynamics of the antiprogesterone RU486 in women after oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2840310/),[l] / [kg],1.47,162793,DB00396,Progesterone
,2840310,clearance rate,"The mean apparent volume of distribution and clearance rate were 1.47 +/- 0.25 l/kg and 1.04 +/- 0.09 1/hour, respectively.",Pharmacodynamics of the antiprogesterone RU486 in women after oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2840310/),[1] / [h],1.04,162794,DB00396,Progesterone
,10887750,durations of,"Peak cortisol, progesterone and prostaglandin F2 alpha metabolite levels were reached at 80 +/- 10.0, 80 +/- 10.0 and 46.6 +/- 13.3 min after ACTH administration and the durations of the peaks were 181.8 +/- 19.8, 308.1 +/- 49.7 and 181.8 +/- 7.9 min, respectively.","Plasma levels of cortisol, progesterone, oestradiol-17 beta and prostaglandin F2 alpha metabolite after ACTH (Synacthen Depot) administration in ovariectomized gilts. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10887750/),min,181.8,162806,DB00396,Progesterone
,10887750,durations of,"Peak cortisol, progesterone and prostaglandin F2 alpha metabolite levels were reached at 80 +/- 10.0, 80 +/- 10.0 and 46.6 +/- 13.3 min after ACTH administration and the durations of the peaks were 181.8 +/- 19.8, 308.1 +/- 49.7 and 181.8 +/- 7.9 min, respectively.","Plasma levels of cortisol, progesterone, oestradiol-17 beta and prostaglandin F2 alpha metabolite after ACTH (Synacthen Depot) administration in ovariectomized gilts. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10887750/),min,308.1,162807,DB00396,Progesterone
,10887750,durations of,"Peak cortisol, progesterone and prostaglandin F2 alpha metabolite levels were reached at 80 +/- 10.0, 80 +/- 10.0 and 46.6 +/- 13.3 min after ACTH administration and the durations of the peaks were 181.8 +/- 19.8, 308.1 +/- 49.7 and 181.8 +/- 7.9 min, respectively.","Plasma levels of cortisol, progesterone, oestradiol-17 beta and prostaglandin F2 alpha metabolite after ACTH (Synacthen Depot) administration in ovariectomized gilts. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10887750/),min,181.8,162808,DB00396,Progesterone
,9089002,elimination half-lives,"The elimination half-lives of LNG did not differ between the test and reference preparations (25.08 +/- 11.94 h, and 25.70 +/- 10.08 h, respectively).",Bioavailability study with 2 different levonorgestrel-containing drugs in women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089002/),h,25.08,163074,DB00396,Progesterone
,9089002,elimination half-lives,"The elimination half-lives of LNG did not differ between the test and reference preparations (25.08 +/- 11.94 h, and 25.70 +/- 10.08 h, respectively).",Bioavailability study with 2 different levonorgestrel-containing drugs in women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089002/),h,25.70,163075,DB00396,Progesterone
,7850448,half-lives (t 1/2),"In five ovariectomized gilts given single i.v. doses of 47.7 mumol progesterone, the steroid was cleared from the circulating plasma bi-exponentially; the mean half-lives (t 1/2) of the two components were 2.47 (+/- 0.36) and 33.5 (+/- 6.63) min.",Preliminary evidence for the enterohepatic circulation of progesterone in the pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850448/),min,2.47,165210,DB00396,Progesterone
,7850448,half-lives (t 1/2),"In five ovariectomized gilts given single i.v. doses of 47.7 mumol progesterone, the steroid was cleared from the circulating plasma bi-exponentially; the mean half-lives (t 1/2) of the two components were 2.47 (+/- 0.36) and 33.5 (+/- 6.63) min.",Preliminary evidence for the enterohepatic circulation of progesterone in the pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850448/),min,33.5,165211,DB00396,Progesterone
,17977567,t(1/2beta),"Thus, progesterone remained in plasma for a longer time after subcutaneous administration in PG than in OO (t(1/2beta): 60.65+/-13.07 vs. 27.51+/-3.59 h; P<0.05); the mean residence time being higher in SC-PG than in SC-OO group (88.99+/-18.36 vs. 41.04+/-5.31h; P<0.05).",Influence of vehicle on kinetics of exogenous progesterone administered either by subcutaneous and intramuscular routes to sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17977567/),h,60.65,165329,DB00396,Progesterone
,17977567,t(1/2beta),"Thus, progesterone remained in plasma for a longer time after subcutaneous administration in PG than in OO (t(1/2beta): 60.65+/-13.07 vs. 27.51+/-3.59 h; P<0.05); the mean residence time being higher in SC-PG than in SC-OO group (88.99+/-18.36 vs. 41.04+/-5.31h; P<0.05).",Influence of vehicle on kinetics of exogenous progesterone administered either by subcutaneous and intramuscular routes to sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17977567/),h,27.51,165330,DB00396,Progesterone
,17977567,mean residence time,"Thus, progesterone remained in plasma for a longer time after subcutaneous administration in PG than in OO (t(1/2beta): 60.65+/-13.07 vs. 27.51+/-3.59 h; P<0.05); the mean residence time being higher in SC-PG than in SC-OO group (88.99+/-18.36 vs. 41.04+/-5.31h; P<0.05).",Influence of vehicle on kinetics of exogenous progesterone administered either by subcutaneous and intramuscular routes to sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17977567/),h,88.99,165331,DB00396,Progesterone
,17977567,mean residence time,"Thus, progesterone remained in plasma for a longer time after subcutaneous administration in PG than in OO (t(1/2beta): 60.65+/-13.07 vs. 27.51+/-3.59 h; P<0.05); the mean residence time being higher in SC-PG than in SC-OO group (88.99+/-18.36 vs. 41.04+/-5.31h; P<0.05).",Influence of vehicle on kinetics of exogenous progesterone administered either by subcutaneous and intramuscular routes to sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17977567/),h,41.04,165332,DB00396,Progesterone
,28473770,Cmax,"Following single dose, The geometric mean Cmax values for Test 4%, Test 8%, and Crinone 8% were 6.35, 10.34, 10.45 ng/mL, and their geometric mean AUC0-t (AUC0-∞) were 113.73 (118.00), 169.39 (173.98), and 190.07 (201.13) ng⋅h/mL, respectively.",Pharmacokinetic Properties of Three Forms of Vaginal Progesterone Administered in Either Single Or Multiple Dose Regimen in Healthy Post-menopausal Chinese Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28473770/),[ng] / [ml],6.35,167433,DB00396,Progesterone
,28473770,Cmax,"Following single dose, The geometric mean Cmax values for Test 4%, Test 8%, and Crinone 8% were 6.35, 10.34, 10.45 ng/mL, and their geometric mean AUC0-t (AUC0-∞) were 113.73 (118.00), 169.39 (173.98), and 190.07 (201.13) ng⋅h/mL, respectively.",Pharmacokinetic Properties of Three Forms of Vaginal Progesterone Administered in Either Single Or Multiple Dose Regimen in Healthy Post-menopausal Chinese Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28473770/),[ng] / [ml],10.34,167434,DB00396,Progesterone
,28473770,Cmax,"Following single dose, The geometric mean Cmax values for Test 4%, Test 8%, and Crinone 8% were 6.35, 10.34, 10.45 ng/mL, and their geometric mean AUC0-t (AUC0-∞) were 113.73 (118.00), 169.39 (173.98), and 190.07 (201.13) ng⋅h/mL, respectively.",Pharmacokinetic Properties of Three Forms of Vaginal Progesterone Administered in Either Single Or Multiple Dose Regimen in Healthy Post-menopausal Chinese Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28473770/),[ng] / [ml],10.45,167435,DB00396,Progesterone
,28473770,AUC0-t (AUC0-∞),"Following single dose, The geometric mean Cmax values for Test 4%, Test 8%, and Crinone 8% were 6.35, 10.34, 10.45 ng/mL, and their geometric mean AUC0-t (AUC0-∞) were 113.73 (118.00), 169.39 (173.98), and 190.07 (201.13) ng⋅h/mL, respectively.",Pharmacokinetic Properties of Three Forms of Vaginal Progesterone Administered in Either Single Or Multiple Dose Regimen in Healthy Post-menopausal Chinese Women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28473770/),[h·ng] / [ml],113.73,167436,DB00396,Progesterone
,28473770,AUC0-t (AUC0-∞),"Following single dose, The geometric mean Cmax values for Test 4%, Test 8%, and Crinone 8% were 6.35, 10.34, 10.45 ng/mL, and their geometric mean AUC0-t (AUC0-∞) were 113.73 (118.00), 169.39 (173.98), and 190.07 (201.13) ng⋅h/mL, respectively.",Pharmacokinetic Properties of Three Forms of Vaginal Progesterone Administered in Either Single Or Multiple Dose Regimen in Healthy Post-menopausal Chinese Women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28473770/),[h·ng] / [ml],169.39,167437,DB00396,Progesterone
,28473770,AUC0-t (AUC0-∞),"Following single dose, The geometric mean Cmax values for Test 4%, Test 8%, and Crinone 8% were 6.35, 10.34, 10.45 ng/mL, and their geometric mean AUC0-t (AUC0-∞) were 113.73 (118.00), 169.39 (173.98), and 190.07 (201.13) ng⋅h/mL, respectively.",Pharmacokinetic Properties of Three Forms of Vaginal Progesterone Administered in Either Single Or Multiple Dose Regimen in Healthy Post-menopausal Chinese Women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28473770/),[h·ng] / [ml],190.07,167438,DB00396,Progesterone
,28473770,T1/2,"The mean T1/2 values of progesterone were 11.00, 10.92, and 11.40 h, respectively.",Pharmacokinetic Properties of Three Forms of Vaginal Progesterone Administered in Either Single Or Multiple Dose Regimen in Healthy Post-menopausal Chinese Women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28473770/),h,11.00,167439,DB00396,Progesterone
,28473770,T1/2,"The mean T1/2 values of progesterone were 11.00, 10.92, and 11.40 h, respectively.",Pharmacokinetic Properties of Three Forms of Vaginal Progesterone Administered in Either Single Or Multiple Dose Regimen in Healthy Post-menopausal Chinese Women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28473770/),h,10.92,167440,DB00396,Progesterone
,28473770,T1/2,"The mean T1/2 values of progesterone were 11.00, 10.92, and 11.40 h, respectively.",Pharmacokinetic Properties of Three Forms of Vaginal Progesterone Administered in Either Single Or Multiple Dose Regimen in Healthy Post-menopausal Chinese Women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28473770/),h,11.40,167441,DB00396,Progesterone
,9579942,steady-state plasma concentrations (Cmax),"Steady-state plasma levels (trough) occurred after approximately 7 days of dosing, with mean steady-state plasma concentrations (Cmax) in multiple dose studies of between 32 ng/ml (50-mg doses) and 376 ng/ml (500-mg doses).","Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579942/),[ng] / [ml],32,167803,DB00396,Progesterone
,9579942,steady-state plasma concentrations (Cmax),"Steady-state plasma levels (trough) occurred after approximately 7 days of dosing, with mean steady-state plasma concentrations (Cmax) in multiple dose studies of between 32 ng/ml (50-mg doses) and 376 ng/ml (500-mg doses).","Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579942/),[ng] / [ml],376,167804,DB00396,Progesterone
,1737611,peak-levels,"Progesterone peak-levels (3.9-6.7 nmol/l) exceeded the levels which are found in the follicular phase of the menstrual cycle, but did not reach the levels of the luteal phase.",Intranasal administration of estradiol in combination with progesterone to oophorectomized women: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1737611/),[nM] / [l],3.9-6.7,167908,DB00396,Progesterone
,22123335,maximum tolerated dose,The maximum tolerated dose was 12 mg/m and dose-limiting toxicity was grade 3 increased aspartate aminotransferase and alanine aminotransferase.,"Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22123335/),,12,168392,DB00396,Progesterone
,2556239,plasma half-life,It has a plasma half-life of approximately 25-30 hr and approximately 70% of dose is excreted in the urine unchanged.,Review of fluconazole: a new triazole antifungal agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556239/),h,25-30,169591,DB00396,Progesterone
,885117,MCR,The MCR of R 5020 was 163+/-15 (SE) 1/day and was lower than that of progesterone.,"The metabolic clearance rate, the brain extraction and distribution and the uterine extraction and retention of progesterone and R 5020 in estrogen-treated ovariectomized rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/885117/),[1] / [d],163,170636,DB00396,Progesterone
,885117,u,The uterine extraction of R 5020 (51.4+/-3.9 (SE)%) was greater than that of progesterone (33.7+/-7.7%) as was the uterine tissue:arterial blood ratio (28.1+/-4 vs. 7.3).,"The metabolic clearance rate, the brain extraction and distribution and the uterine extraction and retention of progesterone and R 5020 in estrogen-treated ovariectomized rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/885117/),%,51.4,170637,DB00396,Progesterone
,885117,u,The uterine extraction of R 5020 (51.4+/-3.9 (SE)%) was greater than that of progesterone (33.7+/-7.7%) as was the uterine tissue:arterial blood ratio (28.1+/-4 vs. 7.3).,"The metabolic clearance rate, the brain extraction and distribution and the uterine extraction and retention of progesterone and R 5020 in estrogen-treated ovariectomized rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/885117/),%,33.7,170638,DB00396,Progesterone
,885117,extraction,The uterine extraction of R 5020 (51.4+/-3.9 (SE)%) was greater than that of progesterone (33.7+/-7.7%) as was the uterine tissue:arterial blood ratio (28.1+/-4 vs. 7.3).,"The metabolic clearance rate, the brain extraction and distribution and the uterine extraction and retention of progesterone and R 5020 in estrogen-treated ovariectomized rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/885117/),%,51.4,170639,DB00396,Progesterone
,885117,extraction,The uterine extraction of R 5020 (51.4+/-3.9 (SE)%) was greater than that of progesterone (33.7+/-7.7%) as was the uterine tissue:arterial blood ratio (28.1+/-4 vs. 7.3).,"The metabolic clearance rate, the brain extraction and distribution and the uterine extraction and retention of progesterone and R 5020 in estrogen-treated ovariectomized rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/885117/),%,33.7,170640,DB00396,Progesterone
,885117,tissue:arterial blood ratio,The uterine extraction of R 5020 (51.4+/-3.9 (SE)%) was greater than that of progesterone (33.7+/-7.7%) as was the uterine tissue:arterial blood ratio (28.1+/-4 vs. 7.3).,"The metabolic clearance rate, the brain extraction and distribution and the uterine extraction and retention of progesterone and R 5020 in estrogen-treated ovariectomized rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/885117/),,28.1,170641,DB00396,Progesterone
,885117,tissue:arterial blood ratio,The uterine extraction of R 5020 (51.4+/-3.9 (SE)%) was greater than that of progesterone (33.7+/-7.7%) as was the uterine tissue:arterial blood ratio (28.1+/-4 vs. 7.3).,"The metabolic clearance rate, the brain extraction and distribution and the uterine extraction and retention of progesterone and R 5020 in estrogen-treated ovariectomized rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/885117/),,7.3,170642,DB00396,Progesterone
,1301358,urinary to fecal excretion ratio,A urinary to fecal excretion ratio of 1.5 (i.v.) or 1.0 (i.g.) was found.,"Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301358/),,1.5,171434,DB00396,Progesterone
,1301358,urinary to fecal excretion ratio,A urinary to fecal excretion ratio of 1.5 (i.v.) or 1.0 (i.g.) was found.,"Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301358/),,1.0,171435,DB00396,Progesterone
,1301358,half-life,Renal excretion of total radiolabel proceeded with a half-life of about 0.8 (i.v.) or 1.1 (i.g.) days.,"Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301358/),d,0.8,171436,DB00396,Progesterone
,1301358,half-life,Renal excretion of total radiolabel proceeded with a half-life of about 0.8 (i.v.) or 1.1 (i.g.) days.,"Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301358/),d,1.1,171437,DB00396,Progesterone
,1301358,total clearance,Orally administered NETO was highly bioavailable (84.0 +/- 16.9% of dose) but rapidly cleared from plasma (total clearance corresponded to 97% of plasma liver flow).,"Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301358/),,97,171438,DB00396,Progesterone
,11763981,maximum DRSP concentrations,"The maximum DRSP concentrations (data given as mean +/- standard deviation) were reached on average 2.5+/-1.2 and 2.8+/-1.3 h in serum and breast milk, respectively after oral administration of 3 mg DRSP + 30 microg EE, and amounted on average to 30.8+/-14.4 and 13.5+/-11.7 ng DRSP/ml in serum and breast milk.",Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11763981/),h,2.5,172945,DB00396,Progesterone
,11763981,maximum DRSP concentrations,"The maximum DRSP concentrations (data given as mean +/- standard deviation) were reached on average 2.5+/-1.2 and 2.8+/-1.3 h in serum and breast milk, respectively after oral administration of 3 mg DRSP + 30 microg EE, and amounted on average to 30.8+/-14.4 and 13.5+/-11.7 ng DRSP/ml in serum and breast milk.",Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11763981/),h,2.8,172946,DB00396,Progesterone
,11763981,maximum DRSP concentrations,"The maximum DRSP concentrations (data given as mean +/- standard deviation) were reached on average 2.5+/-1.2 and 2.8+/-1.3 h in serum and breast milk, respectively after oral administration of 3 mg DRSP + 30 microg EE, and amounted on average to 30.8+/-14.4 and 13.5+/-11.7 ng DRSP/ml in serum and breast milk.",Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11763981/),[drsp·ng] / [ml],30.8,172947,DB00396,Progesterone
,11763981,maximum DRSP concentrations,"The maximum DRSP concentrations (data given as mean +/- standard deviation) were reached on average 2.5+/-1.2 and 2.8+/-1.3 h in serum and breast milk, respectively after oral administration of 3 mg DRSP + 30 microg EE, and amounted on average to 30.8+/-14.4 and 13.5+/-11.7 ng DRSP/ml in serum and breast milk.",Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11763981/),[drsp·ng] / [ml],13.5,172948,DB00396,Progesterone
,11763981,breast milk versus serum concentration ratios,The mean breast milk versus serum concentration ratios of DRSP increased from 0.16 to 0.57 within 2 h after dosing and decreased to 0.16 after 24 h.,Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11763981/),,0.16,172949,DB00396,Progesterone
,11763981,breast milk versus serum concentration ratios,The mean breast milk versus serum concentration ratios of DRSP increased from 0.16 to 0.57 within 2 h after dosing and decreased to 0.16 after 24 h.,Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11763981/),,0.57,172950,DB00396,Progesterone
,11763981,ratio of AUC0-48 h,"The average ratio of AUC0-48 h, values in breast milk versus serum was 0.23+/-0.09.",Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11763981/),,0.23,172951,DB00396,Progesterone
,11763981,concentration,The mean DRSP concentration in breast milk over the 24-h period after dosing was 3.7+/-1.9 ng/ml.,Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11763981/),[ng] / [ml],3.7,172952,DB00396,Progesterone
,18422273,flow-rate,"The determination was performed on a Hypersil C18 column (150 mm X 3.9 mm , 5 microm) with a mobile phase consisting of methanol and water (60:40) at a flow-rate of 0.6 ml/min.",[Determination of progesterone concentration in plasma after oral administration of progesterone-loaded lipid nanoparticles in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18422273/),[ml] / [min],0.6,174018,DB00396,Progesterone
,18422273,limit of detection,The quantification limit was (0.02 +/-0.004) microg/ml(n=3) and the limit of detection was 0.005 microg.,[Determination of progesterone concentration in plasma after oral administration of progesterone-loaded lipid nanoparticles in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18422273/),μg,0.005,174019,DB00396,Progesterone
>,18422273,S/N,mL(-1)(S/N = or >3).,[Determination of progesterone concentration in plasma after oral administration of progesterone-loaded lipid nanoparticles in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18422273/),,3,174020,DB00396,Progesterone
,18422273,absolute recovery rate,The average absolute recovery rate was 90.5 % and the average method recovery was in the range of 93.4 %-107.5%.,[Determination of progesterone concentration in plasma after oral administration of progesterone-loaded lipid nanoparticles in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18422273/),%,90.5,174021,DB00396,Progesterone
,18422273,method recovery,The average absolute recovery rate was 90.5 % and the average method recovery was in the range of 93.4 %-107.5%.,[Determination of progesterone concentration in plasma after oral administration of progesterone-loaded lipid nanoparticles in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18422273/),%,93.4,174022,DB00396,Progesterone
,18422273,method recovery,The average absolute recovery rate was 90.5 % and the average method recovery was in the range of 93.4 %-107.5%.,[Determination of progesterone concentration in plasma after oral administration of progesterone-loaded lipid nanoparticles in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18422273/),%,107.5,174023,DB00396,Progesterone
,1830266,area under the plasma concentration versus time curve (AUC),"The area under the plasma concentration versus time curve (AUC) for oral EE2 alone was 867 +/- 338 pg/ml x h, for oral EE2 in the presence of gestodene it was 795 +/- 206 pg/ml x h and for oral EE2 in the presence of desogestrel it was 614 +/- 132 pg/ml x h.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[pg] / [h·ml],867,174414,DB00396,Progesterone
,1830266,area under the plasma concentration versus time curve (AUC),"The area under the plasma concentration versus time curve (AUC) for oral EE2 alone was 867 +/- 338 pg/ml x h, for oral EE2 in the presence of gestodene it was 795 +/- 206 pg/ml x h and for oral EE2 in the presence of desogestrel it was 614 +/- 132 pg/ml x h.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[pg] / [h·ml],795,174415,DB00396,Progesterone
,1830266,area under the plasma concentration versus time curve (AUC),"The area under the plasma concentration versus time curve (AUC) for oral EE2 alone was 867 +/- 338 pg/ml x h, for oral EE2 in the presence of gestodene it was 795 +/- 206 pg/ml x h and for oral EE2 in the presence of desogestrel it was 614 +/- 132 pg/ml x h.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[pg] / [h·ml],614,174416,DB00396,Progesterone
,1830266,bioavailability,"Comparing the relative oral and iv doses, the bioavailability of EE2 (alone) was 59.0 +/- 13% (n = 6), for EE2 plus gestodene it was 62.1 +/- 10% and for EE2 in the presence of desogestrel it was 62.1 +/- 4.4%.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),%,59.0,174417,DB00396,Progesterone
,1830266,bioavailability,"Comparing the relative oral and iv doses, the bioavailability of EE2 (alone) was 59.0 +/- 13% (n = 6), for EE2 plus gestodene it was 62.1 +/- 10% and for EE2 in the presence of desogestrel it was 62.1 +/- 4.4%.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),%,62.1,174418,DB00396,Progesterone
,1830266,bioavailability,"Comparing the relative oral and iv doses, the bioavailability of EE2 (alone) was 59.0 +/- 13% (n = 6), for EE2 plus gestodene it was 62.1 +/- 10% and for EE2 in the presence of desogestrel it was 62.1 +/- 4.4%.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),%,62.1,174419,DB00396,Progesterone
,1830266,clearance,The clearance of EE2 (alone) was 19.9 +/- 5.5 l/h and in the presence of gestodene it was 19.4 +/- 9.6 l/h.,The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[l] / [h],19.9,174420,DB00396,Progesterone
,1830266,clearance,The clearance of EE2 (alone) was 19.9 +/- 5.5 l/h and in the presence of gestodene it was 19.4 +/- 9.6 l/h.,The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[l] / [h],19.4,174421,DB00396,Progesterone
,1830266,clearance,The clearance of EE2 in the presence of desogestrel appeared slightly greater at 27.7 +/- 8.9 l/h but none of these clearance values were significantly different from each other.,The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[l] / [h],27.7,174422,DB00396,Progesterone
,15563063,Cmax,"Cmax of P in plasma was (508 +/- 62) microg x L(-1), Tmax was (3.2 +/- 0.4) h, T1/2 (ke) was (10 +/- 4) h and mean AUC0-48h was (5886 +/- 1573) microg x L(-1) x h.",[Determination of progesterone and its main metabolite in rat plasma and uterus using HPLC]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563063/),[μg] / [l],508,175380,DB00396,Progesterone
,15563063,Tmax,"Cmax of P in plasma was (508 +/- 62) microg x L(-1), Tmax was (3.2 +/- 0.4) h, T1/2 (ke) was (10 +/- 4) h and mean AUC0-48h was (5886 +/- 1573) microg x L(-1) x h.",[Determination of progesterone and its main metabolite in rat plasma and uterus using HPLC]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563063/),h,3.2,175381,DB00396,Progesterone
,15563063,T1/2 (ke),"Cmax of P in plasma was (508 +/- 62) microg x L(-1), Tmax was (3.2 +/- 0.4) h, T1/2 (ke) was (10 +/- 4) h and mean AUC0-48h was (5886 +/- 1573) microg x L(-1) x h.",[Determination of progesterone and its main metabolite in rat plasma and uterus using HPLC]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563063/),h,10,175382,DB00396,Progesterone
,15563063,AUC0-48h,"Cmax of P in plasma was (508 +/- 62) microg x L(-1), Tmax was (3.2 +/- 0.4) h, T1/2 (ke) was (10 +/- 4) h and mean AUC0-48h was (5886 +/- 1573) microg x L(-1) x h.",[Determination of progesterone and its main metabolite in rat plasma and uterus using HPLC]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563063/),[h·μg] / [l],5886,175383,DB00396,Progesterone
,15563063,maximum concentration,The maximum concentration of P in uterus was (1.7 +/- 1.1) microg x g(-1) and the peak time was (5.2 +/- 1.11) h.,[Determination of progesterone and its main metabolite in rat plasma and uterus using HPLC]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563063/),[μg] / [g],1.7,175384,DB00396,Progesterone
,15563063,peak time,The maximum concentration of P in uterus was (1.7 +/- 1.1) microg x g(-1) and the peak time was (5.2 +/- 1.11) h.,[Determination of progesterone and its main metabolite in rat plasma and uterus using HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563063/),h,5.2,175385,DB00396,Progesterone
,15735610,clearance,"Nicotine clearance was 1000 +/- 315 mL/min and 1047 +/- 271 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.06; 90% confidence interval, 0.87-1.29).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],1000,176980,DB00396,Progesterone
,15735610,clearance,"Nicotine clearance was 1000 +/- 315 mL/min and 1047 +/- 271 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.06; 90% confidence interval, 0.87-1.29).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],1047,176981,DB00396,Progesterone
,15735610,clearance,"Cotinine clearance was 44 +/- 20 mL/min and 55 +/- 42 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.13; 90% confidence interval, 0.90-1.41).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],44,176982,DB00396,Progesterone
,15735610,clearance,"Cotinine clearance was 44 +/- 20 mL/min and 55 +/- 42 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.13; 90% confidence interval, 0.90-1.41).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],55,176983,DB00396,Progesterone
,9751449,oral clearance,The oral clearance values of the recirculations were constant (590Lh(-1)).,Enterohepatic cycling and pharmacokinetics of oestradiol in postmenopausal women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9751449/),1/[lh],590,177308,DB00396,Progesterone
,28087972,area under the plasma concentration-time curve over the dosing interval of duration τ,"LNG alone for LNG area under the plasma concentration-time curve over the dosing interval of duration τ and maximum observed plasma concentration were 1.12 (1.07-1.18) and 1.05 (0.96-1.15), respectively.",Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28087972/),,1.12,178605,DB00396,Progesterone
,28087972,maximum observed plasma concentration,"LNG alone for LNG area under the plasma concentration-time curve over the dosing interval of duration τ and maximum observed plasma concentration were 1.12 (1.07-1.18) and 1.05 (0.96-1.15), respectively.",Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28087972/),,1.05,178606,DB00396,Progesterone
,22727346,concentrations,"Mean day 0-21 EE(2) concentrations were lower among obese vs normal weight women (15.0 vs 22.0 pg/mL, respectively, P = .004), whereas etonorgestrel concentrations were similar (1138 vs 1256 pg/mL, respectively, P = .39).",Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22727346/),[pg] / [ml],1138,179852,DB00396,Progesterone
,22727346,concentrations,"Mean day 0-21 EE(2) concentrations were lower among obese vs normal weight women (15.0 vs 22.0 pg/mL, respectively, P = .004), whereas etonorgestrel concentrations were similar (1138 vs 1256 pg/mL, respectively, P = .39).",Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22727346/),[pg] / [ml],1256,179853,DB00396,Progesterone
,11180022,terminal half-life,Cetrorelix pharmacokinetics were described by a 2-compartment model with a terminal half-life of 56.9 +/- 27.1 hours.,"Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180022/),h,56.9,180037,DB00396,Progesterone
,11180022,inhibitory concentration of 50%,"The inhibitory concentration of 50% (for LH suppression) and median effective concentration (for surge shift) estimates were 3.6 ng/mL and 1.6 ng/mL, respectively.","Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180022/),[ng] / [ml],3.6,180038,DB00396,Progesterone
,11180022,effective concentration,"The inhibitory concentration of 50% (for LH suppression) and median effective concentration (for surge shift) estimates were 3.6 ng/mL and 1.6 ng/mL, respectively.","Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180022/),[ng] / [ml],1.6,180039,DB00396,Progesterone
,11180022,inhibitory concentration of 50%,"The suppression of follicle-stimulating hormone was described by a similar Emax model, with an inhibitory concentration of 50% of 7.25 ng/mL.","Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180022/),[ng] / [ml],7.25,180040,DB00396,Progesterone
,29330782,absolute oral bioavailability,The absolute oral bioavailability of vilaprisan was ~ 60%.,"Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29330782/),%,60,180557,DB00396,Progesterone
,29330782,clearance,The mean clearance was ~ 7 L/h and the volume of distribution at steady state was ~ 360 L.,"Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29330782/),[l] / [h],7,180558,DB00396,Progesterone
,29330782,volume of distribution at steady state,The mean clearance was ~ 7 L/h and the volume of distribution at steady state was ~ 360 L.,"Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29330782/),l,360,180559,DB00396,Progesterone
,29330782,total recovery,"Excretion occurred primarily via feces (73.5 ± 3.70% of dose; urine: 13.1 ± 1.71%; total recovery: 86.6 ± 2.81%), mostly in a metabolized form.","Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29330782/),%,86.6,180560,DB00396,Progesterone
below,1936077,t1/2,"Rat hepatocytes showed an extremely high metabolic activity towards NET, LN and GEST resulting in t1/2 values of below 2 min.",Investigations on the in vitro metabolism of five synthetic 19-norprogestins using hepatocyte suspensions isolated from five laboratory animal species. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936077/),min,2,181047,DB00396,Progesterone
above,1936077,half-lives,"Respective values for rabbit hepatocytes ranged from 5-8 min, whereas half-lives calculated for liver cells from guinea pig, dog and monkey were generally above 30 min.",Investigations on the in vitro metabolism of five synthetic 19-norprogestins using hepatocyte suspensions isolated from five laboratory animal species. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936077/),min,30,181048,DB00396,Progesterone
,27420975,flow rate,"The analytes were separated by a Waters Sun Fire C18 column (50 mm x 2 mm, 5 μm) and eluted with 1:1000 methanol and formic acid/water (v/v) mobile phase with a flow rate of 0.5 mL/min.",Rapid and sensitive LC-MS/MS method for the determination of auraptene in rat plasma and its application in a pharmacokinetic and bioavailability study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27420975/),[ml] / [min],0.5,182092,DB00396,Progesterone
,27420975,m/z,"Multiple reaction monitoring was used to monitor the transition of the deprotonated auraptene molecule with an m/z of 299.3 [M+H](+), to the product ion with an m/z of 162.9 [M+H](+).",Rapid and sensitive LC-MS/MS method for the determination of auraptene in rat plasma and its application in a pharmacokinetic and bioavailability study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27420975/),M+h,299.3,182093,DB00396,Progesterone
,27420975,m/z,"Multiple reaction monitoring was used to monitor the transition of the deprotonated auraptene molecule with an m/z of 299.3 [M+H](+), to the product ion with an m/z of 162.9 [M+H](+).",Rapid and sensitive LC-MS/MS method for the determination of auraptene in rat plasma and its application in a pharmacokinetic and bioavailability study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27420975/),M+h,162.9,182094,DB00396,Progesterone
,27420975,m/z,"Progesterone, with an m/z of 315.2→ 96.9 was used as an internal standard.",Rapid and sensitive LC-MS/MS method for the determination of auraptene in rat plasma and its application in a pharmacokinetic and bioavailability study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27420975/),→,315.2,182095,DB00396,Progesterone
,27420975,m/z,"Progesterone, with an m/z of 315.2→ 96.9 was used as an internal standard.",Rapid and sensitive LC-MS/MS method for the determination of auraptene in rat plasma and its application in a pharmacokinetic and bioavailability study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27420975/),→,96.9,182096,DB00396,Progesterone
,27420975,limits of,"The limits of detection and of quantification of auraptene in the rat plasma were 1 and 5 ng/mL, respectively.",Rapid and sensitive LC-MS/MS method for the determination of auraptene in rat plasma and its application in a pharmacokinetic and bioavailability study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27420975/),[ng] / [ml],1,182097,DB00396,Progesterone
,27420975,maximum plasma concentration,"After auraptene (100 mg/kg, p.o.) administration, the maximum plasma concentration and the time taken to reach maximum concentration were 1719.5 ± 384.3 g/mL and 108.0 ± 25.3 min, respectively.",Rapid and sensitive LC-MS/MS method for the determination of auraptene in rat plasma and its application in a pharmacokinetic and bioavailability study in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27420975/),[g] / [ml],1719.5,182098,DB00396,Progesterone
,27420975,time taken to reach maximum concentration,"After auraptene (100 mg/kg, p.o.) administration, the maximum plasma concentration and the time taken to reach maximum concentration were 1719.5 ± 384.3 g/mL and 108.0 ± 25.3 min, respectively.",Rapid and sensitive LC-MS/MS method for the determination of auraptene in rat plasma and its application in a pharmacokinetic and bioavailability study in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27420975/),min,108.0,182099,DB00396,Progesterone
,27420975,elimination half-life,"The elimination half-life was 108.0 ± 25.3 for auraptene (100 mg/kg, p.o.) and 3.0 ± 0 min for auraptene (2 mg/kg, i.v.).",Rapid and sensitive LC-MS/MS method for the determination of auraptene in rat plasma and its application in a pharmacokinetic and bioavailability study in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27420975/),min,108.0,182100,DB00396,Progesterone
,27420975,elimination half-life,"The elimination half-life was 108.0 ± 25.3 for auraptene (100 mg/kg, p.o.) and 3.0 ± 0 min for auraptene (2 mg/kg, i.v.).",Rapid and sensitive LC-MS/MS method for the determination of auraptene in rat plasma and its application in a pharmacokinetic and bioavailability study in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27420975/),min,3.0,182101,DB00396,Progesterone
,27420975,oral bioavailability,The oral bioavailability was about 8.5%.,Rapid and sensitive LC-MS/MS method for the determination of auraptene in rat plasma and its application in a pharmacokinetic and bioavailability study in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27420975/),%,8.5,182102,DB00396,Progesterone
,11858883,bioavailability,It is an orally active compound with nearly 70% absorption rate but its bioavailability is reduced to around 40% because of the first-pass effect.,"Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11858883/),%,40,184067,DB00396,Progesterone
,11858883,Peak plasma concentrations,"Peak plasma concentrations of 1.9 +/- 0.8, 3.8 +/- 0.9 and 5.3 +/- 1.3 micromol/l are reached within 1-2 h after oral administration of 50, 200 and 600 mg mifepristone in women, respectively, and are maintained at relatively high level up to 48 or 72 h depending on the ingested dose.","Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11858883/),[μM] / [l],1.9,184068,DB00396,Progesterone
,11858883,Peak plasma concentrations,"Peak plasma concentrations of 1.9 +/- 0.8, 3.8 +/- 0.9 and 5.3 +/- 1.3 micromol/l are reached within 1-2 h after oral administration of 50, 200 and 600 mg mifepristone in women, respectively, and are maintained at relatively high level up to 48 or 72 h depending on the ingested dose.","Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11858883/),[μM] / [l],3.8,184069,DB00396,Progesterone
,11858883,Peak plasma concentrations,"Peak plasma concentrations of 1.9 +/- 0.8, 3.8 +/- 0.9 and 5.3 +/- 1.3 micromol/l are reached within 1-2 h after oral administration of 50, 200 and 600 mg mifepristone in women, respectively, and are maintained at relatively high level up to 48 or 72 h depending on the ingested dose.","Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11858883/),[μM] / [l],5.3,184070,DB00396,Progesterone
,11858883,alpha-half-life,"The plasma kinetics of mifepristone followed two-compartment open model with a mean alpha-half-life of 1.4h, volume of distribution 1.47 l/kg and beta-half-life of 20-30 h in most of the subjects studied.","Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11858883/),h,1.4,184071,DB00396,Progesterone
,11858883,volume of distribution,"The plasma kinetics of mifepristone followed two-compartment open model with a mean alpha-half-life of 1.4h, volume of distribution 1.47 l/kg and beta-half-life of 20-30 h in most of the subjects studied.","Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11858883/),[l] / [kg],1.47,184072,DB00396,Progesterone
,11858883,beta-half-life,"The plasma kinetics of mifepristone followed two-compartment open model with a mean alpha-half-life of 1.4h, volume of distribution 1.47 l/kg and beta-half-life of 20-30 h in most of the subjects studied.","Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11858883/),h,20-30,184073,DB00396,Progesterone
,15385829,Cmax,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,104.89,184428,DB00396,Progesterone
,15385829,Cmax,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,103.27,184429,DB00396,Progesterone
,15385829,AUC0-24,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,1900.30,184430,DB00396,Progesterone
,15385829,AUC0-24,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,1783.70,184431,DB00396,Progesterone
,15385829,AUC0-infinity,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,5576.06,184432,DB00396,Progesterone
,15385829,AUC0-infinity,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,5317.89,184433,DB00396,Progesterone
,15385829,ka,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,1.06,184434,DB00396,Progesterone
,15385829,ka,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,1.09,184435,DB00396,Progesterone
,15385829,t1/2,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,35.65,184436,DB00396,Progesterone
,15385829,t1/2,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,36.12,184437,DB00396,Progesterone
,15385829,MRT,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,16.29,184438,DB00396,Progesterone
,15385829,MRT,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,16.27,184439,DB00396,Progesterone
,15385829,V/F,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,16.29,184440,DB00396,Progesterone
,15385829,V/F,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,16.27,184441,DB00396,Progesterone
,1867115,serum half-lives,"The serum half-lives (200 mg group-400 mg group) of RU38486, RU42698, RU42848 and RU42633 were 31.8-33.1 h, 41.2-39.3 h, 33.9-36.6 h and 29.2-36.6 h, respectively.","Automated direct assay system for RU38486, an antiprogesterone-antiglucocorticoid agent, and its metabolites using high performance liquid chromatography. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867115/),h,31.8-33.1,185549,DB00396,Progesterone
,1867115,serum half-lives,"The serum half-lives (200 mg group-400 mg group) of RU38486, RU42698, RU42848 and RU42633 were 31.8-33.1 h, 41.2-39.3 h, 33.9-36.6 h and 29.2-36.6 h, respectively.","Automated direct assay system for RU38486, an antiprogesterone-antiglucocorticoid agent, and its metabolites using high performance liquid chromatography. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867115/),h,41.2-39.3,185550,DB00396,Progesterone
,1867115,serum half-lives,"The serum half-lives (200 mg group-400 mg group) of RU38486, RU42698, RU42848 and RU42633 were 31.8-33.1 h, 41.2-39.3 h, 33.9-36.6 h and 29.2-36.6 h, respectively.","Automated direct assay system for RU38486, an antiprogesterone-antiglucocorticoid agent, and its metabolites using high performance liquid chromatography. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867115/),h,33.9-36.6,185551,DB00396,Progesterone
,1867115,serum half-lives,"The serum half-lives (200 mg group-400 mg group) of RU38486, RU42698, RU42848 and RU42633 were 31.8-33.1 h, 41.2-39.3 h, 33.9-36.6 h and 29.2-36.6 h, respectively.","Automated direct assay system for RU38486, an antiprogesterone-antiglucocorticoid agent, and its metabolites using high performance liquid chromatography. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867115/),h,29.2-36.6,185552,DB00396,Progesterone
,21204827,area under the curve (AUC),"Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04).","Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204827/),[h·pg] / [ml],"1,778",185596,DB00396,Progesterone
,21204827,area under the curve (AUC),"Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04).","Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204827/),[h·pg] / [ml],986,185597,DB00396,Progesterone
,21204827,area under the curve (AUC),"Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04).","Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204827/),[h·pg] / [ml],24.8,185598,DB00396,Progesterone
,21204827,area under the curve (AUC),"Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04).","Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204827/),[h·pg] / [ml],13.8,185599,DB00396,Progesterone
,1492579,maximum progesterone concentration (Cmax,"The formulation with almond oil yielded a maximum progesterone concentration (Cmax of 3.75 ng/ml at Tmax = 60 min, and the area under the curve (AUC0-720) value was 1481.6 +/- 343.",Progesterone administration by nasal spray in menopausal women: comparison between two different spray formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492579/),[ng] / [ml],3.75,186884,DB00396,Progesterone
,1492579,Tmax,"The formulation with almond oil yielded a maximum progesterone concentration (Cmax of 3.75 ng/ml at Tmax = 60 min, and the area under the curve (AUC0-720) value was 1481.6 +/- 343.",Progesterone administration by nasal spray in menopausal women: comparison between two different spray formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492579/),min,60,186885,DB00396,Progesterone
,1492579,area under the curve (AUC0-720),"The formulation with almond oil yielded a maximum progesterone concentration (Cmax of 3.75 ng/ml at Tmax = 60 min, and the area under the curve (AUC0-720) value was 1481.6 +/- 343.",Progesterone administration by nasal spray in menopausal women: comparison between two different spray formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492579/),,1481.6,186886,DB00396,Progesterone
,1492579,Cmax,The formulation with dimethicone yielded a mean Cmax of 1.049 ng/ml at Tmax = 30 min; the AUC0-720 value was 302.06 +/- 37.5.,Progesterone administration by nasal spray in menopausal women: comparison between two different spray formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492579/),[ng] / [ml],1.049,186887,DB00396,Progesterone
,1492579,Tmax,The formulation with dimethicone yielded a mean Cmax of 1.049 ng/ml at Tmax = 30 min; the AUC0-720 value was 302.06 +/- 37.5.,Progesterone administration by nasal spray in menopausal women: comparison between two different spray formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492579/),min,30,186888,DB00396,Progesterone
,1492579,AUC0-720,The formulation with dimethicone yielded a mean Cmax of 1.049 ng/ml at Tmax = 30 min; the AUC0-720 value was 302.06 +/- 37.5.,Progesterone administration by nasal spray in menopausal women: comparison between two different spray formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492579/),,302.06,186889,DB00396,Progesterone
,10641872,MCR,"Postprandial MCR was greater in H than in L gilts, 103.0 vs.",The effects of feed intake and body fatness on progesterone metabolism in ovariectomized gilts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10641872/),,103.0,187693,DB00396,Progesterone
,10641872,half-life,"Feed intake did not affect the disappearance rate constant of progesterone (mean -.019), and the estimated half-life of progesterone was 36.5 h.",The effects of feed intake and body fatness on progesterone metabolism in ovariectomized gilts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10641872/),h,36.5,187694,DB00396,Progesterone
,20472113,area under the curve (AUC,"Obese women had a lower area under the curve (AUC; 1077.2 vs. 1413.7 pg*h/mL) and lower maximum values (85.7 vs. 129.5 pg/mL) for EE than normal-weight women (p=.04 and <0.01, respectively); EE trough levels were similar between BMI groups.",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[h·pg] / [ml],1077.2,188119,DB00396,Progesterone
,20472113,area under the curve (AUC,"Obese women had a lower area under the curve (AUC; 1077.2 vs. 1413.7 pg*h/mL) and lower maximum values (85.7 vs. 129.5 pg/mL) for EE than normal-weight women (p=.04 and <0.01, respectively); EE trough levels were similar between BMI groups.",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[h·pg] / [ml],1413.7,188120,DB00396,Progesterone
,20472113,maximum values,"Obese women had a lower area under the curve (AUC; 1077.2 vs. 1413.7 pg*h/mL) and lower maximum values (85.7 vs. 129.5 pg/mL) for EE than normal-weight women (p=.04 and <0.01, respectively); EE trough levels were similar between BMI groups.",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[pg] / [ml],85.7,188121,DB00396,Progesterone
,20472113,maximum values,"Obese women had a lower area under the curve (AUC; 1077.2 vs. 1413.7 pg*h/mL) and lower maximum values (85.7 vs. 129.5 pg/mL) for EE than normal-weight women (p=.04 and <0.01, respectively); EE trough levels were similar between BMI groups.",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[pg] / [ml],129.5,188122,DB00396,Progesterone
,20472113,trough levels,"While peak values differed somewhat, the LNG trough levels were similar for obese and normal-weight women (2.6 and 2.5 ng/mL, respectively).",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[ng] / [ml],2.6,188123,DB00396,Progesterone
,20472113,trough levels,"While peak values differed somewhat, the LNG trough levels were similar for obese and normal-weight women (2.6 and 2.5 ng/mL, respectively).",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[ng] / [ml],2.5,188124,DB00396,Progesterone
,12527084,area under the curve (AUC),"Calculation of the area under the curve (AUC) for progesterone secretion from Day 7 to Day 12 also revealed a significant decrease in progesterone secretion in the dilatation group (dilatation: 34.1+/-7.3, insertion: 35.6+/-7.8, control: 39.1+/-5.9 ng/ml; P<0.05).",Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[ng] / [ml],34.1,192157,DB00396,Progesterone
,12527084,area under the curve (AUC),"Calculation of the area under the curve (AUC) for progesterone secretion from Day 7 to Day 12 also revealed a significant decrease in progesterone secretion in the dilatation group (dilatation: 34.1+/-7.3, insertion: 35.6+/-7.8, control: 39.1+/-5.9 ng/ml; P<0.05).",Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[ng] / [ml],35.6,192158,DB00396,Progesterone
,12527084,area under the curve (AUC),"Calculation of the area under the curve (AUC) for progesterone secretion from Day 7 to Day 12 also revealed a significant decrease in progesterone secretion in the dilatation group (dilatation: 34.1+/-7.3, insertion: 35.6+/-7.8, control: 39.1+/-5.9 ng/ml; P<0.05).",Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[ng] / [ml],39.1,192159,DB00396,Progesterone
,12527084,maximum peaks,Cervical insertion and dilatation caused a rapid and pronounced increase in plasma concentrations of oxytocin from basal levels (1.0-6.1 pg/ml) to maximum peaks (insertion: 125.5 pg/ml and dilatation: 305.2 pg/ml).,Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[pg] / [ml],125.5,192160,DB00396,Progesterone
,12527084,maximum peaks,Cervical insertion and dilatation caused a rapid and pronounced increase in plasma concentrations of oxytocin from basal levels (1.0-6.1 pg/ml) to maximum peaks (insertion: 125.5 pg/ml and dilatation: 305.2 pg/ml).,Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[pg] / [ml],305.2,192161,DB00396,Progesterone
,12527084,AUC,The AUC for oxytocin was significantly higher after insertion (Day 5: 858.4+/-469.9; Day 7: 411.9+/-213 pg/ml/h) and dilatation (Day 5: 1697+/-1725; Day 7: 1078.5+/-764 pg/ml/h) when compared to controls (Day 5: 186+/-98; Day 7: 156+/-23.5 pg/ml/h; P<0.05).,Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[pg] / [h·ml],858.4,192162,DB00396,Progesterone
,12527084,AUC,The AUC for oxytocin was significantly higher after insertion (Day 5: 858.4+/-469.9; Day 7: 411.9+/-213 pg/ml/h) and dilatation (Day 5: 1697+/-1725; Day 7: 1078.5+/-764 pg/ml/h) when compared to controls (Day 5: 186+/-98; Day 7: 156+/-23.5 pg/ml/h; P<0.05).,Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[pg] / [h·ml],411.9,192163,DB00396,Progesterone
,12527084,AUC,The AUC for oxytocin was significantly higher after insertion (Day 5: 858.4+/-469.9; Day 7: 411.9+/-213 pg/ml/h) and dilatation (Day 5: 1697+/-1725; Day 7: 1078.5+/-764 pg/ml/h) when compared to controls (Day 5: 186+/-98; Day 7: 156+/-23.5 pg/ml/h; P<0.05).,Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[pg] / [h·ml],1697,192164,DB00396,Progesterone
,12527084,AUC,The AUC for oxytocin was significantly higher after insertion (Day 5: 858.4+/-469.9; Day 7: 411.9+/-213 pg/ml/h) and dilatation (Day 5: 1697+/-1725; Day 7: 1078.5+/-764 pg/ml/h) when compared to controls (Day 5: 186+/-98; Day 7: 156+/-23.5 pg/ml/h; P<0.05).,Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[pg] / [h·ml],1078.5,192165,DB00396,Progesterone
,12527084,AUC,The AUC for oxytocin was significantly higher after insertion (Day 5: 858.4+/-469.9; Day 7: 411.9+/-213 pg/ml/h) and dilatation (Day 5: 1697+/-1725; Day 7: 1078.5+/-764 pg/ml/h) when compared to controls (Day 5: 186+/-98; Day 7: 156+/-23.5 pg/ml/h; P<0.05).,Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[pg] / [h·ml],186,192166,DB00396,Progesterone
,12527084,AUC,The AUC for oxytocin was significantly higher after insertion (Day 5: 858.4+/-469.9; Day 7: 411.9+/-213 pg/ml/h) and dilatation (Day 5: 1697+/-1725; Day 7: 1078.5+/-764 pg/ml/h) when compared to controls (Day 5: 186+/-98; Day 7: 156+/-23.5 pg/ml/h; P<0.05).,Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[pg] / [h·ml],156,192167,DB00396,Progesterone
,8654651,Cmax,"After the first administration, a mean Cmax of 5.40 +/- 0.92 ng/mL (mean +/- SD) was reached at a Tmax of 45 minutes (range 30 to 480 minutes).",Pharmacokinetics and endometrial effects of the vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8654651/),[ng] / [ml],5.40,193702,DB00396,Progesterone
,8654651,Tmax,"After the first administration, a mean Cmax of 5.40 +/- 0.92 ng/mL (mean +/- SD) was reached at a Tmax of 45 minutes (range 30 to 480 minutes).",Pharmacokinetics and endometrial effects of the vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8654651/),min,45,193703,DB00396,Progesterone
,8654651,Cmax,"The second P administration reached a mean Cmax of 5.30 +/- 1.04 ng/mL at a Tmax of 60 minutes (range 30 to 240 minutes); after 24 hours, the serum P levels still were significantly higher than at baseline and at the same time after the first administration.",Pharmacokinetics and endometrial effects of the vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8654651/),[ng] / [ml],5.30,193704,DB00396,Progesterone
,8654651,Tmax,"The second P administration reached a mean Cmax of 5.30 +/- 1.04 ng/mL at a Tmax of 60 minutes (range 30 to 240 minutes); after 24 hours, the serum P levels still were significantly higher than at baseline and at the same time after the first administration.",Pharmacokinetics and endometrial effects of the vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8654651/),min,60,193705,DB00396,Progesterone
,19567522,bioavailability,"We report a 14.5-year-old boy with CAH who had reduced bioavailability [42% (normal 80% orally and 100% by im route)] and increased clearance [half-life 50 min (normal range, 70-100 min)] of oral doses of hydrocortisone leading to ambient serum 17-hydroxyprogesterone concentrations of 400 nmol/liter (14.5 ng/ml) and androstenedione concentrations of 24.9 nmol/liter (7.1 ng/ml).",Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567522/),%,42,196903,DB00396,Progesterone
,19567522,bioavailability,"We report a 14.5-year-old boy with CAH who had reduced bioavailability [42% (normal 80% orally and 100% by im route)] and increased clearance [half-life 50 min (normal range, 70-100 min)] of oral doses of hydrocortisone leading to ambient serum 17-hydroxyprogesterone concentrations of 400 nmol/liter (14.5 ng/ml) and androstenedione concentrations of 24.9 nmol/liter (7.1 ng/ml).",Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567522/),%,80,196904,DB00396,Progesterone
,19567522,bioavailability,"We report a 14.5-year-old boy with CAH who had reduced bioavailability [42% (normal 80% orally and 100% by im route)] and increased clearance [half-life 50 min (normal range, 70-100 min)] of oral doses of hydrocortisone leading to ambient serum 17-hydroxyprogesterone concentrations of 400 nmol/liter (14.5 ng/ml) and androstenedione concentrations of 24.9 nmol/liter (7.1 ng/ml).",Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567522/),%,100,196905,DB00396,Progesterone
,2943134,half-life of the absorption process,Following oral administration MPA is rapidly transferred from the gastrointestinal tract to the blood circulation with a half-life of the absorption process of 15-30 min.,Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),min,15-30,199005,DB00396,Progesterone
,2943134,biological half-life,"The peak plasma concentration is reached 1-3 hrs after administration, and the biological half-life of MPA is 40-60 hrs.",Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),h,40-60,199006,DB00396,Progesterone
,2943134,areas under the plasma concentration-time curves (AUC 0-infinity),"Following administration of 1000 mg MPA the areas under the plasma concentration-time curves (AUC 0-infinity) were calculated to (mean and S.E.): 3357 (438) nmol/l and 2403 (245) nmol/l for Leo formulation A and Farlutal, respectively (P less than 0.02).",Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),[nM] / [l],3357,199007,DB00396,Progesterone
,2943134,areas under the plasma concentration-time curves (AUC 0-infinity),"Following administration of 1000 mg MPA the areas under the plasma concentration-time curves (AUC 0-infinity) were calculated to (mean and S.E.): 3357 (438) nmol/l and 2403 (245) nmol/l for Leo formulation A and Farlutal, respectively (P less than 0.02).",Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),[nM] / [l],2403,199008,DB00396,Progesterone
,2943134,areas,"Following administration of 500 mg the areas were: 2325 (389) nmol/l, 1793 (312) nmol/l, 1778 (239) nmol/l, 1178 (209) nmol/l, and 556 (89) nmol/l for Gestapuran, Leo formulation A (P = n.s.), Leo formulation B (P = n.s.), Provera (P less than 0.001), and Lutopolar (P less than 0.001), respectively.",Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),[nM] / [l],2325,199009,DB00396,Progesterone
,2943134,areas,"Following administration of 500 mg the areas were: 2325 (389) nmol/l, 1793 (312) nmol/l, 1778 (239) nmol/l, 1178 (209) nmol/l, and 556 (89) nmol/l for Gestapuran, Leo formulation A (P = n.s.), Leo formulation B (P = n.s.), Provera (P less than 0.001), and Lutopolar (P less than 0.001), respectively.",Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),[nM] / [l],1793,199010,DB00396,Progesterone
,2943134,areas,"Following administration of 500 mg the areas were: 2325 (389) nmol/l, 1793 (312) nmol/l, 1778 (239) nmol/l, 1178 (209) nmol/l, and 556 (89) nmol/l for Gestapuran, Leo formulation A (P = n.s.), Leo formulation B (P = n.s.), Provera (P less than 0.001), and Lutopolar (P less than 0.001), respectively.",Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),[nM] / [l],1778,199011,DB00396,Progesterone
,2943134,areas,"Following administration of 500 mg the areas were: 2325 (389) nmol/l, 1793 (312) nmol/l, 1778 (239) nmol/l, 1178 (209) nmol/l, and 556 (89) nmol/l for Gestapuran, Leo formulation A (P = n.s.), Leo formulation B (P = n.s.), Provera (P less than 0.001), and Lutopolar (P less than 0.001), respectively.",Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),[nM] / [l],1178,199012,DB00396,Progesterone
,2943134,areas,"Following administration of 500 mg the areas were: 2325 (389) nmol/l, 1793 (312) nmol/l, 1778 (239) nmol/l, 1178 (209) nmol/l, and 556 (89) nmol/l for Gestapuran, Leo formulation A (P = n.s.), Leo formulation B (P = n.s.), Provera (P less than 0.001), and Lutopolar (P less than 0.001), respectively.",Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),[nM] / [l],556,199013,DB00396,Progesterone
,5103749,metabolic clearance rate,"The mean dihydrotestosterone metabolic clearance rate was higher in men (336 liters/24 hr per m(2) [range, 239-448]) than in women (153 liters/24 hr per m(2) [range, 108-184]).",The metabolic clearance rate and origin of plasma dihydrotestosterone in man and its conversion to the 5-alpha-androstanediols. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5103749/),[24·h·l] / [m(2],336,200510,DB00396,Progesterone
,5103749,metabolic clearance rate,"The mean dihydrotestosterone metabolic clearance rate was higher in men (336 liters/24 hr per m(2) [range, 239-448]) than in women (153 liters/24 hr per m(2) [range, 108-184]).",The metabolic clearance rate and origin of plasma dihydrotestosterone in man and its conversion to the 5-alpha-androstanediols. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5103749/),[24·h·l] / [m(2],153,200511,DB00396,Progesterone
,7058686,MCR,"No significant change in the MCR of NETA was observed at 1 week (459 +/- 72 1/day), 1 month (489 +/- 113 1/day) and 2 months (522 +/- 144 1/day) compared with that of control (525 +/- 108 1/day).",Pharmacokinetics of norethindrone acetate in women after the insertion of a single subdermal implant releasing norethindrone acetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058686/),[1] / [d],459,201305,DB00396,Progesterone
,7058686,MCR,"No significant change in the MCR of NETA was observed at 1 week (459 +/- 72 1/day), 1 month (489 +/- 113 1/day) and 2 months (522 +/- 144 1/day) compared with that of control (525 +/- 108 1/day).",Pharmacokinetics of norethindrone acetate in women after the insertion of a single subdermal implant releasing norethindrone acetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058686/),[1] / [d],489,201306,DB00396,Progesterone
,7058686,MCR,"No significant change in the MCR of NETA was observed at 1 week (459 +/- 72 1/day), 1 month (489 +/- 113 1/day) and 2 months (522 +/- 144 1/day) compared with that of control (525 +/- 108 1/day).",Pharmacokinetics of norethindrone acetate in women after the insertion of a single subdermal implant releasing norethindrone acetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058686/),[1] / [d],522,201307,DB00396,Progesterone
,7058686,MCR,"No significant change in the MCR of NETA was observed at 1 week (459 +/- 72 1/day), 1 month (489 +/- 113 1/day) and 2 months (522 +/- 144 1/day) compared with that of control (525 +/- 108 1/day).",Pharmacokinetics of norethindrone acetate in women after the insertion of a single subdermal implant releasing norethindrone acetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058686/),[1] / [d],525,201308,DB00396,Progesterone
,7058686,MCR,"However, MCR of NETA showed significant increase in women exposed to continuous presence of NETA for a period of 6 months (608 +/- 121 1/day; P less than 0.025).",Pharmacokinetics of norethindrone acetate in women after the insertion of a single subdermal implant releasing norethindrone acetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058686/),[1] / [d],608,201309,DB00396,Progesterone
,34327754,Pmax,The exposure at which 50% of Pmax is obtained was 36.9 μg*h/L (95% CI: 27.7-48.7 μg*h/L).,Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34327754/),[h·μg] / [l],36.9,204000,DB00396,Progesterone
,3433369,overall remission rate,"An overall remission rate of 48% was achieved with i.m. MPA, 50% with combined (i.m. + p.o.) modalities; only a 19% remission rate was recorded in the p.o. group.",High-dose medroxyprogesterone in disseminated breast cancer. Correlation between bioavailability and clinical response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433369/),%,48,204086,DB00396,Progesterone
,3433369,overall remission rate,"An overall remission rate of 48% was achieved with i.m. MPA, 50% with combined (i.m. + p.o.) modalities; only a 19% remission rate was recorded in the p.o. group.",High-dose medroxyprogesterone in disseminated breast cancer. Correlation between bioavailability and clinical response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433369/),%,50,204087,DB00396,Progesterone
,22028489,OR,"ORR was 4.7%: two patients had confirmed partial responses lasting 14 and 58 weeks, respectively.",Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028489/),,4,205951,DB00396,Progesterone
,22028489,PFS,Median PFS was 8.3 weeks (95% CI: 7.3-15.3).,Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028489/),weeks,8.3,205952,DB00396,Progesterone
,14698071,half-life,"The pharmacokinetics of mifepristone is characterized by rapid absorption, a long half-life of 25-30 h, and high micromolar serum concentrations following ingestion of doses of >/=100 mg of the drug.",The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14698071/),h,25-30,206822,DB00396,Progesterone
,14698071,metabolic clearance rate,"Binding to AAG limits the tissue availability of mifepristone, explaining its low volume of distribution and low metabolic clearance rate of 0.55 L/kg per day.",The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14698071/),[l] / [d·kg],0.55,206823,DB00396,Progesterone
,23360419,AUC,"The AUC of ethinylestradiol alone versus together with lacosamide was 1,067 ± 404 versus 1,173 ± 330 pg h/ml.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[h·pg] / [ml],"1,067",208129,DB00396,Progesterone
,23360419,AUC,"The AUC of ethinylestradiol alone versus together with lacosamide was 1,067 ± 404 versus 1,173 ± 330 pg h/ml.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[h·pg] / [ml],"1,173",208130,DB00396,Progesterone
,23360419,Cmax,Corresponding values of Cmax were 116.9 ± 48.8 versus 135.7 ± 28.6 pg/ml.,Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[pg] / [ml],116.9,208131,DB00396,Progesterone
,23360419,Cmax,Corresponding values of Cmax were 116.9 ± 48.8 versus 135.7 ± 28.6 pg/ml.,Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[pg] / [ml],135.7,208132,DB00396,Progesterone
,23360419,AUC,"For levonorgestrel, the AUC alone was 74.2 ± 21.4 versus 80.9 ± 18.5 ng h/ml with lacosamide.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[h·ng] / [ml],74.2,208133,DB00396,Progesterone
,23360419,AUC,"For levonorgestrel, the AUC alone was 74.2 ± 21.4 versus 80.9 ± 18.5 ng h/ml with lacosamide.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[h·ng] / [ml],80.9,208134,DB00396,Progesterone
,23360419,Cmax,Corresponding values of Cmax were 6.7 ± 1.9 versus 7.4 ± 1.5 ng/ml.,Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[ng] / [ml],6.7,208135,DB00396,Progesterone
,23360419,Cmax,Corresponding values of Cmax were 6.7 ± 1.9 versus 7.4 ± 1.5 ng/ml.,Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[ng] / [ml],7.4,208136,DB00396,Progesterone
,23360419,tmax,"The AUC and Cmax point estimates and almost all 90% confidence intervals (except for Cmax of ethinylestradiol) for ethinylestradiol and levonorgestrel (with and without lacosamide) were within the conventional bioequivalence range, and no relevant changes in tmax were observed for ethinylestradiol (1.5 ± 0.6 h alone vs. 1.4 ± 0.7 h with lacosamide) or for levonorgestrel (1.5 ± 1.0 h alone vs. 1.1 ± 0.6 h with lacosamide).",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),h,1.5,208137,DB00396,Progesterone
,23360419,tmax,"The AUC and Cmax point estimates and almost all 90% confidence intervals (except for Cmax of ethinylestradiol) for ethinylestradiol and levonorgestrel (with and without lacosamide) were within the conventional bioequivalence range, and no relevant changes in tmax were observed for ethinylestradiol (1.5 ± 0.6 h alone vs. 1.4 ± 0.7 h with lacosamide) or for levonorgestrel (1.5 ± 1.0 h alone vs. 1.1 ± 0.6 h with lacosamide).",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),h,1.4,208138,DB00396,Progesterone
,23360419,tmax,"The AUC and Cmax point estimates and almost all 90% confidence intervals (except for Cmax of ethinylestradiol) for ethinylestradiol and levonorgestrel (with and without lacosamide) were within the conventional bioequivalence range, and no relevant changes in tmax were observed for ethinylestradiol (1.5 ± 0.6 h alone vs. 1.4 ± 0.7 h with lacosamide) or for levonorgestrel (1.5 ± 1.0 h alone vs. 1.1 ± 0.6 h with lacosamide).",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),h,1.5,208139,DB00396,Progesterone
,23360419,tmax,"The AUC and Cmax point estimates and almost all 90% confidence intervals (except for Cmax of ethinylestradiol) for ethinylestradiol and levonorgestrel (with and without lacosamide) were within the conventional bioequivalence range, and no relevant changes in tmax were observed for ethinylestradiol (1.5 ± 0.6 h alone vs. 1.4 ± 0.7 h with lacosamide) or for levonorgestrel (1.5 ± 1.0 h alone vs. 1.1 ± 0.6 h with lacosamide).",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),h,1.1,208140,DB00396,Progesterone
,23360419,AUC,"Lacosamide pharmacokinetics were consistent with those observed in previous studies of lacosamide alone, with values for AUC of 113.5 ± 20.7 μg h/ml, Cmax of 13.8 ± 2.2 μg/ml, and tmax of 1.1 ± 0.4 h.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[h·μg] / [ml],113.5,208141,DB00396,Progesterone
,23360419,Cmax,"Lacosamide pharmacokinetics were consistent with those observed in previous studies of lacosamide alone, with values for AUC of 113.5 ± 20.7 μg h/ml, Cmax of 13.8 ± 2.2 μg/ml, and tmax of 1.1 ± 0.4 h.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[μg] / [ml],13.8,208142,DB00396,Progesterone
,23360419,tmax,"Lacosamide pharmacokinetics were consistent with those observed in previous studies of lacosamide alone, with values for AUC of 113.5 ± 20.7 μg h/ml, Cmax of 13.8 ± 2.2 μg/ml, and tmax of 1.1 ± 0.4 h.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),h,1.1,208143,DB00396,Progesterone
,939191,MPA,The MCRMPA (696 +/- 51 l/day) was only one-half that of progesterone (1332 +/- 59).,The in vivo metabolism of progestins. I. The metabolic clearance rates of progesterone and medroxyprogesterone acetate in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/939191/),[l] / [d],696,208628,DB00396,Progesterone
,939191,MPA,The MCRMPA (696 +/- 51 l/day) was only one-half that of progesterone (1332 +/- 59).,The in vivo metabolism of progestins. I. The metabolic clearance rates of progesterone and medroxyprogesterone acetate in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/939191/),,1332,208629,DB00396,Progesterone
,9241042,Vd,"In most queens (> 90%) given single gonadotropins (i.m. or i.v.), eCG and hCG persisted in circulation for at least 120 h and 96 h after injection, respectively, reflecting similar (p > 0.05) pharmacokinetic (i.v.) values for Vd (eCG, 91.4 +/- 24.8 ml/kg; hCG, 59.1 +/- 7.9 ml/kg), t1/2beta (eCG, 23.0 +/- 2.4 h; hCG, 22.9 +/- 4.1 h), and Clr (eCG, 2.7 +/- 0.5 ml/h per kg; hCG, 1.8 +/- 0.1 ml/h per kg).",Pharmacokinetics and ovarian-stimulatory effects of equine and human chorionic gonadotropins administered singly and in combination in the domestic cat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241042/),[ml] / [kg],91.4,208805,DB00396,Progesterone
,9241042,Vd,"In most queens (> 90%) given single gonadotropins (i.m. or i.v.), eCG and hCG persisted in circulation for at least 120 h and 96 h after injection, respectively, reflecting similar (p > 0.05) pharmacokinetic (i.v.) values for Vd (eCG, 91.4 +/- 24.8 ml/kg; hCG, 59.1 +/- 7.9 ml/kg), t1/2beta (eCG, 23.0 +/- 2.4 h; hCG, 22.9 +/- 4.1 h), and Clr (eCG, 2.7 +/- 0.5 ml/h per kg; hCG, 1.8 +/- 0.1 ml/h per kg).",Pharmacokinetics and ovarian-stimulatory effects of equine and human chorionic gonadotropins administered singly and in combination in the domestic cat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241042/),[ml] / [kg],59.1,208806,DB00396,Progesterone
,9241042,t1/2beta,"In most queens (> 90%) given single gonadotropins (i.m. or i.v.), eCG and hCG persisted in circulation for at least 120 h and 96 h after injection, respectively, reflecting similar (p > 0.05) pharmacokinetic (i.v.) values for Vd (eCG, 91.4 +/- 24.8 ml/kg; hCG, 59.1 +/- 7.9 ml/kg), t1/2beta (eCG, 23.0 +/- 2.4 h; hCG, 22.9 +/- 4.1 h), and Clr (eCG, 2.7 +/- 0.5 ml/h per kg; hCG, 1.8 +/- 0.1 ml/h per kg).",Pharmacokinetics and ovarian-stimulatory effects of equine and human chorionic gonadotropins administered singly and in combination in the domestic cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241042/),h,23.0,208807,DB00396,Progesterone
,9241042,t1/2beta,"In most queens (> 90%) given single gonadotropins (i.m. or i.v.), eCG and hCG persisted in circulation for at least 120 h and 96 h after injection, respectively, reflecting similar (p > 0.05) pharmacokinetic (i.v.) values for Vd (eCG, 91.4 +/- 24.8 ml/kg; hCG, 59.1 +/- 7.9 ml/kg), t1/2beta (eCG, 23.0 +/- 2.4 h; hCG, 22.9 +/- 4.1 h), and Clr (eCG, 2.7 +/- 0.5 ml/h per kg; hCG, 1.8 +/- 0.1 ml/h per kg).",Pharmacokinetics and ovarian-stimulatory effects of equine and human chorionic gonadotropins administered singly and in combination in the domestic cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241042/),h,22.9,208808,DB00396,Progesterone
,9241042,Clr,"In most queens (> 90%) given single gonadotropins (i.m. or i.v.), eCG and hCG persisted in circulation for at least 120 h and 96 h after injection, respectively, reflecting similar (p > 0.05) pharmacokinetic (i.v.) values for Vd (eCG, 91.4 +/- 24.8 ml/kg; hCG, 59.1 +/- 7.9 ml/kg), t1/2beta (eCG, 23.0 +/- 2.4 h; hCG, 22.9 +/- 4.1 h), and Clr (eCG, 2.7 +/- 0.5 ml/h per kg; hCG, 1.8 +/- 0.1 ml/h per kg).",Pharmacokinetics and ovarian-stimulatory effects of equine and human chorionic gonadotropins administered singly and in combination in the domestic cat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241042/),[ml] / [h·kg],2.7,208809,DB00396,Progesterone
,9241042,Clr,"In most queens (> 90%) given single gonadotropins (i.m. or i.v.), eCG and hCG persisted in circulation for at least 120 h and 96 h after injection, respectively, reflecting similar (p > 0.05) pharmacokinetic (i.v.) values for Vd (eCG, 91.4 +/- 24.8 ml/kg; hCG, 59.1 +/- 7.9 ml/kg), t1/2beta (eCG, 23.0 +/- 2.4 h; hCG, 22.9 +/- 4.1 h), and Clr (eCG, 2.7 +/- 0.5 ml/h per kg; hCG, 1.8 +/- 0.1 ml/h per kg).",Pharmacokinetics and ovarian-stimulatory effects of equine and human chorionic gonadotropins administered singly and in combination in the domestic cat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241042/),[ml] / [h·kg],1.8,208810,DB00396,Progesterone
,19608168,Cmax,"On the single day of dosing, mean Cmax was 17.0+/-2.7 ng/mL in the two times a day group, 19.8+/-2.9 ng/mL in the three times a day group, and 6.82+/-1.69 ng/mL in the gel group.",Single and multidose pharmacokinetic study of a vaginal micronized progesterone insert (Endometrin) compared with vaginal gel in healthy reproductive-aged female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19608168/),[ng] / [ml],17.0,209821,DB00396,Progesterone
,19608168,Cmax,"On the single day of dosing, mean Cmax was 17.0+/-2.7 ng/mL in the two times a day group, 19.8+/-2.9 ng/mL in the three times a day group, and 6.82+/-1.69 ng/mL in the gel group.",Single and multidose pharmacokinetic study of a vaginal micronized progesterone insert (Endometrin) compared with vaginal gel in healthy reproductive-aged female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19608168/),[ng] / [ml],19.8,209822,DB00396,Progesterone
,19608168,Cmax,"On the single day of dosing, mean Cmax was 17.0+/-2.7 ng/mL in the two times a day group, 19.8+/-2.9 ng/mL in the three times a day group, and 6.82+/-1.69 ng/mL in the gel group.",Single and multidose pharmacokinetic study of a vaginal micronized progesterone insert (Endometrin) compared with vaginal gel in healthy reproductive-aged female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19608168/),[ng] / [ml],6.82,209823,DB00396,Progesterone
,2065793,maximum concentration (CMax,"Sixty minutes after administration, the maximum concentration (CMax, 3.75 +/- 0.214 ng/mL) was reached.",Progesterone administration by nasal spray. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2065793/),[ng] / [ml],3.75,210060,DB00396,Progesterone
,2065793,AUC 0 to 720,"High P levels (greater than 2 ng/mL) lasted until 360 minutes, and the AUC 0 to 720 was 1,481.6 +/- 343 ng.h/mL.",Progesterone administration by nasal spray. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2065793/),[h·ng] / [ml],"1,481.6",210061,DB00396,Progesterone
up to,25853478,transit time,"The colon is a promising target for drug delivery owing to its long transit time of up to 78 h, which is likely to increase the time available for drug absorption.",Development and in vitro/in vivo evaluation of Zn-pectinate microparticles reinforced with chitosan for the colonic delivery of progesterone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25853478/),h,78,212413,DB00396,Progesterone
,25853478,oral bioavailability,"Progesterone has a short elimination half-life and undergoes extensive first-pass metabolism, which results in very low oral bioavailability (∼25%).",Development and in vitro/in vivo evaluation of Zn-pectinate microparticles reinforced with chitosan for the colonic delivery of progesterone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25853478/),%,∼25,212414,DB00396,Progesterone
,25853478,entrapment efficiency,Drug entrapment efficiency of ∼75-100% was obtained depending on the microparticle composition.,Development and in vitro/in vivo evaluation of Zn-pectinate microparticles reinforced with chitosan for the colonic delivery of progesterone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25853478/),%,∼75-100,212415,DB00396,Progesterone
,25853478,relative bioavailability,"The in vivo study revealed that the microparticles significantly increased progesterone residence time in the plasma and increased its relative bioavailability to ∼168%, compared to the drug alone.",Development and in vitro/in vivo evaluation of Zn-pectinate microparticles reinforced with chitosan for the colonic delivery of progesterone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25853478/),%,∼168,212416,DB00396,Progesterone
,11572441,relative bioavailability,The relative bioavailability of J956 after oral administration was approximately 10% of the parenteral administration.,Administration of antiprogestin J956 for contraception in bears: a pharmacological study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11572441/),%,10,213776,DB00396,Progesterone
,11572441,half-life,The estimated half-life was 12 to 16 hours after oral administration.,Administration of antiprogestin J956 for contraception in bears: a pharmacological study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11572441/),h,12 to 16,213777,DB00396,Progesterone
,11572441,sustain,Parenteral treatment of J956 (10 mg/kg body mass) led to sustain plasma concentrations (6.4 +/- 1.3 ng/mL) in one black bear and in five brown bears.,Administration of antiprogestin J956 for contraception in bears: a pharmacological study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11572441/),[ng] / [ml],6.4,213778,DB00396,Progesterone
,11572441,plasma concentrations,Parenteral treatment of J956 (10 mg/kg body mass) led to sustain plasma concentrations (6.4 +/- 1.3 ng/mL) in one black bear and in five brown bears.,Administration of antiprogestin J956 for contraception in bears: a pharmacological study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11572441/),[ng] / [ml],6.4,213779,DB00396,Progesterone
,24694337,plasma clearance,"Estradiol treatment, in contrast, reduced VLDL-TG concentration by approximately 30% due to accelerated VLDL-TG plasma clearance (25.1 ± 2.5 vs. 17.4 ± 2.7 mL/min; P < .01).","Systemic delivery of estradiol, but not testosterone or progesterone, alters very low density lipoprotein-triglyceride kinetics in postmenopausal women. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694337/),[ml] / [min],25.1,214776,DB00396,Progesterone
,24694337,plasma clearance,"Estradiol treatment, in contrast, reduced VLDL-TG concentration by approximately 30% due to accelerated VLDL-TG plasma clearance (25.1 ± 2.5 vs. 17.4 ± 2.7 mL/min; P < .01).","Systemic delivery of estradiol, but not testosterone or progesterone, alters very low density lipoprotein-triglyceride kinetics in postmenopausal women. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694337/),[ml] / [min],17.4,214777,DB00396,Progesterone
,8246031,steady-state plasma concentration,"The steady-state plasma concentration of progesterone at a dose level of 4 g was 4.1 +/- 0.9 mumol/L, which was higher than the minimal concentration required to reverse multidrug resistance (MDR) in vitro.",Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8246031/),[μM] / [l],4.1,215185,DB00396,Progesterone
,2522811,survival time,The median survival time was significantly longer for responders (19.9 months) than nonresponders (4.8 months).,High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2522811/),month,19.9,216216,DB00396,Progesterone
,2522811,survival time,The median survival time was significantly longer for responders (19.9 months) than nonresponders (4.8 months).,High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2522811/),month,4.8,216217,DB00396,Progesterone
,33178479,recovery,"Method recovery was from 86.0% to 103%, and repeatability was lower than 5.5%.",LC-MS/MS Method for Rapid Quantification of Progesterone in Rabbit Plasma and Its Application in a Pharmacokinetic Study of the Transdermal Formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33178479/),%,86.0,218302,DB00396,Progesterone
,33178479,recovery,"Method recovery was from 86.0% to 103%, and repeatability was lower than 5.5%.",LC-MS/MS Method for Rapid Quantification of Progesterone in Rabbit Plasma and Its Application in a Pharmacokinetic Study of the Transdermal Formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33178479/),%,103,218303,DB00396,Progesterone
,15208047,time for return to o,"Median time for return to ovulation was 30 weeks, with a 97.4% cumulative rate of return to ovulation at 12 months.","Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15208047/),weeks,30,218545,DB00396,Progesterone
,19631786,half-life,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),h,52.1,218919,DB00396,Progesterone
,19631786,half-life,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),h,25.6,218920,DB00396,Progesterone
,19631786,maximum LNG concentration,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),[ng] / [ml],1.9,218921,DB00396,Progesterone
,19631786,maximum LNG concentration,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),[ng] / [ml],2.5,218922,DB00396,Progesterone
,19631786,time to reach steady state,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),d,10,218923,DB00396,Progesterone
,19631786,time to reach steady state,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),d,5,218924,DB00396,Progesterone
,2150632,plateau levels,"Mean plateau levels (+/- s.d.) of 3-keto-desogestrel were 2.3 +/- 0.9, 2.8 +/- 1.1 and 3.8 +/- 1.1 pmol/ml for CVR 75/15, 100/15 and 150/15, respectively.",Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150632/),[pM] / [ml],2.3,219693,DB00396,Progesterone
,2150632,plateau levels,"Mean plateau levels (+/- s.d.) of 3-keto-desogestrel were 2.3 +/- 0.9, 2.8 +/- 1.1 and 3.8 +/- 1.1 pmol/ml for CVR 75/15, 100/15 and 150/15, respectively.",Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150632/),[pM] / [ml],2.8,219694,DB00396,Progesterone
,2150632,plateau levels,"Mean plateau levels (+/- s.d.) of 3-keto-desogestrel were 2.3 +/- 0.9, 2.8 +/- 1.1 and 3.8 +/- 1.1 pmol/ml for CVR 75/15, 100/15 and 150/15, respectively.",Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150632/),[pM] / [ml],3.8,219695,DB00396,Progesterone
,2150632,plateau levels,"Mean plateau levels of ethinylestradiol were 184 +/- 75, 262 +/- 102 and 233 +/- 102 pmol/l, respectively.",Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150632/),[pM] / [l],184,219696,DB00396,Progesterone
,2150632,plateau levels,"Mean plateau levels of ethinylestradiol were 184 +/- 75, 262 +/- 102 and 233 +/- 102 pmol/l, respectively.",Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150632/),[pM] / [l],262,219697,DB00396,Progesterone
,2150632,plateau levels,"Mean plateau levels of ethinylestradiol were 184 +/- 75, 262 +/- 102 and 233 +/- 102 pmol/l, respectively.",Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150632/),[pM] / [l],233,219698,DB00396,Progesterone
,14666137,elimination half-lives,"Intravenous E2 and P4 in DMSO vehicle had elimination half-lives of approximately 10 and 11 hours, respectively.","Pharmacokinetics of ovarian steroids in Sprague-Dawley rats after acute exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14666137/),h,10,220619,DB00396,Progesterone
,14666137,elimination half-lives,"Intravenous E2 and P4 in DMSO vehicle had elimination half-lives of approximately 10 and 11 hours, respectively.","Pharmacokinetics of ovarian steroids in Sprague-Dawley rats after acute exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14666137/),h,11,220620,DB00396,Progesterone
,8222659,terminal half-life,"Following single dose administration, a mean terminal half-life of 18 h was observed for GEST.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),h,18,222309,DB00396,Progesterone
,8222659,total clearance,The total clearance was 0.9 ml x min-1 x kg-1 and the volume of distribution was 84 l.,Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[ml] / [kg·min],0.9,222310,DB00396,Progesterone
,8222659,volume of distribution,The total clearance was 0.9 ml x min-1 x kg-1 and the volume of distribution was 84 l.,Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),l,84,222311,DB00396,Progesterone
,8222659,terminal half-life,"As compared to single dose administration, the following changes were observed for GEST at the end of treatment cycles one and three: prolonged terminal half-life (20 to 22 h), reduced total (0.16 ml x min-1 x kg-1) and free clearance (ca. 27 ml x min-1 x kg-1), reduced volume of distribution (ca. 18 l).",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),h,20 to 22,222312,DB00396,Progesterone
,8222659,total,"As compared to single dose administration, the following changes were observed for GEST at the end of treatment cycles one and three: prolonged terminal half-life (20 to 22 h), reduced total (0.16 ml x min-1 x kg-1) and free clearance (ca. 27 ml x min-1 x kg-1), reduced volume of distribution (ca. 18 l).",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[ml] / [kg·min],0.16,222313,DB00396,Progesterone
,8222659,free clearance,"As compared to single dose administration, the following changes were observed for GEST at the end of treatment cycles one and three: prolonged terminal half-life (20 to 22 h), reduced total (0.16 ml x min-1 x kg-1) and free clearance (ca. 27 ml x min-1 x kg-1), reduced volume of distribution (ca. 18 l).",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[ml] / [kg·min],27,222314,DB00396,Progesterone
,8222659,volume of distribution,"As compared to single dose administration, the following changes were observed for GEST at the end of treatment cycles one and three: prolonged terminal half-life (20 to 22 h), reduced total (0.16 ml x min-1 x kg-1) and free clearance (ca. 27 ml x min-1 x kg-1), reduced volume of distribution (ca. 18 l).",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),l,18,222315,DB00396,Progesterone
,8222659,free fraction,"After single dose administration, the free fraction of GEST was 1.3% and the fractions bound to SHBG and albumin were 69.4% and 29.3%, respectively.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),%,1.3,222316,DB00396,Progesterone
,8222659,fractions,"After single dose administration, the free fraction of GEST was 1.3% and the fractions bound to SHBG and albumin were 69.4% and 29.3%, respectively.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),%,69.4,222317,DB00396,Progesterone
,8222659,fractions,"After single dose administration, the free fraction of GEST was 1.3% and the fractions bound to SHBG and albumin were 69.4% and 29.3%, respectively.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),%,29.3,222318,DB00396,Progesterone
,8222659,free fraction,"At the end of cycle one, the free fraction was only 0.6% and the fractions bound to SHBG and albumin were 81.4% and 18.0%, respectively.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),%,0.6,222319,DB00396,Progesterone
,8222659,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 299.2 and 278.1 pg x ml-1 x h, respectively, which corresponds to an about 30% increase as compared to single dose administration, where an AUC(0-4h) value of 216.1 pg x ml-1 x h was found.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[h·pg] / [ml],299.2,222320,DB00396,Progesterone
,8222659,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 299.2 and 278.1 pg x ml-1 x h, respectively, which corresponds to an about 30% increase as compared to single dose administration, where an AUC(0-4h) value of 216.1 pg x ml-1 x h was found.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[h·pg] / [ml],278.1,222321,DB00396,Progesterone
,8222659,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 299.2 and 278.1 pg x ml-1 x h, respectively, which corresponds to an about 30% increase as compared to single dose administration, where an AUC(0-4h) value of 216.1 pg x ml-1 x h was found.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[h·pg] / [ml],216.1,222322,DB00396,Progesterone
,22018130,percentage cumulative release,"The percentage cumulative release of F6 (optimized formulation) named as 'AGARPRU' was found to be 99.94%±1.25% and 69.99%±1.02% (mean±SD) through rat skin and 92.69%±2.22% and 53.51%±2.11% (mean±SD) through cadaver skin for EE and MPA, respectively.",Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),%,99.94,226877,DB00396,Progesterone
,22018130,percentage cumulative release,"The percentage cumulative release of F6 (optimized formulation) named as 'AGARPRU' was found to be 99.94%±1.25% and 69.99%±1.02% (mean±SD) through rat skin and 92.69%±2.22% and 53.51%±2.11% (mean±SD) through cadaver skin for EE and MPA, respectively.",Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),%,69.99,226878,DB00396,Progesterone
,22018130,percentage cumulative release,"The percentage cumulative release of F6 (optimized formulation) named as 'AGARPRU' was found to be 99.94%±1.25% and 69.99%±1.02% (mean±SD) through rat skin and 92.69%±2.22% and 53.51%±2.11% (mean±SD) through cadaver skin for EE and MPA, respectively.",Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),%,92.69,226879,DB00396,Progesterone
,22018130,percentage cumulative release,"The percentage cumulative release of F6 (optimized formulation) named as 'AGARPRU' was found to be 99.94%±1.25% and 69.99%±1.02% (mean±SD) through rat skin and 92.69%±2.22% and 53.51%±2.11% (mean±SD) through cadaver skin for EE and MPA, respectively.",Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),%,53.51,226880,DB00396,Progesterone
,22018130,T(max),The in vivo results showed prolonged T(max) of 36 h for both EE and MPA after transdermal administration compared to oral route (2 h).,Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),h,36,226881,DB00396,Progesterone
,22018130,T(max),The in vivo results showed prolonged T(max) of 36 h for both EE and MPA after transdermal administration compared to oral route (2 h).,Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),h,2,226882,DB00396,Progesterone
,23242585,overall response (complete response (CR) + partial response (PR)) rate,The overall response (complete response (CR) + partial response (PR)) rate was 4 %.,A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23242585/),%,4,227378,DB00396,Progesterone
,23242585,overall survival,"Median overall survival in patients with TP53 mutant tumors was poor compared to wild type (5.5 vs. 20.3 months, p = 0.004).",A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23242585/),month,5.5,227379,DB00396,Progesterone
,23242585,overall survival,"Median overall survival in patients with TP53 mutant tumors was poor compared to wild type (5.5 vs. 20.3 months, p = 0.004).",A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23242585/),month,20.3,227380,DB00396,Progesterone
,27133963,CL/F,"The final population mean estimates were: CL/F 1797 l/d, Vmaternal /F 32 610 l and mother to cord rate constant 0.005 day(-1) .",Population pharmacokinetics of 17α-hydroxyprogesterone caproate in singleton gestation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27133963/),[l] / [d],1797,229868,DB00396,Progesterone
,27133963,Vmaternal /F,"The final population mean estimates were: CL/F 1797 l/d, Vmaternal /F 32 610 l and mother to cord rate constant 0.005 day(-1) .",Population pharmacokinetics of 17α-hydroxyprogesterone caproate in singleton gestation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27133963/),l,32 610,229869,DB00396,Progesterone
,27133963,mother to cord rate constant,"The final population mean estimates were: CL/F 1797 l/d, Vmaternal /F 32 610 l and mother to cord rate constant 0.005 day(-1) .",Population pharmacokinetics of 17α-hydroxyprogesterone caproate in singleton gestation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27133963/),1/[day],0.005,229870,DB00396,Progesterone
,1157762,t1/2,"After a single injection of progesterone in 20-day pregnant rabbits, the disappearance of the steroid from the circulation consisted of two components; an initial phase during which progesterone disappeared rapidly (t1/2 = 2.4 +/- 0.2 min) followed by a slower rate of disappearance (t1/2 = 21.5 +/- 2.2 min).",Metabolic clearance rates (MCR) and production rates (PR) plasma progesterone in pregnant and pseudopregnant rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1157762/),min,2.4,229981,DB00396,Progesterone
,1157762,t1/2,"After a single injection of progesterone in 20-day pregnant rabbits, the disappearance of the steroid from the circulation consisted of two components; an initial phase during which progesterone disappeared rapidly (t1/2 = 2.4 +/- 0.2 min) followed by a slower rate of disappearance (t1/2 = 21.5 +/- 2.2 min).",Metabolic clearance rates (MCR) and production rates (PR) plasma progesterone in pregnant and pseudopregnant rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1157762/),min,21.5,229982,DB00396,Progesterone
,1300055,T1/2ka,"The pharmacokinetic parameters were: T1/2ka 0.79 +/- 0.08 h, T1/2 alpha 0.96 +/- 0.08 h, T1/2 beta 6.6 +/- 1.5 h, Vc 14 +/- 3 ml.kg-1, AUC 12.0 +/- 1.9 micrograms.h.ml-1, Tmax 1.8 +/- 0.5 h, Cmax 3.3 +/- 0.5 microgram.",[Pharmacokinetics of epostane in rabbits by HPLC method]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1300055/),h,0.79,230928,DB00396,Progesterone
,1300055,T1/2 alpha,"The pharmacokinetic parameters were: T1/2ka 0.79 +/- 0.08 h, T1/2 alpha 0.96 +/- 0.08 h, T1/2 beta 6.6 +/- 1.5 h, Vc 14 +/- 3 ml.kg-1, AUC 12.0 +/- 1.9 micrograms.h.ml-1, Tmax 1.8 +/- 0.5 h, Cmax 3.3 +/- 0.5 microgram.",[Pharmacokinetics of epostane in rabbits by HPLC method]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1300055/),h,0.96,230929,DB00396,Progesterone
,1300055,T1/2 beta,"The pharmacokinetic parameters were: T1/2ka 0.79 +/- 0.08 h, T1/2 alpha 0.96 +/- 0.08 h, T1/2 beta 6.6 +/- 1.5 h, Vc 14 +/- 3 ml.kg-1, AUC 12.0 +/- 1.9 micrograms.h.ml-1, Tmax 1.8 +/- 0.5 h, Cmax 3.3 +/- 0.5 microgram.",[Pharmacokinetics of epostane in rabbits by HPLC method]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1300055/),h,6.6,230930,DB00396,Progesterone
,1300055,Vc,"The pharmacokinetic parameters were: T1/2ka 0.79 +/- 0.08 h, T1/2 alpha 0.96 +/- 0.08 h, T1/2 beta 6.6 +/- 1.5 h, Vc 14 +/- 3 ml.kg-1, AUC 12.0 +/- 1.9 micrograms.h.ml-1, Tmax 1.8 +/- 0.5 h, Cmax 3.3 +/- 0.5 microgram.",[Pharmacokinetics of epostane in rabbits by HPLC method]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1300055/),[ml] / [kg],14,230931,DB00396,Progesterone
,1300055,AUC,"The pharmacokinetic parameters were: T1/2ka 0.79 +/- 0.08 h, T1/2 alpha 0.96 +/- 0.08 h, T1/2 beta 6.6 +/- 1.5 h, Vc 14 +/- 3 ml.kg-1, AUC 12.0 +/- 1.9 micrograms.h.ml-1, Tmax 1.8 +/- 0.5 h, Cmax 3.3 +/- 0.5 microgram.",[Pharmacokinetics of epostane in rabbits by HPLC method]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1300055/),[h·μg] / [ml],12.0,230932,DB00396,Progesterone
,1300055,Tmax,"The pharmacokinetic parameters were: T1/2ka 0.79 +/- 0.08 h, T1/2 alpha 0.96 +/- 0.08 h, T1/2 beta 6.6 +/- 1.5 h, Vc 14 +/- 3 ml.kg-1, AUC 12.0 +/- 1.9 micrograms.h.ml-1, Tmax 1.8 +/- 0.5 h, Cmax 3.3 +/- 0.5 microgram.",[Pharmacokinetics of epostane in rabbits by HPLC method]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1300055/),h,1.8,230933,DB00396,Progesterone
,1300055,Cmax,"The pharmacokinetic parameters were: T1/2ka 0.79 +/- 0.08 h, T1/2 alpha 0.96 +/- 0.08 h, T1/2 beta 6.6 +/- 1.5 h, Vc 14 +/- 3 ml.kg-1, AUC 12.0 +/- 1.9 micrograms.h.ml-1, Tmax 1.8 +/- 0.5 h, Cmax 3.3 +/- 0.5 microgram.",[Pharmacokinetics of epostane in rabbits by HPLC method]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1300055/),μg,3.3,230934,DB00396,Progesterone
,3158549,length of the luteal phase,There also was no change in mean length of the luteal phase (13.7 +/- 2.1 days [control] versus 13.6 +/- 1.4 days).,Effect on corpus luteum function of luteal phase administration of a potent gonadotropin-releasing hormone analog (nafarelin). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158549/),d,13.7,232142,DB00396,Progesterone
,3158549,length of the luteal phase,There also was no change in mean length of the luteal phase (13.7 +/- 2.1 days [control] versus 13.6 +/- 1.4 days).,Effect on corpus luteum function of luteal phase administration of a potent gonadotropin-releasing hormone analog (nafarelin). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158549/),d,13.6,232143,DB00396,Progesterone
,21187946,zeta potential,The selected nanoparticles showed an average particle size of 267 nm and a zeta potential approaching-41 mV.,Sustained-release progesterone nanosuspension following intramuscular injection in ovariectomized rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21187946/),m,41,232200,DB00396,Progesterone
,21187946,maximum serum concentration,"After the administration of PNS in F127/MC gel into the rats, a maximum serum concentration of 22.1 ± 1.9 ng/mL was reached at a T(max) of 4.05 ± 0.1 h.",Sustained-release progesterone nanosuspension following intramuscular injection in ovariectomized rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21187946/),[ng] / [ml],22.1,232201,DB00396,Progesterone
,21187946,T(max),"After the administration of PNS in F127/MC gel into the rats, a maximum serum concentration of 22.1 ± 1.9 ng/mL was reached at a T(max) of 4.05 ± 0.1 h.",Sustained-release progesterone nanosuspension following intramuscular injection in ovariectomized rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21187946/),h,4.05,232202,DB00396,Progesterone
,21187946,terminal half life,The terminal half life was 12.7 ± 0.8 h.,Sustained-release progesterone nanosuspension following intramuscular injection in ovariectomized rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21187946/),h,12.7,232203,DB00396,Progesterone
,21187946,area under the curve AUC₀₋∞,The area under the curve AUC₀₋∞ of the injected formula was 452.75 ± 42.8 ng·h/mL and the total mean residence time was 18.57 ± 1.44 h.,Sustained-release progesterone nanosuspension following intramuscular injection in ovariectomized rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21187946/),[h·ng] / [ml],452.75,232204,DB00396,Progesterone
,21187946,total mean residence time,The area under the curve AUC₀₋∞ of the injected formula was 452.75 ± 42.8 ng·h/mL and the total mean residence time was 18.57 ± 1.44 h.,Sustained-release progesterone nanosuspension following intramuscular injection in ovariectomized rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21187946/),h,18.57,232205,DB00396,Progesterone
,1541918,serum half-life,Analysis of the clearance curves for the bolus injection suggested a single-compartment model and a serum half-life of 7.25 min.,Serum half-life and in-vivo actions of recombinant bovine placental lactogen in the dairy cow. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1541918/),min,7.25,233851,DB00396,Progesterone
,18079079,concentration,"In the high progesterone group (n=11), the mean concentration was 11.1+/-3.5ng/ml and in the low progesterone group (n=50) the mean was 0.6+/-0.3ng/ml.",The influence of sex hormones on the elimination kinetics of ethanol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18079079/),[ng] / [ml],11.1,236249,DB00396,Progesterone
,18079079,concentration,"In the high progesterone group (n=11), the mean concentration was 11.1+/-3.5ng/ml and in the low progesterone group (n=50) the mean was 0.6+/-0.3ng/ml.",The influence of sex hormones on the elimination kinetics of ethanol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18079079/),[ng] / [ml],0.6,236250,DB00396,Progesterone
,18079079,hourly elimination rate (beta60),The mean hourly elimination rate (beta60) was 0.1677+/-0.0311g/kg/h in men.,The influence of sex hormones on the elimination kinetics of ethanol. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18079079/),[g] / [h·kg],0.1677,236251,DB00396,Progesterone
,18079079,hourly elimination rate,"In women, the mean hourly elimination rate was 0.2044+/-0.0414g/kg/h in the high progesterone group and 0.1850+/-0.0276g/kg/h in the low progesterone group (p<0.05).",The influence of sex hormones on the elimination kinetics of ethanol. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18079079/),[g] / [h·kg],0.2044,236252,DB00396,Progesterone
,18079079,hourly elimination rate,"In women, the mean hourly elimination rate was 0.2044+/-0.0414g/kg/h in the high progesterone group and 0.1850+/-0.0276g/kg/h in the low progesterone group (p<0.05).",The influence of sex hormones on the elimination kinetics of ethanol. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18079079/),[g] / [h·kg],0.1850,236253,DB00396,Progesterone
,24686129,clearance,"Median paracetamol clearance at delivery was significantly higher when compared to postpartum or non-pregnant women (11.9 vs. 6.42 and 8.4 l/h·m(2), at least p < 0.05), while an association between paracetamol clearance and estradiol was observed (R = 0.494, p < 0.0001).",Estradiol and weight are covariates of paracetamol clearance in young women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24686129/),[h·l] / [m(2],11.9,238151,DB00396,Progesterone
,24686129,clearance,"Median paracetamol clearance at delivery was significantly higher when compared to postpartum or non-pregnant women (11.9 vs. 6.42 and 8.4 l/h·m(2), at least p < 0.05), while an association between paracetamol clearance and estradiol was observed (R = 0.494, p < 0.0001).",Estradiol and weight are covariates of paracetamol clearance in young women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24686129/),[h·l] / [m(2],6.42,238152,DB00396,Progesterone
,24686129,clearance,"Median paracetamol clearance at delivery was significantly higher when compared to postpartum or non-pregnant women (11.9 vs. 6.42 and 8.4 l/h·m(2), at least p < 0.05), while an association between paracetamol clearance and estradiol was observed (R = 0.494, p < 0.0001).",Estradiol and weight are covariates of paracetamol clearance in young women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24686129/),[h·l] / [m(2],8.4,238153,DB00396,Progesterone
,32716091,time to reach Cmax,Median time to reach Cmax was 1.5 hours after both single and multiple vilaprisan administration.,Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716091/),h,1.5,238398,DB00396,Progesterone
,32716091,Cmax,Mean Cmax values obtained after multiple dosing (23.3 μg/L [standard deviation (SD) = 6.73]) were 1.92-fold (SD = 0.554) higher compared to single dosing (12.5 μg/L [SD = 3.04]).,Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716091/),[μg] / [l],23.3,238399,DB00396,Progesterone
,32716091,Cmax,Mean Cmax values obtained after multiple dosing (23.3 μg/L [standard deviation (SD) = 6.73]) were 1.92-fold (SD = 0.554) higher compared to single dosing (12.5 μg/L [SD = 3.04]).,Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716091/),[μg] / [l],12.5,238400,DB00396,Progesterone
,32716091,area under the plasma concentration-time curve,Mean area under the plasma concentration-time curve in the dosing interval increased with an accumulation factor of 2.98 (SD = 0.767) between single (91.3 μg · h/L [SD = 20.4]) and multiple dosing (276 μg · h/L [SD = 109]).,Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716091/),,2.98,238401,DB00396,Progesterone
,32716091,area under the plasma concentration-time curve,Mean area under the plasma concentration-time curve in the dosing interval increased with an accumulation factor of 2.98 (SD = 0.767) between single (91.3 μg · h/L [SD = 20.4]) and multiple dosing (276 μg · h/L [SD = 109]).,Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716091/),[h·μg] / [l],91.3,238402,DB00396,Progesterone
,32716091,area under the plasma concentration-time curve,Mean area under the plasma concentration-time curve in the dosing interval increased with an accumulation factor of 2.98 (SD = 0.767) between single (91.3 μg · h/L [SD = 20.4]) and multiple dosing (276 μg · h/L [SD = 109]).,Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716091/),[h·μg] / [l],276,238403,DB00396,Progesterone
,32716091,accumulation factor,Mean area under the plasma concentration-time curve in the dosing interval increased with an accumulation factor of 2.98 (SD = 0.767) between single (91.3 μg · h/L [SD = 20.4]) and multiple dosing (276 μg · h/L [SD = 109]).,Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716091/),,2.98,238404,DB00396,Progesterone
,32716091,accumulation factor,Mean area under the plasma concentration-time curve in the dosing interval increased with an accumulation factor of 2.98 (SD = 0.767) between single (91.3 μg · h/L [SD = 20.4]) and multiple dosing (276 μg · h/L [SD = 109]).,Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716091/),[h·μg] / [l],91.3,238405,DB00396,Progesterone
,32716091,accumulation factor,Mean area under the plasma concentration-time curve in the dosing interval increased with an accumulation factor of 2.98 (SD = 0.767) between single (91.3 μg · h/L [SD = 20.4]) and multiple dosing (276 μg · h/L [SD = 109]).,Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716091/),[h·μg] / [l],276,238406,DB00396,Progesterone
,32716091,terminal half-life,The mean terminal half-life of vilaprisan was 44.5 hours (SD = 10.3) after multiple dosing.,Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716091/),h,44.5,238407,DB00396,Progesterone
,23110788,tmax,"Co-administration of esomeprazole decreased geometric mean Cmax of ulipristal acetate by 65% (geometric mean ratio point estimate (90% CI): 0.35 (0.28 - 0.42)), and delayed median tmax from 0.75 to 1.00 h (Hodges-Lehmann estimate of difference (90% CI): tmax 0.63 (0.25 - 1.25)) but had minor effects on AUCs of +15% and +11% (geometric mean ratio point estimates (90% CI): AUC0-t 1.15 (1.02 - 1.31) and AUC0-∞ (1.11 (0.98 - 1.27)), respectively.",Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23110788/),h,0.75,238667,DB00396,Progesterone
,23110788,tmax,"Co-administration of esomeprazole decreased geometric mean Cmax of ulipristal acetate by 65% (geometric mean ratio point estimate (90% CI): 0.35 (0.28 - 0.42)), and delayed median tmax from 0.75 to 1.00 h (Hodges-Lehmann estimate of difference (90% CI): tmax 0.63 (0.25 - 1.25)) but had minor effects on AUCs of +15% and +11% (geometric mean ratio point estimates (90% CI): AUC0-t 1.15 (1.02 - 1.31) and AUC0-∞ (1.11 (0.98 - 1.27)), respectively.",Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23110788/),h,1.00,238668,DB00396,Progesterone
over,3695508,half-life,With a low dose of 50 mg the pharmacokinetics followed an open two-compartment model with a half-life of over 27 h.,Pharmacokinetics and metabolism of RU 486. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3695508/),h,27,240241,DB00396,Progesterone
,3695508,elimination phase half-life,"The elimination phase half-life with this dose, calculated between day 5 and 6, was 24 h.",Pharmacokinetics and metabolism of RU 486. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3695508/),h,24,240242,DB00396,Progesterone
,3695508,relative binding affinities,"The relative binding affinities of RU 486, monodemethylated, didemethylated and hydroxylated metabolites (progesterone = 100%) to the human progesterone receptor were 232, 50, 21, and 36, respectively.",Pharmacokinetics and metabolism of RU 486. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3695508/),,232,240243,DB00396,Progesterone
,3695508,relative binding affinities,"The relative binding affinities of RU 486, monodemethylated, didemethylated and hydroxylated metabolites (progesterone = 100%) to the human progesterone receptor were 232, 50, 21, and 36, respectively.",Pharmacokinetics and metabolism of RU 486. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3695508/),,50,240244,DB00396,Progesterone
,3695508,relative binding affinities,"The relative binding affinities of RU 486, monodemethylated, didemethylated and hydroxylated metabolites (progesterone = 100%) to the human progesterone receptor were 232, 50, 21, and 36, respectively.",Pharmacokinetics and metabolism of RU 486. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3695508/),,21,240245,DB00396,Progesterone
,3695508,relative binding affinities,"The relative binding affinities of RU 486, monodemethylated, didemethylated and hydroxylated metabolites (progesterone = 100%) to the human progesterone receptor were 232, 50, 21, and 36, respectively.",Pharmacokinetics and metabolism of RU 486. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3695508/),,36,240246,DB00396,Progesterone
,32652643,apparent clearance,"Cortisol was characterized by a one-compartment model with apparent clearance and volume of distribution estimated at 22.9 L/h/70 kg and 41.1 L/70 kg, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),[l] / [70·h·kg],22.9,240366,DB00396,Progesterone
,32652643,volume of distribution,"Cortisol was characterized by a one-compartment model with apparent clearance and volume of distribution estimated at 22.9 L/h/70 kg and 41.1 L/70 kg, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),[l] / [70·kg],41.1,240367,DB00396,Progesterone
,32652643,IC50,"The IC50 values of cortisol concentrations for cortisol, 17-hydroxyprogesterone and androstenedione were estimated to be 1.36, 0.45 and 0.75 μg/dL, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),[μg] / [dl],1.36,240368,DB00396,Progesterone
,32652643,IC50,"The IC50 values of cortisol concentrations for cortisol, 17-hydroxyprogesterone and androstenedione were estimated to be 1.36, 0.45 and 0.75 μg/dL, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),[μg] / [dl],0.45,240369,DB00396,Progesterone
,32652643,IC50,"The IC50 values of cortisol concentrations for cortisol, 17-hydroxyprogesterone and androstenedione were estimated to be 1.36, 0.45 and 0.75 μg/dL, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),[μg] / [dl],0.75,240370,DB00396,Progesterone
,32652643,Half-lives,"Half-lives of cortisol, 17-hydroxyprogesterone and androstenedione were 60, 47 and 77 minutes, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),min,60,240371,DB00396,Progesterone
,32652643,Half-lives,"Half-lives of cortisol, 17-hydroxyprogesterone and androstenedione were 60, 47 and 77 minutes, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),min,47,240372,DB00396,Progesterone
,32652643,Half-lives,"Half-lives of cortisol, 17-hydroxyprogesterone and androstenedione were 60, 47 and 77 minutes, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),min,77,240373,DB00396,Progesterone
,1165451,production rate,"The mean production rate of progesterone was 173 +/- 23-3 (S.ET) mug/min, with values ranging from 80 to 276 mug/min in pregnancy.","Metabolic clearance rate, production rate, and mammary uptake and metabolism of progesterone in cows. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1165451/),[μg] / [min],173,240856,DB00396,Progesterone
,1165451,production rate,"The mean production rate of progesterone was 173 +/- 23-3 (S.ET) mug/min, with values ranging from 80 to 276 mug/min in pregnancy.","Metabolic clearance rate, production rate, and mammary uptake and metabolism of progesterone in cows. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1165451/),[μg] / [min],80 to 276,240857,DB00396,Progesterone
,1165451,metabolic clearance rate,"The metabolic clearance rate was 22-5 +/- 2-0 1/min, or 0-21 +/- 0-025 1/min/kg metabolic body weight.","Metabolic clearance rate, production rate, and mammary uptake and metabolism of progesterone in cows. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1165451/),[1] / [min],22-5,240858,DB00396,Progesterone
,1165451,metabolic clearance rate,"The metabolic clearance rate was 22-5 +/- 2-0 1/min, or 0-21 +/- 0-025 1/min/kg metabolic body weight.","Metabolic clearance rate, production rate, and mammary uptake and metabolism of progesterone in cows. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1165451/),[1] / [kg·min],0-21,240859,DB00396,Progesterone
,1165451,mammary uptake,"The mammary uptake of progesterone was low, 3-1 +/- mug/min, and udder uptake accounted for about 3% of progesterone production rate.","Metabolic clearance rate, production rate, and mammary uptake and metabolism of progesterone in cows. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1165451/),[μg] / [min],3-1,240860,DB00396,Progesterone
,1743318,Peak plasma P concentrations,"Peak plasma P concentrations attained within 4 hours after oral administration ranged from 8.5 to 70.6 ng/mL, whereas after vaginal administration the peak levels were attained within 8 hours and ranged from 4.4 to 181.1 ng/mL.",Comparative bioavailability of orally and vaginally administered progesterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743318/),[ng] / [ml],8.5 to 70.6,241699,DB00396,Progesterone
,1743318,peak levels,"Peak plasma P concentrations attained within 4 hours after oral administration ranged from 8.5 to 70.6 ng/mL, whereas after vaginal administration the peak levels were attained within 8 hours and ranged from 4.4 to 181.1 ng/mL.",Comparative bioavailability of orally and vaginally administered progesterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743318/),[ng] / [ml],4.4 to 181.1,241700,DB00396,Progesterone
,3087697,peak level,The plasma LNOG levels were found to reach a peak level ranging from 2.7-7.5 ng/ml within 4 days after the IVR insertion.,Bioavailability of levonorgestrel from intravaginal rings in women of low income groups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3087697/),[ng] / [ml],2.7-7.5,241883,DB00396,Progesterone
,3087697,release rates,The range of release rates calculated from plasma steady-state values was 51-119 micrograms/day.,Bioavailability of levonorgestrel from intravaginal rings in women of low income groups. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3087697/),[μg] / [d],51-119,241884,DB00396,Progesterone
,3087697,release rates,The average release rates over the entire period of observation based on area under curve were 102-200 micrograms/day.,Bioavailability of levonorgestrel from intravaginal rings in women of low income groups. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3087697/),[μg] / [d],102-200,241885,DB00396,Progesterone
,3087697,area under curve,The average release rates over the entire period of observation based on area under curve were 102-200 micrograms/day.,Bioavailability of levonorgestrel from intravaginal rings in women of low income groups. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3087697/),[μg] / [d],102-200,241886,DB00396,Progesterone
,3087697,release rates,"On the other hand, the release rates obtained from the residual drug in the ring after a period of use ranged from 184-259 micrograms/day.",Bioavailability of levonorgestrel from intravaginal rings in women of low income groups. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3087697/),[μg] / [d],184-259,241887,DB00396,Progesterone
,20570083,hourly elimination rate ss(60),"In 10 of the volunteers, who had a normal increase in progesterone in the luteal phase, the average hourly elimination rate ss(60) in the follicular phase amounted to 0.0194+/-0.0020g%/h (BAC) and 0.0975+/-0.0068mg/L/h (BrAC), and in the luteal phase to 0.0193+/-0.0031g%/h (BAC) and 0.1026+/-0.0101mg/L/h (BrAC).",The influence of the luteal and follicular phases on major pharmacokinetic parameters of blood and breath alcohol kinetics in women. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570083/),[g%] / [h],0.0194,243003,DB00396,Progesterone
,20570083,hourly elimination rate ss(60),"In 10 of the volunteers, who had a normal increase in progesterone in the luteal phase, the average hourly elimination rate ss(60) in the follicular phase amounted to 0.0194+/-0.0020g%/h (BAC) and 0.0975+/-0.0068mg/L/h (BrAC), and in the luteal phase to 0.0193+/-0.0031g%/h (BAC) and 0.1026+/-0.0101mg/L/h (BrAC).",The influence of the luteal and follicular phases on major pharmacokinetic parameters of blood and breath alcohol kinetics in women. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570083/),[mg] / [h·l],0.0975,243004,DB00396,Progesterone
,20570083,hourly elimination rate ss(60),"In 10 of the volunteers, who had a normal increase in progesterone in the luteal phase, the average hourly elimination rate ss(60) in the follicular phase amounted to 0.0194+/-0.0020g%/h (BAC) and 0.0975+/-0.0068mg/L/h (BrAC), and in the luteal phase to 0.0193+/-0.0031g%/h (BAC) and 0.1026+/-0.0101mg/L/h (BrAC).",The influence of the luteal and follicular phases on major pharmacokinetic parameters of blood and breath alcohol kinetics in women. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570083/),[g%] / [h],0.0193,243005,DB00396,Progesterone
,20570083,hourly elimination rate ss(60),"In 10 of the volunteers, who had a normal increase in progesterone in the luteal phase, the average hourly elimination rate ss(60) in the follicular phase amounted to 0.0194+/-0.0020g%/h (BAC) and 0.0975+/-0.0068mg/L/h (BrAC), and in the luteal phase to 0.0193+/-0.0031g%/h (BAC) and 0.1026+/-0.0101mg/L/h (BrAC).",The influence of the luteal and follicular phases on major pharmacokinetic parameters of blood and breath alcohol kinetics in women. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570083/),[mg] / [h·l],0.1026,243006,DB00396,Progesterone
,8173196,Css min,"A wide inter-patient variability was noted in MPA Css min for the 70 patients receiving 1000 mg/day per os: median 51 ng/ml, range 10-269 ng/ml.",[Clinical pharmacokinetics and practical consequences of optimal use of medroxyprogesterone acetate]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173196/),[ng] / [ml],51,243395,DB00396,Progesterone
,8173196,Css min,These data suggested an optimal therapeutic window for MPA Css min located within 50-70 ng/ml.,[Clinical pharmacokinetics and practical consequences of optimal use of medroxyprogesterone acetate]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173196/),[ng] / [ml],50-70,243396,DB00396,Progesterone
,19347334,maximum concentration in plasma (C(max),"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],3.0 to 6.0,244163,DB00396,Progesterone
,19347334,maximum concentration in plasma (C(max),"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],6.4 to 13.4,244164,DB00396,Progesterone
,19347334,area under the plasma concentration time curve (AUC,"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],38.2 to 88.3,244165,DB00396,Progesterone
,19347334,area under the plasma concentration time curve (AUC,"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],88.3 to 217.2,244166,DB00396,Progesterone
,19347334,C(max),Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],5.2 to 1.5,244167,DB00396,Progesterone
,19347334,C(max),Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],6.8 to 1.9,244168,DB00396,Progesterone
,19347334,AUC,Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],62.4 to 14.4,244169,DB00396,Progesterone
,19347334,AUC,Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],87.8 to 19.6,244170,DB00396,Progesterone
,31439579,ORR,Objective responses were seen in 6 of 25 patients with RECIST-measurable disease (ORR 24%).,"POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31439579/),%,24,245642,DB00396,Progesterone
,31439579,time to disease progression,Median time to disease progression was 3.7 months.,"POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31439579/),month,3.7,245643,DB00396,Progesterone
,16988492,peak plasma progesterone concentrations,"The means (+/- SE) of the peak plasma progesterone concentrations after the 3, 6, 12 and 25 IU ACTH challenge tests were 0.6 +/- 0.1, 1.3 +/- 0.4, 1.5 +/- 0.3 and 2.4 +/- 0.3 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],0.6,248400,DB00396,Progesterone
,16988492,peak plasma progesterone concentrations,"The means (+/- SE) of the peak plasma progesterone concentrations after the 3, 6, 12 and 25 IU ACTH challenge tests were 0.6 +/- 0.1, 1.3 +/- 0.4, 1.5 +/- 0.3 and 2.4 +/- 0.3 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],1.3,248401,DB00396,Progesterone
,16988492,peak plasma progesterone concentrations,"The means (+/- SE) of the peak plasma progesterone concentrations after the 3, 6, 12 and 25 IU ACTH challenge tests were 0.6 +/- 0.1, 1.3 +/- 0.4, 1.5 +/- 0.3 and 2.4 +/- 0.3 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],1.5,248402,DB00396,Progesterone
,16988492,peak plasma progesterone concentrations,"The means (+/- SE) of the peak plasma progesterone concentrations after the 3, 6, 12 and 25 IU ACTH challenge tests were 0.6 +/- 0.1, 1.3 +/- 0.4, 1.5 +/- 0.3 and 2.4 +/- 0.3 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],2.4,248403,DB00396,Progesterone
,16988492,peak plasma cortisol concentrations,"The means of the peak plasma cortisol concentrations in the 3 cows after the ACTH challenge were 14.0 +/- 1.5, 17.0 +/- 2.5, 23.3 +/- 3.0, and 33.3 +/- 7.0 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],14.0,248404,DB00396,Progesterone
,16988492,peak plasma cortisol concentrations,"The means of the peak plasma cortisol concentrations in the 3 cows after the ACTH challenge were 14.0 +/- 1.5, 17.0 +/- 2.5, 23.3 +/- 3.0, and 33.3 +/- 7.0 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],17.0,248405,DB00396,Progesterone
,16988492,peak plasma cortisol concentrations,"The means of the peak plasma cortisol concentrations in the 3 cows after the ACTH challenge were 14.0 +/- 1.5, 17.0 +/- 2.5, 23.3 +/- 3.0, and 33.3 +/- 7.0 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],23.3,248406,DB00396,Progesterone
,16988492,peak plasma cortisol concentrations,"The means of the peak plasma cortisol concentrations in the 3 cows after the ACTH challenge were 14.0 +/- 1.5, 17.0 +/- 2.5, 23.3 +/- 3.0, and 33.3 +/- 7.0 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],33.3,248407,DB00396,Progesterone
,26801247,PFS,"Median PFS for all 50 patients was 5.5 months (95% confidence interval, 4.1-6.7).",Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26801247/),month,5.5,251225,DB00396,Progesterone
,16326369,apparent steady-state,The time-course of serum 17beta-estradiol and progesterone released from these capsules in the OVX rat is characterized by an initial increase in serum hormone levels followed by a decline and then an apparent steady-state that persists from 7 to 24 days postimplant.,Pharmacokinetics and effects of 17beta-estradiol and progesterone implants in ovariectomized rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326369/),d,7 to 24,254208,DB00396,Progesterone
,16326369,total clearance,Both hormones have large clearance values (total clearance is 97.7 L/day for 17beta-estradiol and 20.9 L/day for progesterone).,Pharmacokinetics and effects of 17beta-estradiol and progesterone implants in ovariectomized rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326369/),[l] / [d],97.7,254209,DB00396,Progesterone
,16326369,total clearance,Both hormones have large clearance values (total clearance is 97.7 L/day for 17beta-estradiol and 20.9 L/day for progesterone).,Pharmacokinetics and effects of 17beta-estradiol and progesterone implants in ovariectomized rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326369/),[l] / [d],20.9,254210,DB00396,Progesterone
,1467457,distribution,"The distribution and elimination phase half-lives were 0.13 +/- 0.024 (mean +/- SD) and 1.21 +/- 0.21 h, respectively.",Pharmacokinetics of progesterone in ovariectomized rats after single dose intravenous administration. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467457/),h,0.13,254332,DB00396,Progesterone
,1467457,elimination phase half-lives,"The distribution and elimination phase half-lives were 0.13 +/- 0.024 (mean +/- SD) and 1.21 +/- 0.21 h, respectively.",Pharmacokinetics of progesterone in ovariectomized rats after single dose intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467457/),h,1.21,254333,DB00396,Progesterone
,1467457,total clearance,Elimination of the steroid was rapid with a total clearance of 2.75 +/- 0.42 l h-1 kg-1.,Pharmacokinetics of progesterone in ovariectomized rats after single dose intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467457/),[l] / [h·kg],2.75,254334,DB00396,Progesterone
,1467457,steady state volume of distribution,"Progesterone was widely distributed in the rat with a steady state volume of distribution of 2.36 +/- 0.23 l kg-1, a volume of the central compartment of 0.86 +/- 0.24 l kg-1 and a volume of the peripheral compartment of 1.50 +/- 0.19 l kg-1.",Pharmacokinetics of progesterone in ovariectomized rats after single dose intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467457/),[l] / [kg],2.36,254335,DB00396,Progesterone
,1467457,volume of the central compartment,"Progesterone was widely distributed in the rat with a steady state volume of distribution of 2.36 +/- 0.23 l kg-1, a volume of the central compartment of 0.86 +/- 0.24 l kg-1 and a volume of the peripheral compartment of 1.50 +/- 0.19 l kg-1.",Pharmacokinetics of progesterone in ovariectomized rats after single dose intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467457/),[l] / [kg],0.86,254336,DB00396,Progesterone
,1467457,volume of the peripheral compartment,"Progesterone was widely distributed in the rat with a steady state volume of distribution of 2.36 +/- 0.23 l kg-1, a volume of the central compartment of 0.86 +/- 0.24 l kg-1 and a volume of the peripheral compartment of 1.50 +/- 0.19 l kg-1.",Pharmacokinetics of progesterone in ovariectomized rats after single dose intravenous administration. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467457/),[l] / [kg],1.50,254337,DB00396,Progesterone
<,9619751,AUC,Five patients demonstrated extremely low AUC and Cmax (< 10 ng/ml) values on day 1.,Pharmacokinetic study of low- versus high-dose medroxyprogesterone acetate (MPA) in women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9619751/),[ng] / [ml],10,257240,DB00396,Progesterone
<,9619751,Cmax,Five patients demonstrated extremely low AUC and Cmax (< 10 ng/ml) values on day 1.,Pharmacokinetic study of low- versus high-dose medroxyprogesterone acetate (MPA) in women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9619751/),[ng] / [ml],10,257241,DB00396,Progesterone
,9693401,maximum serum concentrations (Cmax),"After the 1st, 6th, and 12th injection, the maximum serum concentrations (Cmax) of MPA were observed on days 3.4 +/- 0.9, 4.3 +/- 2.2, and 3.7 +/- 2.6, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),,3.4,257830,DB00396,Progesterone
,9693401,maximum serum concentrations (Cmax),"After the 1st, 6th, and 12th injection, the maximum serum concentrations (Cmax) of MPA were observed on days 3.4 +/- 0.9, 4.3 +/- 2.2, and 3.7 +/- 2.6, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),,4.3,257831,DB00396,Progesterone
,9693401,maximum serum concentrations (Cmax),"After the 1st, 6th, and 12th injection, the maximum serum concentrations (Cmax) of MPA were observed on days 3.4 +/- 0.9, 4.3 +/- 2.2, and 3.7 +/- 2.6, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),,3.7,257832,DB00396,Progesterone
,9693401,Cmax,"Cmax of serum MPA during the 1st, 6th, and 12th treatment cycles were 3.75 +/- 1.27, 5.54 +/- 1.79, and 5.55 +/- 1.80 nmol/L, whereas the areas under the curve (AUC0-28 days) were 55.84 +/- 28.15, 95.45 +/- 26.56, and 98.81 +/- 21.84 nmol/L.day, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),[nM] / [l],3.75,257833,DB00396,Progesterone
,9693401,Cmax,"Cmax of serum MPA during the 1st, 6th, and 12th treatment cycles were 3.75 +/- 1.27, 5.54 +/- 1.79, and 5.55 +/- 1.80 nmol/L, whereas the areas under the curve (AUC0-28 days) were 55.84 +/- 28.15, 95.45 +/- 26.56, and 98.81 +/- 21.84 nmol/L.day, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),[nM] / [l],5.54,257834,DB00396,Progesterone
,9693401,Cmax,"Cmax of serum MPA during the 1st, 6th, and 12th treatment cycles were 3.75 +/- 1.27, 5.54 +/- 1.79, and 5.55 +/- 1.80 nmol/L, whereas the areas under the curve (AUC0-28 days) were 55.84 +/- 28.15, 95.45 +/- 26.56, and 98.81 +/- 21.84 nmol/L.day, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),[nM] / [l],5.55,257835,DB00396,Progesterone
,9693401,areas under the curve (AUC0-28 days),"Cmax of serum MPA during the 1st, 6th, and 12th treatment cycles were 3.75 +/- 1.27, 5.54 +/- 1.79, and 5.55 +/- 1.80 nmol/L, whereas the areas under the curve (AUC0-28 days) were 55.84 +/- 28.15, 95.45 +/- 26.56, and 98.81 +/- 21.84 nmol/L.day, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),[nM] / [d·l],55.84,257836,DB00396,Progesterone
,9693401,areas under the curve (AUC0-28 days),"Cmax of serum MPA during the 1st, 6th, and 12th treatment cycles were 3.75 +/- 1.27, 5.54 +/- 1.79, and 5.55 +/- 1.80 nmol/L, whereas the areas under the curve (AUC0-28 days) were 55.84 +/- 28.15, 95.45 +/- 26.56, and 98.81 +/- 21.84 nmol/L.day, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),[nM] / [d·l],95.45,257837,DB00396,Progesterone
,9693401,areas under the curve (AUC0-28 days),"Cmax of serum MPA during the 1st, 6th, and 12th treatment cycles were 3.75 +/- 1.27, 5.54 +/- 1.79, and 5.55 +/- 1.80 nmol/L, whereas the areas under the curve (AUC0-28 days) were 55.84 +/- 28.15, 95.45 +/- 26.56, and 98.81 +/- 21.84 nmol/L.day, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),[nM] / [d·l],98.81,257838,DB00396,Progesterone
,1255043,MCRB,"The mean MCRB of oestradiol was 162 ml/min (0 X 079 1/min/weight0 X 75), and at equilibrium a significant proportion of the radioactivity in the circulation was present as oestrone (conversion ratio oestradiol to oestrone, 27 X 6%).",Metabolic clearance rate and production rate of oestradiol in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1255043/),[ml] / [min],162,259391,DB00396,Progesterone
,1255043,MCRB,"The mean MCRB of oestradiol was 162 ml/min (0 X 079 1/min/weight0 X 75), and at equilibrium a significant proportion of the radioactivity in the circulation was present as oestrone (conversion ratio oestradiol to oestrone, 27 X 6%).",Metabolic clearance rate and production rate of oestradiol in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1255043/),[1] / [min·weight],0 X 079,259392,DB00396,Progesterone
,1255043,conversion ratio,"The mean MCRB of oestradiol was 162 ml/min (0 X 079 1/min/weight0 X 75), and at equilibrium a significant proportion of the radioactivity in the circulation was present as oestrone (conversion ratio oestradiol to oestrone, 27 X 6%).",Metabolic clearance rate and production rate of oestradiol in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1255043/),%,27 X 6,259393,DB00396,Progesterone
,1255043,PRB,"The mean PRB of oestradiol was 4 X 3 ng/min, which is equivalent to about 5 mug/day.",Metabolic clearance rate and production rate of oestradiol in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1255043/),[ng] / [min],4 X 3,259394,DB00396,Progesterone
,1255043,PRB,"The mean PRB of oestradiol was 4 X 3 ng/min, which is equivalent to about 5 mug/day.",Metabolic clearance rate and production rate of oestradiol in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1255043/),[μg] / [d],5,259395,DB00396,Progesterone
,15901745,C(SS),"C(SS) values were 337 +/- 135 ng/mL, which were significantly lower than the target concentration of 450 +/- 100 ng/mL.",Steady-state serum concentrations of progesterone following continuous intravenous infusion in patients with acute moderate to severe traumatic brain injury. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901745/),[ng] / [ml],337,259532,DB00396,Progesterone
,31504342,clearance,The median clearance of MPA was 19 681 L/week compared with 12 118 L/week for historical controls.,Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31504342/),[l] / [week],19 681,261371,DB00396,Progesterone
,31504342,clearance,The median clearance of MPA was 19 681 L/week compared with 12 118 L/week for historical controls.,Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31504342/),[l] / [week],12 118,261372,DB00396,Progesterone
,898233,plasma MCR6MP,"The plasma MCR6MP was 4047 +/- 298 L/day (59 +/- 15 L/day/kg) which was higher than the MCR of progesterone and medroxyprogesterone acetate (6alpha-methyl-17alpha-hydroxy-pregna-4-ene-3,20-dione acetate).","The in vivo metabolism of progestins. The metabolic clearance rate and plasma binding of 6alpha-methylpregn-4-ene-3, 20-dione in women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/898233/),[l] / [d],4047,261773,DB00396,Progesterone
,898233,plasma MCR6MP,"The plasma MCR6MP was 4047 +/- 298 L/day (59 +/- 15 L/day/kg) which was higher than the MCR of progesterone and medroxyprogesterone acetate (6alpha-methyl-17alpha-hydroxy-pregna-4-ene-3,20-dione acetate).","The in vivo metabolism of progestins. The metabolic clearance rate and plasma binding of 6alpha-methylpregn-4-ene-3, 20-dione in women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/898233/),[l] / [d·kg],59,261774,DB00396,Progesterone
,9640267,area under the curve,"The mean amplitude and amount of oxytocin released, as calculated by the area under the curve of ovarian oxytocin pulses, were 6.27 +/- 1.98 ng min-1 and (10.05 +/- 8.91 ng min-1)tau, respectively (where tau is the number of hours between the last time point before and the first time point after a significant increase in hormone concentration was detected by the Pulsar program).",Stimulation of ovarian oxytocin secretion and uterine prostaglandin release by exogenous progesterone early in the cycle of the ovarian auto-transplanted ewe. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640267/),[ng] / [min],10.05,262099,DB00396,Progesterone
,9640267,amplitude,"The mean amplitude and area under the curve of PGFM pulses were 317.22 +/- 5.65 pg ml-1 and (383.36 +/- 1.77 pg ml-1)tau, respectively.",Stimulation of ovarian oxytocin secretion and uterine prostaglandin release by exogenous progesterone early in the cycle of the ovarian auto-transplanted ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640267/),[pg] / [ml],317.22,262100,DB00396,Progesterone
,9640267,area under the curve,"The mean amplitude and area under the curve of PGFM pulses were 317.22 +/- 5.65 pg ml-1 and (383.36 +/- 1.77 pg ml-1)tau, respectively.",Stimulation of ovarian oxytocin secretion and uterine prostaglandin release by exogenous progesterone early in the cycle of the ovarian auto-transplanted ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640267/),[pg] / [ml],383.36,262101,DB00396,Progesterone
,9640267,number,The average number of pulses of plasma PGFM observed per ewe was 5.8 +/- 1.9 and interpulse interval for plasma PGFM pulses was 10.32 +/- 8.7 h between day 7 and day 9 after oestrus.,Stimulation of ovarian oxytocin secretion and uterine prostaglandin release by exogenous progesterone early in the cycle of the ovarian auto-transplanted ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640267/),,5.8,262102,DB00396,Progesterone
,9640267,interpulse interval,The average number of pulses of plasma PGFM observed per ewe was 5.8 +/- 1.9 and interpulse interval for plasma PGFM pulses was 10.32 +/- 8.7 h between day 7 and day 9 after oestrus.,Stimulation of ovarian oxytocin secretion and uterine prostaglandin release by exogenous progesterone early in the cycle of the ovarian auto-transplanted ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640267/),h,10.32,262103,DB00396,Progesterone
,32227643,Cmax,"Cmax was similar in participants with moderate renal impairment and normal renal function (least squares mean, 1.026; 90% confidence interval, 0.779-1.351).",Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32227643/),,1.026,263269,DB00396,Progesterone
,23550906,tmax,"UPA median tmax was 0·75 and 0·89 h, and mean plasma half-life was between 38 and 49 h.",Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23550906/),h,0·75,268942,DB00396,Progesterone
,23550906,tmax,"UPA median tmax was 0·75 and 0·89 h, and mean plasma half-life was between 38 and 49 h.",Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23550906/),h,0·89,268943,DB00396,Progesterone
,23550906,plasma half-life,"UPA median tmax was 0·75 and 0·89 h, and mean plasma half-life was between 38 and 49 h.",Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23550906/),h,38 and 49,268944,DB00396,Progesterone
,23550906,Cmax,"Cmax values (Day 1) were 42·2, 130·9 and 354·8 ng/mL for the UPA 10, 20 and 50 mg treatment groups, respectively.",Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23550906/),[ng] / [ml],42·2,268945,DB00396,Progesterone
,23550906,Cmax,"Cmax values (Day 1) were 42·2, 130·9 and 354·8 ng/mL for the UPA 10, 20 and 50 mg treatment groups, respectively.",Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23550906/),[ng] / [ml],130·9,268946,DB00396,Progesterone
,23550906,Cmax,"Cmax values (Day 1) were 42·2, 130·9 and 354·8 ng/mL for the UPA 10, 20 and 50 mg treatment groups, respectively.",Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23550906/),[ng] / [ml],354·8,268947,DB00396,Progesterone
,23550906,Cmax,"Corresponding Cmax values for Day 10 were 63·7, 169·8 and 454·9 ng/mL.",Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23550906/),[ng] / [ml],63·7,268948,DB00396,Progesterone
,23550906,Cmax,"Corresponding Cmax values for Day 10 were 63·7, 169·8 and 454·9 ng/mL.",Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23550906/),[ng] / [ml],169·8,268949,DB00396,Progesterone
,23550906,Cmax,"Corresponding Cmax values for Day 10 were 63·7, 169·8 and 454·9 ng/mL.",Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23550906/),[ng] / [ml],454·9,268950,DB00396,Progesterone
,23550906,AUCSS,"AUCSS values on Day 10 were 216·6, 602·8 and 1655·7 ng h/mL after 10, 20 and 50 mg UPA, respectively.",Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23550906/),[h·ng] / [ml],216·6,268951,DB00396,Progesterone
,23550906,AUCSS,"AUCSS values on Day 10 were 216·6, 602·8 and 1655·7 ng h/mL after 10, 20 and 50 mg UPA, respectively.",Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23550906/),[h·ng] / [ml],602·8,268952,DB00396,Progesterone
,23550906,AUCSS,"AUCSS values on Day 10 were 216·6, 602·8 and 1655·7 ng h/mL after 10, 20 and 50 mg UPA, respectively.",Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23550906/),[h·ng] / [ml],1655·7,268953,DB00396,Progesterone
,23550906,AUCSS Day 10,"PGL4002 AUCSS Day 10 values were 84·7, 203·6 and 452·1 ng h/mL for 10, 20 and 50 mg groups, respectively.",Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23550906/),[h·ng] / [ml],84·7,268954,DB00396,Progesterone
,23550906,AUCSS Day 10,"PGL4002 AUCSS Day 10 values were 84·7, 203·6 and 452·1 ng h/mL for 10, 20 and 50 mg groups, respectively.",Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23550906/),[h·ng] / [ml],203·6,268955,DB00396,Progesterone
,23550906,AUCSS Day 10,"PGL4002 AUCSS Day 10 values were 84·7, 203·6 and 452·1 ng h/mL for 10, 20 and 50 mg groups, respectively.",Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23550906/),[h·ng] / [ml],452·1,268956,DB00396,Progesterone
,9871424,area under the plasma concentration-time curve (AUC0-infinity),"The mean +/- SD area under the plasma concentration-time curve (AUC0-infinity) for ethinyl estradiol was 6580 +/- 1100 ng.h/L at baseline and 5970 +/- 1560 ng.h/L after the thalidomide regimen (paired t test, P > .05).",Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871424/),[h·ng] / [l],6580,269060,DB00396,Progesterone
,9871424,area under the plasma concentration-time curve (AUC0-infinity),"The mean +/- SD area under the plasma concentration-time curve (AUC0-infinity) for ethinyl estradiol was 6580 +/- 1100 ng.h/L at baseline and 5970 +/- 1560 ng.h/L after the thalidomide regimen (paired t test, P > .05).",Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871424/),[h·ng] / [l],5970,269061,DB00396,Progesterone
,9871424,AUC0-infinity,"No accumulation of thalidomide was seen after 21 days of therapy: day 1 AUC0-infinity 41.1 +/- 13.9 micrograms.h/mL; day 21 AUC0-infinity 59.6 +/- 27.3 micrograms.h/mL (paired t test, P > .05).",Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871424/),[h·μg] / [ml],41.1,269062,DB00396,Progesterone
,9871424,AUC0-infinity,"No accumulation of thalidomide was seen after 21 days of therapy: day 1 AUC0-infinity 41.1 +/- 13.9 micrograms.h/mL; day 21 AUC0-infinity 59.6 +/- 27.3 micrograms.h/mL (paired t test, P > .05).",Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871424/),[h·μg] / [ml],59.6,269063,DB00396,Progesterone
,7276795,half-lives,The disappearance of [3H]progesterone from blood was described by two half-lives of 0.5 and 11.7 min.,Dynamics of progesterone metabolism in the pseudopregnant rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7276795/),min,0.5,270112,DB00396,Progesterone
,7276795,half-lives,The disappearance of [3H]progesterone from blood was described by two half-lives of 0.5 and 11.7 min.,Dynamics of progesterone metabolism in the pseudopregnant rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7276795/),min,11.7,270113,DB00396,Progesterone
,7276795,metabolic clearance rate,"The metabolic clearance rate for this steroid was 2.9 litre/day, equivalent to a production rate of 3.9 mumol/day.",Dynamics of progesterone metabolism in the pseudopregnant rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7276795/),[l] / [d],2.9,270114,DB00396,Progesterone
,7276795,production rate,"The metabolic clearance rate for this steroid was 2.9 litre/day, equivalent to a production rate of 3.9 mumol/day.",Dynamics of progesterone metabolism in the pseudopregnant rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7276795/),[μM] / [d],3.9,270115,DB00396,Progesterone
,7276795,volume of distribution,"The initial volume of distribution of the injected [3H]progesterone was 5.0 ml, a volume similar in size to the expected plasma volume.",Dynamics of progesterone metabolism in the pseudopregnant rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7276795/),ml,5.0,270116,DB00396,Progesterone
,7276795,total volume of distribution,The total volume of distribution of [3H]progesterone (i.e. 'inner' and 'outer' pools) was in the range 24.8-35.4 ml.,Dynamics of progesterone metabolism in the pseudopregnant rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7276795/),ml,24.8-35.4,270117,DB00396,Progesterone
,7276795,half-lives,The disappearance of endogenous progesterone from the blood of pseudopregnant rats after vascular isolation of the ovaries showed two half-lives of 1.1 and 11.4 min respectively.,Dynamics of progesterone metabolism in the pseudopregnant rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7276795/),min,1.1,270118,DB00396,Progesterone
,7276795,half-lives,The disappearance of endogenous progesterone from the blood of pseudopregnant rats after vascular isolation of the ovaries showed two half-lives of 1.1 and 11.4 min respectively.,Dynamics of progesterone metabolism in the pseudopregnant rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7276795/),min,11.4,270119,DB00396,Progesterone
,7276795,half-life,"The disappearance of a product of reductive metabolism of progesterone, 20 alpha-dihydroprogesterone, was apparently uniphasic, with a half-life of 41.3 min.",Dynamics of progesterone metabolism in the pseudopregnant rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7276795/),min,41.3,270120,DB00396,Progesterone
,8499584,disposition half-lives,"Dog plasma MPA levels from the intravenous dose were characterized by a triexponential decay with disposition half-lives of 0.3, 1.8, and 21.6 h.",Pharmacokinetics and bioavailability of medroxyprogesterone acetate in the dog and the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8499584/),h,0.3,271715,DB00396,Progesterone
,8499584,disposition half-lives,"Dog plasma MPA levels from the intravenous dose were characterized by a triexponential decay with disposition half-lives of 0.3, 1.8, and 21.6 h.",Pharmacokinetics and bioavailability of medroxyprogesterone acetate in the dog and the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8499584/),h,1.8,271716,DB00396,Progesterone
,8499584,disposition half-lives,"Dog plasma MPA levels from the intravenous dose were characterized by a triexponential decay with disposition half-lives of 0.3, 1.8, and 21.6 h.",Pharmacokinetics and bioavailability of medroxyprogesterone acetate in the dog and the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8499584/),h,21.6,271717,DB00396,Progesterone
,8499584,absolute bioavailability,"The oral absorption of MPA in dogs appears to be dose-linear over the dosage range studied, and the absolute bioavailability was estimated at 27 per cent.",Pharmacokinetics and bioavailability of medroxyprogesterone acetate in the dog and the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8499584/),%,27,271718,DB00396,Progesterone
